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EDITORIAL 
THE CHANGING REALM OF 
IN MEDICINE 
WOMEN 
One of the reasons that this particular volume was assembled was the need to recognize the changes that North American women have gone through in 
all aspects of contemporary We. This is clear here at the 
UWO Faculty of Medicine simply by the quantity and 
breadth of the material submitted for the topic of 
Women's Health for the UWO Medical Journal. Although 
many of these changes have brought women greater 
benefits, it has also brought greater risks particularly with 
regards to their health. 
The topic of ' women's health' has meant a wide 
variety of things to a wide variety of people over the 
centuries. Until relatively recently, women's health meant 
obstetrics and gynecology, putting women in the 
unenviable position of being viewed medically only in the 
context of their reproductive role.1 As a result, solutions to 
women's health needs had been limited to improving 
maternal and child health, while ignoring the wide 
spectrum of other health concerns that enter a woman's 
life. However, it soon became apparent that 'women's 
health ' not only encompassed much more than 
reproduction, but also influenced a larger spectrum of the 
population than the previously targeted reproductive 
female. Indeed, the pendulum has swung recently so far to 
the other side that some women's groups are complaining 
that 'women's health' has become an umbrella term for 
everything from pediatric health to geriatric health to 
global health trends.2 This incredibly broad spectrum of 
influence can be at least partially explained by the 
extremely important roles women continue to play in 
nearly all societies as primary caregivers in the home. The 
care of society's dependants-<:hildren, the elderly, the 
infirm-<:ontinues to fall upon the shoulders of women/ 
and health organizations such as the WHO, have come to 
realize that women-and their health-thus have a very 
direct effect on these segments of the population's health 
care I. 
However, this significant role as caregivers comes in 
addition to increasing work hours outside the home, and, 
in North America, increasing age of this population of 
caregivers .4 Thus, it is not surprising that women are 
experiencing an increase in chronic diseases, eating 
disorders, depression, stress-related illnesses, physical and 
substance abuse, etc.1'4.s This situation is compounded by 
the fact that neither the medical profession nor society nor 
women themselves appear well informed on certain 
aspects of their health. For example, both lung cancer and 
smoking continue to rise alarmingly in women, despite 
efforts at education and prevention,6 and only recently has 
By Aaron M. Glickman & Carla Garcia 
the medical community come to accept that female 
pulmonary physiology may indeed vary significantly 
from the 'standardized male' values that all patients are 
traditionally measured against.7 In fact, that same medical 
tendency to treat women based on data collected from 
males has developed into a significant obstacle on many 
fronts, and recent studies have found a wide variety of 
gender specific differences that are currently not being 
accounted for properly in the treatment of women.8 
Perhaps the most worrisome combination of 
ignorance on the part of women, their healthcare workers, 
and society at large is observed in the management and 
outcome of ischemic heart disease in women vs. men. The 
misinformation exists at every level. Clinical trial s 
evaluating drug therapy for IHD do not adequately 
represent women (even those that claim to have gender-
related policies).9 Physicians tend to diagnose women with 
IHD later than men, and tend to refer them for bypass 
surgery at a much more advanced disease state than their 
male patients, 10•11 which may help to explain the fact that 
women's outcomes and prognosis are significantly poorer 
than men' s for this disease. Women are similar!~ 
misinformed about their relative risk for heart disease, 2 
and in fact, many were under the impression that their 
gender reduced the risk of cardiac disease to the point of 
inconsequence, and took few if any preventativ e 
measuresY Fortunately, previous misapprehensions are 
being corrected, and there have been great strides in the 
education of both women and their health care providers 
in both the treatment and prevention of IHD. Two papers 
in this issue deal with post-menopausal hormone 
replacement therapy, and its emerginr role as a 
cardioprotective agent in high risk women.14•1 
This naturally leads to the inevitable question-how 
well are we as students being educated in women 's 
health? As several of the papers in this issue reveal, there 
are certainly significant gaps in our current curriculum. 
For example, Briar Sexton's paper16 discovered a startling 
lack of formal training for one of the most important 
clinical skills in women' s health-the breast exam. 
Baugniet et a/. found that their workshops on 
menstruation filled a significant knowledge gap in both 
young girls and medical students.17 Tess Pitre comments 
in her article on the consequences of lack of physician 
knowledge with respect to breastfeeding and neonatal 
nutrition. 18 Jim Grochowski ' s paper emphasizes the 
important role that emergency room physicians play in 
the management of spousal abuse (which remains one of 
the greatest threats to women's health), and yet there was 
6 
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little forma l training on this subject in the old 
curriculum-a situation which has fortunately been 
corrected in the new system at Westem.19 
However, despite these still-lingering problems, great 
strides have been made in other areas of women's health. 
Three articles in this issue deal with the progress that has 
been made in the.Jrevention, diagnosis, and treatment of 
breast cancer.20.21 In particular, Mason. Ross' article on 
breast reconstruction is an excellent example of medicine 
ass is ting women in their p hys ical and psychological 
recovery following mastectomy.22 Rupinder Singh Sahsi 
has found a wealth of useful, accurate information for 
wo men and heal th care profess ionals alike on the 
intemet.23 The increasing presence of women in medicine 
have also lead to significant changes in both how the 
profession views itself and its female patients-an issue 
w hich is addressed in Rodin & Saibil ' s paper in this 
issue.24 And, the profile of Dr. Nisker reveals a physician 
educator who has made a great effort to educate medical 
students and facul ty at UWO about one of the mos t 
tenuous realms of women's health-the ethical issues 
surrounding current advances in fertility treatments.25 
Thus, the scope of th is issue remains necessarily 
broad, in an effort to reflect some of the span of topics that 
fall into the domain of women's health. While a complete, 
thorough review of this area of medicine would be near-
impossible, it is our hope to present a collection of articles 
reflecting some of its recent triumphs and more pressing 
concerns. 
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PROFILES 
EDITOR: HELEN LEWANDOWSKI 
INTERVIEW WITH DR. JEFF NISKER 
and 
of 
Professor of Obstetrics and Gynecology 
Coordinator of Bioethics at the University 
Western Ontario Faculty of Medicine 
INTRODUCTION 
Dr. Jeffrey Nisker is a 
Professor of Obstetrics and 
Gynaecology at the 
University of Western 
Ontario who was recently 
chosen by the CBC' s Peter 
Gzowski as one of the 13 
"Best Minds of our Time". 
Perhaps this is because Dr. 
isker wears many hats in 
addition to his hat as a 
clinician. He has won 
international awards for his 
research into how cancer can be caused or prevented by 
hormones, and has done work for Health Canada 
Commissions in the area of reproductive technologies. He 
is also the initiator of a novel approach to address ethical 
issues through plays, stories and poems. He believes that 
in an age of shrinking health care resources, clinicians and 
health care students must find ways to retain their 
empathy for their patients and deliver optimal 
compassionate care. According to Dr. Nisker, "theater and 
poetry and song ... can put us in the skin of a patient and 
approximate empathy for that patient" . When 
interspersed throughout medical education, Dr. isker 
believes that this approach can help medical students 
retain the intelligence, compassion and courage, which 
they possess upon entry to medical school. 
Dr. Nisker received his undergraduate and medical 
education at the University of Toronto, and his training in 
Obstetrics and Gynaecology at the University of Western 
Ontario. He was awarded a Medical Research Council 
fellowship in hormones and cancer and did post-graduate 
at UWO, University of California and McMaster 
University. Dr. Nisker is currently the coordina tor of 
bioethics, spirituality and cultural issues in the faculty of 
Medicine and Dentistry at UWO. His current national 
positions include chair of the Ethics Committee of the 
Society of Obstetricians and Gynaecologists of Canada, 
Canadian Bioethics Society Council member, and Health 
Canada's Advisory Committee on Reproductive and 
Genetic technologies. Dr. Nisker has made other national 
and international contributions such as on the Health 
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Canada Advisory Committee on Embryo Research and as 
national director of the Society of Obstetrics and 
Gynaecologists of Canada (SOGC), and was an author of 
the International Federation of Fertility Society's "Ethical 
Guidelines". Dr. Nisker is also actively involved on the 
new London Health Sciences Centre (LHSC) Patient Care 
Steering Committee. 
Dr. isker has written numerous articles and book 
chapters on scientific and ethical issues. He has also 
written six plays covering issues from woman abuse to 
HIV to moral decision development. He has also written 
many short stories and poems to encourage 
compassionate health care. His play, "Doctor's Call" has 
been performed in Victoria, Vancouver, London, Toronto, 
Halifax, New Hampshire and Nashville. In 1996 Dr. 
Nisker received the Douglas Socking Award presented to 
the UWO "member of faculty who, in the opinion of 
medical s tudents has made the most outstanding 
contribution to their medical education during the 
previous four years". 
RESEARCH IN REPRODUCTIVE TECHNOLOGY 
In the words of CBC's Peter Gzowski, Dr. Nisker was a 
groundbreaking cancer and reproductive technology researcher 
when five years ago, an ethical crisis prompted him to give up 
his research. Since then , Dr. Nisker changed his focus to 
teaching medical students and doctors about ethics. 
Dr. Nisker: I had been exposed as a resident in 
Obstetrics and Gynaecology to what are called "mid-
trimester terminations", where women who are carrying a 
gene for what they feel, or for what society feels, is an 
abnormal condition, go through labor about halfway 
through their pregnancy as part of their termination 
process. It 's absolutely horrible. Chemicals are injected 
into the amniotic fluid to terminate the pregnancy, and 
other drugs are given to induce uterine contractions. 
Sometimes the fetus comes out alive, and it is a horrible 
experience. So, it seemed logical that we could use the 
technology that we were developing in our In Vitro 
Fertilization program to be able to make these diagnoses 
earlier so the women would never have to go through this 
process. We would just not put in the embryos that were 
affected with Tay-Sach's syndrome, for example. We'd 
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been experimenting in mice and abnormal multi-
pronucleate human embryos for years to get us to this 
stage. These are not human embryos, because they only 
consist of several cells and we didn't want to experiment 
with human embryos, since they can't give consent and 
we didn' t want to get into that. This whole process is 
called "Preimplantation Genetic Diagnosis". 
When we were doing this research, we were highly 
criticized by the Canadian Feminist movement, which was 
a very helpful and positive watchdog. They said that I was 
being naive, and that although I thought this research that 
we were doing at LHSC was for the good, a lot of people 
were going to take the research and use it for cloning and 
mass-producing human beings. As it turned out, they 
were right. 
At the time, the only centers doing this type of 
research were the Hammersmith Hospital in London, 
England and ourselves at LHSC at UWO. Now, this is 
being done in at least 20 centres all over the world, mostly 
in the US. Where we got into a problem was when the 
technology that we were developing was used by 
scientists at George Washington University, and they did 
their famous cloning experiment. They were taking eight-
cell embryos and making eight potential human beings 
out of them . That was where the Canadian Feminist 
movement said, I told you so, you can't do technology in a 
void. That was when it hit me that we had this technology 
and we were seeing what we could do with it instead of 
letting society tell science what they wanted us to 
investigate. As the Canadian Feminist movement was 
clear in saying, technology would then shape society 
instead of society shaping technology. I believe that this 
was prophetic, that I was naive and that we are now 
moving down those lines. 
The problem is more than just cloning, it's the idea of 
a perfect society. It's the concept of what you would do 
genetic testing for . I could buy into doing this for Tay-
Sachs disease, where there's very little quality of life, but 
would we do it for baldness? Would we do it with 
obesity? Where is it going to stop? Recently I read a piece 
in a magazine about how an American company went into 
Iceland, which is a small gene pool and a place where 
there's only a quarter of a million people. They were 
looking into taking genes from Icelanders and making a 
race of blond-haired, blue-eyed, long-legged women, 
which would be commercially available. It's that type of 
si tuation which really scares me, and that caused me to 
give up my research and spend the past five years of my 
life writing plays and addressing the moral issues that are 
involved. 1 
ON CANCER RESEARCH 
Initia lly, the topic that had spurred Dr. Nisker to become 
active as a researcher was the effect of hormones on cancer. In 
this area, the research he carried out contributed to significantly 
improving the state of knowledge on this important issue. 
Dr. Nisker: I come from a family where women don' t 
live past the age of 50 because they all die of breast cancer. 
So I was trying to find a cure for cancer. We thought that 
we had a way that we could detect breast cancer through 
Profiles 
hormones, and prevent breast cancer through hormones, 
but we did not. Instead we found a way to prevent 
endometrial cancer through hormones, by giving 
progesterone. We did it in rabbits, since it had been found 
that rabbits could develop uterine cancer. Female rabbits 
are the only animal species that don't have estrous cycles 
and that don' t have progesterone. A female rabbit will 
only ovulate during coitus. Thus, a female rabbit without 
access to male rabbits is in the same situation as a post-
menopausal woman, in that a post-menopausal woman 
may still have estrogen especially if they take it in pills but 
the ir body never sees this protective hormone, 
progesterone, because they don' t ovulate. So the rabbit 
w as a very exact model, physiologically, for what 
h appened . When the rabbits got cancer, I got the 
pathology slides, randomized them and presented them to 
our human pathologist who said that they looked exactly 
the same as human cancers. When we gave half the rabbits 
progesterone, the group that got the progesterone were 
prevented from getting endometrial cancer but the group 
who didn' t get the progesterone still got cancer.1 
MEDICAL ETHICS AND MEDICAL HUMANITIES 
The "Yellow Brick Road" is a narrative bioethics pilot that 
was init iated by Dr. Nisker at the University of Wes tern 
Ontario. Every other Monday evening during the fall semester, 
it provides thirty minutes of narrative presentation which 
includes original plays, adapted plays, and "readers' theater" 
fo llowed by discussion of relevant ethical issues . Local and 
invited fa culty enrich the conversation , and f ilming the 
performances fo r later use at Western and other universities 
permits future in depth digestion of issues and more personal 
debate. 
Dr. Nisker: The program is named the Yellow Brick 
Road after the Wizard of Oz, because I believe that people 
who go into the medical professions have the brains and 
the heart and the courage to be the great caregivers that 
they want to be. Then, here we take these health care 
s tudents, and we give them miles of medical ink to 
memorize, tons of tutored words to carry with them, and 
we dissolve their hearts, their brains and their courage. 
Especially their hearts, and this is in the name of the 
science of health care. Actually, I got the idea for this not 
from the Wizard of Oz, but from a little book by Antoine 
de St-Exupery called " Le Petit Prince". While reading it to 
my children, I noticed a gorgeous line in it that said, "It is 
only with the heart that thou can see correctly what is 
essential is invisible to the eye". That's why I feel that 
theater and poetry and song can touch us in the heart and 
can approximate empathy for a patient. We don't want to 
have "That's the myocardial infarction in bed 10", we 
want to ha ve "That's James Jones". At Wes tern, this 
concept of health care humanities will be involved in 
teaching bioethics with soul in medical school, and will 
also encompass spirituality, alternative medicine, history 
of medicine, and what we can learn from the evolution of 
medicine over the years.1 
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ON WOMEN'S HEALTH ISSUES 
Dr. Nisker: I think that women's health is a huge 
issue, and as someone who takes care of the health of 
women I believe it's extremely important for these issues 
tQ be brought forward. There are so many of them ... For 
example, women and men are not the same. They have 
different health needs and different expectations, and they 
become ill differently. Thus the prevention of illness is 
quite different in women. Yet, most of the research that 
comes out has been done in men, and it makes quite a 
difference in terms of the technology. For example, in 
Canada it is extremely difficult to get a vaginal ultrasound 
probe that's designed specifically for women. The one that 
exists is basically a modified version of a rectal probe for 
men, and it's used in clinics across Canada. I think that it's 
a cruel instrument, and we've refused to use it. We used a 
specific vaginal probe that was invented in Sweden but 
that was extremely difficult to repair once it breaks. I 
would have preferred that someone design an appropriate 
vaginal ultrasound for women rather than having to adapt 
one. That's just one example of how we need to be 
cognizant of the fact that women's health is differen t than 
men's. 
The issue of genetic testing for cancer, and more 
specifically breast cancer, is also important. This is 
something that's not covered under our health care 
system. There are women who have a family history of 
breast cancer which is perhaps not strong enough to 
qualify them as participants in studies where genetic 
testing for breast cancer is done. But to them, it was 
extremely traumatic to watch their mother or aunt die of 
breast cancer. While that may not qualify them to be part 
of a study, I think that funding should exist for a woman 
to be able to be tested for the BRCAl gene if she wishes. 
Many women may choose not to be tested, but right now 
they don' t have that choice. Wealthy women can go to the 
US to be tested but poor women can't do that and I think 
that all women should have the same choices. Many 
women with a family history of breast cancer come to me 
with this question, because they're considering going on 
Hormone Replacement Therapy. If they're carrying the 
gene, they don' t want to go on HRT, but if they're not 
carrying it they do want to go on it because they're having 
hot flushes . Unfortunately I can't access that information 
to help them choose, and that's an example of how women 
aren't able to make choices because of a lack of 
information. 
I think another issue that' s important right now in 
women's health, if I take off my hat as a clinician and put 
on my hat as an ethicist, is that the pregnant woman is 
becoming a moral battleground. The case of Mrs. G., the 
native woman in Manitoba who was arrested because of 
her solvent addiction, has really shown the moral issues 
that we're grappling with right now in Canadian society, 
such as the rights of the fetus and the right to compulsory 
medical care. I think that we have to be doing these moral 
explorations in advance of pregnant women getting into 
those types of situations. I chair the Socie ty of 
Obstetricians and Gynaecologists' ethics committee and 
we try to stay ahead of these questions but it's very 
difficult. In reproductive medicine, there's a tremendous 
amount of issues and there are many complex situations 
that women can be put into. 
In general, prevention is a very important part of 
women's health, and one area that' s important with 
respect to prevention is sexually transmitted diseases. In 
the age of the birth control pill, condoms are used less and 
probably with less proficiency than previously. It is 
difficult for young women to ask their partner to use 
condoms when he knows that she is on the pill. When a 
young woman asks her partner to use a condom, she feels 
that she is risking the relationship and will often chance 
that he is not carrying HIV I gonorrhea / herpes or any 
other potentially harmful organism rather than risk the 
relationship. We must educate on this issue, even starting 
in primary schools, to explain that if you care for someone 
you must protect them, and that includes using barrier 
methods even if pregnancy is prevented through the birth 
control pill. I think that sexual education programs run by 
health care students in high schools are extremely 
valuable, both for the high school students and the health 
care students. This way, health care students learn the 
importance of prevention and gain the interpersonal skills 
that will make them more communicative caregivers in 
the future. 
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ETHICS 
EDITOR: D AVID J. SATIN 
AN EDITORIAL: 
FEMALE GENITAL MUTILATION AND CULTURAL 
RELATIVISM 
As the Ethics Editor, I have chosen to write an 
editorial on a subject raised by an interesting paper 
which appears elsewhere in this issue entitled, "Female 
Circumcision or Genital Mutilation: a Rational 
Approach", written by Reena Bhargava & Lubna 
Tirmizi. I employ female genital mutilation as an 
example of the interface between Cultural Relativism 
and 'Women's Issues' at large. 
I t is often difficult to question the ethical legitimacy of harmful norms around us, for it is usually only violations of norms, rather than norms themselves, that 
draw that kind of attention. At the crossroads of such 
fields as political science, anthropology, sociology, and 
ethics lies a debate over Cultural Relativism. As its name 
suggests, in a moral context this doctrine implies that "the 
moral code of a society determines what is right within 
that society, and it is mere arrogance for us to try to judge 
the conduct of other peoples." 1 Evidence often cited in 
support of Cultural Relativism includes the disparity of 
ethical judgements about various acts throughout the 
many cultures of the world. Cultural Relativism has in 
turn been used as an ethical defense for many of these 
acts, among them the practice of female genital mutilation 
(FGM).2 
To better understand the overall strategy of this work, 
that is analysing and relating token phenomena such as 
FGM to types supported by Cultural Relativism, consider 
the following analogy: From a valley, many rivers may 
seem unconnected, yet upon ascending a mountain these 
same rivers can be seen as parts of a network. Similarly a 
number of physical phenomena such as planetary motion 
and pendulum clocks conceived of as unconnected on a 
practical level become one in the same phenomenon in the 
context of Universal Gravitation. So too, practical ethical 
debates over FGM, foot -binding, and augmentation 
mammoplasty may be seen as special cases of a greater 
debate over the types of support derivable from Cultural 
Relativism. 
Just as climbing the mountain might help us plan a 
system of dams, ascending to a metatheoretical3 level may 
provide the necessary perspective for one to more easily 
locate, among a general class of cultu ral practices, the 
ethical content of one's own. Lastly, considering how no 
physical change can be effected from a mountaintop, it is 
essential to return to the valley floor to begin construction. 
So it will be important to return to the practical ethical 
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forum of our cultural practices with the insight derived 
from high atop our metaethical mountain. 
ANALYSIS 
"It's how things are" 
One might argue that FGM is morally permissible 
solely on the grounds that it is embedded within many 
cultures - that is, in virtue of its entrenchment in the mores 
of its practitioners/recipients and its virtually unanimous 
acceptance as a way of life.4 This argument is grounded in 
the general principle that social acceptability determines 
morality (i.e. mores == morals). Let us examine how 
consistent this principle is with our intuitions. Slavery was 
a public way of life for many of our ancestors from biblical 
times, through antiquity, well into the twentieth century.5 1 
suspect that few would assert that slavery is morally good 
(or neutral) in virtue of its public and widespread practice. 
ow, if such a temporally and geographically popular 
practice as slavery cannot gain moral support from its 
cultural entrenchment, surely FGM cannot expect such 
similar support. But the Cultural Relativist is not yet 
forced to retract on this account, for she may still point out 
the temporal disanalogy between FGM and slavery. 
The Cultural Relativist and proponent of FGM may 
argue that slavery is no longer a publicly supported 
practice while, in many places, FGM certainly is. 
Therefore, it is open to this proponent to claim that a given 
practice may be justified for the period of time in which 
that practice is publicly condoned and commonly 
performed. That is, unlike slavery, FGM is morally 
permissible because it is presently entrenched within 
many cultures. Let us examine the implications of such a 
principle. If we grant that a practice is morally permissible 
because it is presently accepted within a culture, then we 
must also grant that slavery was morally permissible in 
early twentieth century America. Similarly, we must 
accept that Apartheid was a just policy in the South Africa 
of the nineteen-eighties, and if you happened to be living 
in WWll Berlin you would be mistaken in assertiJ;l.g that 
azism is wrong. Furthermore, in granting the Cultural 
Relativist's updated principle we must accept that 
whatever practices are currently entrenched is how things 
ought to be ... at very best, an uncomfortable position 
indeed. If one wishes to justify FGM on cultural grounds, 
one had better have more of a story to tell - and the 
Cultural Relativist certainly may. 
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"It works for us" 
The Cultural Relativist and proponent of FGM might 
argue that perhaps certain cultural practices have 
powerful functional roles in societies. This functional role 
may be cashed out in two ways-physiologically and 
psychologically. What I call the physiological role aims to 
justify FGM on the grounds that it has an overall 
physiological benefit for the population (e.g . lower 
incidence of STDs). As the physiological 'success' of a 
given practice is largely a contingent fact, I will grant the 
possibility of a society in which, through some mechanism 
unknown to me, FGM results in a net physiological benefit 
to the overall population. I therefore offer the following, 
standard, 'in principle' counter-argument to the intuitive 
defensibility of such an attractive social arrangement. 
The structure of this hypothetical physiological 
argument is as follows: practice X, which is harmful to a 
given segment <p of population r, ultimately results in 
greater physiological health for population r, thereby 
justifying practice X.6 This argument is grounded in a 
na!ve utilitarian principle that achieving ' the greatest good 
for the greatest number' justifies acts which, in 
themselves, harm individuals. Consider H.J.McCloskey's 
1965 counter-example, highlighting the injustice inherent 
to a practice which harms individuals for the purpose of 
the good of society: 
Suppose a utilitarian were visiting an area in which 
there was racial strife, and that, during his visit, a 
Negro rapes a white woman, and that race riots occur 
as a result of the crime, white mobs, with the 
connivance of the police, bashing and killing 
Negroes, etc. Suppose too that our utilitarian is in the 
area of the crime when it is committed such that his 
testimony would bring about the conviction of a 
particular Negro. U he knows that a quick arrest will 
stop the riots and lynchings, surely, as a utilitarian, he 
must conclude that he has a duty to bear false witness 
in order to bring about the punishment of an innocent 
person.7 
If one is swayed by the intuition that it would be 
unjust to harm an innocent individual for the good a 
larger group, then one cannot employ the physiological 
argument in defense of social practices that are harmful to 
a segment of the population-lest one sanction injustices. 
The second role, the psychological role, can be 
presented as justification for practices like FGM on the 
grounds that the population gains psychological comfort, 
stability, and a sense of identity through the maintenance 
of culture. This argument, potentially confused with the 
next argument, falls prey to the same counter-argument as 
the physiological argument. 
"Every thing has a right to self-preservation" 
Justification via a 'social argument' is practically 
orthogonal to the 'psychological argument'. One might 
argue the very existence of a given society is dependent 
upon its particular set of practices. The continuity of 
cultural practices is, ipso facto, a constitutive property of a 
society.8 A 'social argument' in support of integral cultural 
practices (harmful or not) can be extracted from the 
judgement Lord Nelson rendered at the infamous British 
criminal case of R. V. Brown.9 As part of his judgement 
Lord Nelson constructed the following analogy, 
essentially outlining the 'social argument': A society, like 
an individual, has the right to defend itself against danger. 
Just as societies typically reserve their highest penalty for 
treason so as to insulate themselves from foreign attack, so 
too must a society defend against attack from within. 
Manipulation of integral cultural practices constitutes a 
form of treason, for the alteration of these specific 
practices effectively destroys the old society, replacing it 
with a new one. Just as an invasion of Britain by France 
would bring an end to 'British society', replacement of 
typically British practices by 'Neo-British' practices would 
bring about a similar 'social extinction'. 
A Cultural Relativist and proponent of FGM may 
employ this argument to say that FGM is just such an 
integral part of many of the cultures in which it is 
practiced. Furthermore, since each culture has a right to 
protect itself to ensure its survival, maintenance of its 
integral practices, including FGM, is a right. To answer the 
challenge of the 'social argument' we must once again 
return to the slavery analogy. Slavery was an integral part 
of many cultures, including North American. Today we 
look upon slavery unfavorably and openly express 
approval at this change of sociocultural practice. Societies 
are composed of individuals, and just as individuals can 
commit injustices, so too can societies. 
Societies are dynamic entities . Today' s Canadian 
society is markedly different from that of one hundred 
years ago, yet would any of us liken this transformation to 
treason? Who among us views our great innovators of art 
and science as public enemies? Changes in sociocultural 
practices can be beneficial or detrimental to a population. 
There is no reason to believe that the most static society 
ought to be the most ethical. Societies are composed of 
people and it is people that have rights - not practices. 
People have the right to stay the same and people have the 
right to change. The choice to exercise one's rights will be 
the focus of the final culturally relativistic argument we 
will consider. 
"But we choose it" 
The Cultural Relativist and proponent of FGM may 
argue that respect for choice distinguishes practices like 
FGM from those like slavery and that by choosing a 
harmful practice one effectively justifies the practice. The 
Cultural Relativist might phrase the argument as follows: 
An individual may freely choose X, and just because X 
reflects a preference for their culture (not yours) doesn't 
allow you to say that they shouldn't choose X. I will once 
again grant the proponent of FGM the strongest possible 
case. That is, a situation in which a woman, old enough to 
make an informed choice, chooses FGM and quite happily 
celebrates her culture through practice. The proponent of 
FGM may now ask what could be unethical about such a 
scenario. 
To properly address this argument we must first ask 
ourselves what could motivate a person to choose to 
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undergo such a harmful procedure. The answer, in this 
scenario, clearly reads that she does so as a "celebration of 
her culture through practice". Before responding to this 
answer, let us consider analogous practices from other 
cultures. For a millenium, many Chinese women 'chose' 
to bind their feet, enduring pain and incapacitation in the 
name of fulfilling their cultural heritage. Eighteenth 
century English women 'chose' to wear tight corsets, 
restricting a range of physiological functions and inducing 
bouts of fainting, for that was their culture. 10 These 
practices have several things in common with FGM. Most 
saliently however, is the way in which each is a 'chosen' 
practice, yet the social penalty for choosing to forego the 
practice is typically heavy indeed. 
Nonconformity is frowned upon in most societies and 
the coercive force of one's society is often unparalleled in 
one ' s experience. Coercion can be a subtle process, 
especially when it is endemic. This may help explain why 
it is so easy to see the harmful practices of other societies, 
yet so difficult to note them in our own. In many societies, 
'choosing' to forego a social practice carries stigma, 
thereby decreasing one's ability to succeed within those 
societies. We can imagine how an English woman's choice 
to forego a corset would certainly have lowered her social 
status, thereby diminishing her chances of marrying 
successfully, bearing children, and establishing the kind of 
life many expect. The basic drive for social acceptance and 
procreative opportunity may certainly constitute ample 
motivation for conformity. 
Returning now to our woman's choice to undergo 
FGM, we must ask if the conditions for an uncoerced, 
informed choice are present. Would she choose FGM were 
there no social penalties associated with foregoing the 
procedure? Would she prefer a society in which she could 
celebrate the non-harmful aspects of her culture? Recall 
that our analogous Chinese and English women, 
immersed within their culture, may have been looking 
forward to their respective practices since childhood. We 
can however, imagine how these physically harmful 
practices come to be identified with the social successes 
they entail. 
From the many judgements of the R V. Brown case 
alluded to earlier, comes the principle that there are 
criminal acts that cannot be decriminalized by consent 
(e.g. irrespective of consent, it is illegal to duel to death or 
dismemberment}. 11 So it is, I propose, with the morality of 
harmful acts which cannot practically be chosen freely (i.e. 
free of coercion). The Cultural Relativist may argue that 
each culture provides its own unique brand of pressure 
and no choice made within the context of a society can 
truly be free from the coercive force of that society. Few 
would debate this virtual tautology. Nevertheless, when a 
society places a segment of its population in a position 
where they must make a choice regarding a personally 
harmful practice, of which the sole justification is the 
choosing of that practice for sociocultural benefit, the tight 
circularity of justification renders the entire system 
suspect. We are thus lead to ask, "Why must a segment of 
a population suffer harm for a sociocultural benefit 
enjoyed by all?" 
It seems as though there might be an inequality of 
sorts built into the system. There may, however, exist a 
Ethics 
society in which all segments of its population make 
similar uncoerced, informed sacrifices for the sociocultural 
benefit of all. 12 While it would thus seem that there is a 
logical space in which practices such as FGM may be 
justified on culturally relativistic grounds, one must 
eventually descend from the metaethical mountaintop 
and ask if such a hypothetical society actually exists. 
While the actual existence of this hypothetical society 
seems at best implausible, I must defer such research to 
anthropologists. 
COMPLEMENTARY CONSIDERATIONS 
As I've alluded to earlier, while our intuitions may 
speak to us strongly about practices from which we are far 
removed, (e.g. slavery, Apartheid, Nazism, foot-binding, 
and corsets) it is the practices which surround us that we 
are least likely to question. Having pitted (what I hope has 
been) a complete set of culturally relativistic defences for 
FGM against the aforementioned counterexamples, one 
might just as well substitute a number of North American 
practices for FGM. Prescinding from matters of degree, if 
North American readers were under the impression that 
FGM is the kind of practice that could never happen here, 
perhaps we ought to reconsider. 
In order to uncover some North American candidates 
for "harmful practices, the sole justification of which is 
sociocultural", one need only ask members of another 
society.13 They might suggest that we address, as seriously 
as FGM, the following questions: Considering the 
immensely coercive force of the North American media 
and our social infatuation with a given body image, how 
might we justify the prevalence of cosmetic breast 
implants for the otherwise healthy woman? How can we 
explain the prevalence of such an immediately painful 
and eventually harmful practice as bulimia? From the 
mountaintop, one might group these phenomena under 
the heading of 'harmful practices which improve social 
standing'. Subjecting one's own practices to scrutiny 
comparable to that of FGM may indeed allow for a more 
introspective approach to not only FGM, but to one's own 
values as well. 
CONCLUSION 
Cultural Relativism is defensible insomuch as Ethical 
Subjectivism is. There is nothing to stop a person from 
valuing inequality, oppression, or slavery. However, 
within this work I have argued that if one's core values 
include equality and fairness, then barring the 
aforementioned hypothetical society, one cannot defend 
practices like FGM through Cultural Relativity. I have 
grounded these arguments in intuition through analogy 
and in principle via analyticity. I began by noting that it is 
often difficult to question harmful norms that surround 
us. Perhaps even more difficult for physicians, is 
returning from the mountaintop to act in accordance with 
one's beliefs, especially when they are contrary to social 
norms. Mohandas Gandhi proclaimed, "In matter of 
conscience, the law of the majority has no place."14 There 
may be no place where such wisdom is more applicable. 
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MEDICINE ON THE INTERNET 
EDITORS: ANAND PANDYA & MUNSIF BHIMANI 
A LOOK AT WOMEN'S HEALTH ON THE INTERNET: 
There are a number of excellent resources on the World Wide Web related to the topic of Women's Health. By no means can a single article capture the 
vast amount of information that is available at a few clicks 
of the mouse button. From the riches of the Internet, I offer 
the following selections for your perusal. 
Women's Health Interactive (WHI) 
http://www.womens-health.com/ 
This site provides comprehensive resources for 
patients and health professionals alike. Of note are the 
WHI Health Centers that are designed to facilitate patient 
education on issues like gynecology, cardiac health, 
infertility, (peri) menopause, and nutrition. As well, web 
surfers can tap into WHI's lis t of current consumer 
research studies, indices of women's service providers, 
and on-line discussion forums. This award-winning site 
strives to be " an unique and interactive learning 
environment where women gain knowledge and mastery 
of their health through the multidisciplinary resources." 
Definitely worth checking out and potentially a useful site 
to refer to your more net-savvy patients. 
Women's Health & Medical Info 
http://www.cbull.com/health.htm 
It is not exactly Yahoo!, but this site delivers 85+ 
kilobytes of links on online women's resources "for your 
mental and physical health and well being." This site was 
created after over a year of searching for women's health 
and medical sites on the Internet. There is nothing fancy 
here, but a straightforward alphabetized list of links to 
medical sites that might even be slightly related to 
women's health. This site is an offshoot of the "Best Sites 
For Women" web site {http:/ / www.cbull.com) authored 
by Claire Bull. Be warned that there is a lot of content 
here, so if you're looking for something specific in a hurry, 
this might not be the best place to start. 
The American Medical Women's Association 
http://www.amwa-doc.org/ 
The American Medical Women's Association is an 
organization of over 10,000 female physicians and medical 
students "dedicated to the care of the woman patient and 
serving as the unique voice for women's health." This web 
site focuses mainly on the AMW A itself- annual meetings, 
committees, programs, projects, etc. However, if you're 
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looking for information on health topics, scroll down the 
main page to the little graphic of the red cross. It links you 
to a series of online documents geared towards educating 
the public. Although they are well laid out, the graphics 
are nothing to get excited about. I found some of the 
documents a little simplistic, but very effectiv e at 
conveying the key messages that are fundamental for 
patients. 
Medscape Women's Health 
http://WomensHealth.medscape.com/Homerfopics/ 
WomensHealth/WomensHealth.html 
I was first introduced to Medscape 
(http: / / www.medscape.com/ ) a while ago through the 
advice of a colleague, and I've been hooked ever since. 
From the makers of what is probably the #1 medical site 
on the Internet, this page does not disappoint. While many 
sites on the topic of Women's Health have a greater 
patient-education focus, Medscape's page delivers the 
information physicians are looking for. New articles 
relevant to areas of women's health are posted daily with 
access to full-text journal sources. In addition, there are 
case challenges, clinical quiz questions, and the "virtual 
consult" where peculiar but interesting cases are laid out 
by the experts. 
JAMA Women's Health Information Center 
http://www.ama-assn.org/speciaUwomh/womh.html 
This is another excellent resource for physicians and 
health professionals looking for recent and accurate 
information. The clear and simplified layout lets this page 
load up lighting-fast, and enables you navigate the site 
with ease. The Newsline gives you updates from Reuters 
Health, special in-depth articles from major professional 
sources, and coverage of key conferences from around the 
world . Regularly posted Journal Scans keep tabs on 
women's health articles that appeared in the literature, 
presenting abstracts organized by categories including 
adolescent health, breast cancer, menstrual cycle, and 
recurrent pregnancy loss to name a few. Full text articles 
from AMA scientific journals are also available, 
potentially saving one the bother of a full subscription. 
Also of note are the STD and Contraception Information 
centers. Don' t let the initially spartan appearance of this 
site fool you, there is a lot of information available once 
you make just a few simple clicks. 
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And finally ... 
When dealing with sensitive issues related to 
Women's Health, health care professionals have to be alert 
that increasing proportions of their patient population will 
be referring to sites such as these prior seeking medical 
advice. Many even prefer the autonomy and self-reliance 
of being able to access such information on their own time. 
It is helpful to keep an eye out for what information (and 
misinformation) is floating around the information 
superhighway, so that one can help direct patients to 
authoritative sources. Furthermore, letting patients do 
their own reading on the Internet is not only better for 
their ability to process information at their own pace, but 
will likely help to decongest some of the busy schedules 
practitioners face everyday. 
As always, the sites mentioned in this article, and 
others on the subject, can be found in the Medical Links 
database of the Meds2001 Web Site 
(http://meds2001.garage.org/), under the "Women's 
Health" subject heading. Q 
Southwestern Ontario 's Leading Centre for Patient 
Care, Teaching and Innovation 
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MEDICINE LAW 
EDITORS: NA]IB SAFIEDDINE & MAHMOUD SHARAF 
INFERTILITY TREATMENTS 
WOMEN'S HEALTH 
AND 
INTRODUCTION 
The last decade has seen a rapid increase in the 
number of techniques and treatments available to non-
fertile couples for having children. Unfortunately, and 
perhaps quite predictably, legislation has not kept pace 
with medical science. Canadian family law finds itself in a 
situation of great delicacy as it searches for guidelines that 
will prevent the litigation nightmares now common in the 
United States. However, just as important as the custodial 
issue is the item of women's health. 
THE RO YAL CO MMISSI O N 
REPRODUCTIVE TECHN OLOGIES 
O N NEW 
The Royal Commission on New Reproductive Technologies 
(1993) issued a final report that proposed several 
recommendations to standardize and simplify Canadian 
law on assisted conceptions . Some of the proposals 
included: 
1. That the donor's rights and responsibilities of 
parenthood are severed by the act of sperm donation; 
2. That the male partner of the donor insemination 
recipient, if he has given his written consent at the 
time of insemination, be considered the legal father of 
the child; 
3. That the married or cohabiting male partner should 
only be able to disavow paternity if he did not consent 
in writing to the insemination; or he did not enter into 
a parental relationship with the child knowing he was 
not the genetic father; if he had acted as a father to the 
child only because he believed he was the genetic 
father of the child; 
4. That if the legal mother of the child has no male 
partner, the child has the legal status of " father 
unknown''; 
While providing valid recommendations pertaining to 
legal custodial issues, the Royal Commission has not fully 
addressed the im~lications of infertility treatments on 
women's health. This comes despite critical input 
provided by the Canadian Advisory Council on the Status 
of Women in their brief to the Commission.2 Specifically, 
o varian induction is an infertility treatment that 
constitutes a possible health risk that was not seized upon 
by the Commission. 
HEALTH RISKS 
Many women faced with infertility are treated with 
ovulation inducing medicines. However, evidence has 
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raised concerns about the possible risk of ovarian cancer.34 
Agents such as human menopausal gonadotropin (hMG), 
follicle stimulating hormone (FSH), and FSH analogues 
are not without certain " toxic" consequences. Ovulation 
induction can lead not only to higher incidence of 
spontaneous abortions, but also to diseases such as 
ovarian hyperstimulation syndrome (OHSS) which results 
in the secretion of supraphysiological levels of estradiol 
and severe health complications, possibly requiring 
hospitalization.5 Ovulation stimulation drugs have been 
associated with hot flashes, multiple gestations, visual 
disturbances, and cervical mucous abnormalities. 
Thromboembolic disease is also suspected to arise from 
OHSS.6 Evidence suggests that such treatments affect the 
proliferation of epithelial breast cells and thus add to the 
risk of breast cancer? 
Although some of these risks have not yet been 
absolutely confirmed to be the sole and direct result of 
infertility treatment, and research is still underway, the 
possible risks are too grave to ignore. This necessitates the 
intervention of the legal system to address the issue 
immediately. 
CONCLUSION 
In the past, the Food and Drug Act has empowered the 
federal government to intervene in blocking potentially 
risky drugs and therapies from being used in Canada until 
properly studied and validated. It is necessary for Canada 
to uphold its strict tradition of rigorous evaluation of new 
drugs and therapies, particularly when it comes to 
reproductive health. The Canadian courts and the public 
have shown a firm expectation that government and 
business must not only prevent clear obstacles to national 
health and safety but also anticipate them. In Hollis v. Dow 
Corning, a case of silicone breast implant liability, the 
Supreme Court confirmed legal responsibility of the 
manufacturer despite little evidence at the time of the 
inherent danger. In New Brunswick, the provincial 
government was held liable for the adverse effects of DDT 
pesticide use after the fact despite no convincing evidence 
at the time. The ethical-legal principle of government 
exercising due care for the health of the population at the 
stage when treatments are only potentially problematic 
should be appealed to. The urge to provide the choice to 
infertile women to have children if they so desire can only 
be outweighed by concern for their health and safety. 
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HISTORY OF MEDICINE 
EDITORS: SUSANNA YANIVKER & VADIM SHERMAN 
WOMEN & INFERTILITY: 
A HISTORICAL PERSPECTIVE 
I s infertility on the rise because women are delaying childbearing in pursuit of career success? Does it affect white women more than African-American women, or 
the rich more than the poor? Has infertility reached 
epidemic proportions among the educated and affluent? 
Most would answer yes to these questions-and most 
would be wrong. 
The erroneous idea that current infertility rates reflect 
a new phenomenon in orth American society provides a 
di s torted image of the present and obscures the 
relationships between contemporary ways of coping with 
involuntary childlessness and those of past generations. 
For example, in the seventeenth century few women 
would have considered seeking medical advice as 
infertility tended to be viewed as the will of the Lord or 
the work of the Devil.2 By the late nineteenth century, 
physicians were performing surgery, such as ovarian 
transplantation, in an attempt to restore fertility. 2 The late 
twentieth century has seen the development of in vitro and 
related reproductive technologies that have increasingly 
severed reproduction from sexuality. Thus, throughout 
the last three centuries, the inability to procreate has been 
medicalized--converted from a socio-religious state into a 
medical condition. 
ln addition, the approach to infertility, whether 
his torical or contemporary, accommodates a persistent 
gender bias: the tendency to view women's bodies as 
inviting intervention and men's as demanding caution. 
This bias is manifest in relation to the form of medical 
investigations and infertility therapy, and in the 
enthusiasm and frequency with which they are 
performed. This is exemplified by the fact that historically 
many fertile women have been subjected to invasive, often 
dangerous procedures, in order to enhance the capabilities 
of a partner's weakly motile sperm. 
Such relationships will be explored by examining the 
ways in which the inability to conceive has been treated by 
medical practitioners, perceived by society, and experienced 
by individuals from the 17th through to 20th century. 
From the 17th to the early 19th century, popular and 
medical opinion alike held that female sexual pleasure 
w as almost always essential for pregnancy to occur. u 
According to Etmuller the "languishing" of a woman's 
"venereal appetite" often caused barrenness.1.3 Mauriceau 
went so far as to cite "the insensibility of some women, 
who take no pleasure in the venereal act as the most 
frequent reason why this orifice opens not in this act to 
receive the man's seed" .3 Men on the other hand were 
only held accountable if they were impotent or in some 
way "unable to perform their marital duties".2 
Therefore, barrenness was a woman's problem, and 
self-treatment was the usual means employed to alleviate 
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it. American women kept medicinal recipe books which 
often contained specific preparations to treat various 
menstrual irregularities that were believed to cause 
barrenness and that could also be used for the prevention 
of miscarriage. If self-treatment failed, a woman might 
have consulted a midwife, who would have prescribed 
various botanical prepara tions. 1.2 
The first steps towards the medicalization of infertility 
began with James Graham (1745-1794). Graham, 
something of a maverick, built a fortune with his 
ingenious linkage of sexual pleasure to electrotherapy in 
order to cure sterility.4 On his return to Great Britain in the 
late 18th century he constructed the "Temple of Health" in 
London. Here an audience of men was seated in chairs 
that provided mild electrical shocks (coined "magnetic 
thrones") while listening to Graham lecture on potency. 
Women who came to the temple heard lectures on fertility 
given by a member of their own sex.4 The well to do had a 
further option -Graham's vibrating "celestial bed". The 
"superior ecstasy which the parties enjoy in the Celestial 
Bed", promised Graham, was "really astonishing ... the 
barren certainly must become fruitful when they are so 
powerfully agitated in the delights of love".4 The bulk of 
his audience, no doubt, came to the Temple to be titillate 
by the mild electrical shocks or by the lectures themselves. 
In fact, it was hard for his contemporaries, as it has been 
for generations since then, to take Graham seriously.4 
In the 1860's and 1870's technological developments in 
the form of new instruments and surgical techniques burst 
onto the medical scene, thus providing new opportunities 
for seein~, and for reconfiguring the interior of women's 
bodies .2· The use of instrumentation and surgery on 
women's sexual organs became commonplace by the end 
of this period, especially among physicians eager to 
establish themselves as "experts" in an emerging medical 
field . Women themselves, apparently in increasing 
numbers, actively sought surgical treatment, both 
demonstrating the existence of demand for these methods 
and encouraging more physicians to provide them.2 The 
"women's surgeons" of the 1850's and 60's, and the 
women who patronised them, had a profound impact on 
what would become the specialty of gynaecology. 
In terms of the history of infertility, two of the most 
important "women's surgeons" were J. Marion Sims and 
his assistant Thomas Addis Emmett. Both worked at the 
Woman's Hospital in ew York- the first hospital devoted 
exclusively to the surgical treatment of disorders of 
women's reproductive systems. 2 Sims felt that the 
overwhelming majority of the diseases of the female 
reproductive system were structural, and therefore curable 
by surgery. Believing that most dysmenorrhoea and 
sterility resulted from a mechanical blockage of the cervix, 
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Sims thus reasoned that surgery to widen the cervical 
opening should alleviate pain and allow conception. Sims 
and Emmett performed countless "cervical incisions" in 
order to make its opening into the vagina larger. 2 
However, Sims did not consider pregnancy a measure of 
success; rather, women were "cured" if the os was opened, 
the cervical canal straightened, and any of the infections 
that the surgery itself often generated, were alleviated.2 In 
fact, Marsh and Ronner 's historical analysis of Sim's 
records revealed that some women received surgical 
interventions even when they had no obvious symptoms 
that might account for their sterility. Marsh and Ronner 
concluded that much of Sims' surgery for infertility was 
performed to 'correct' what seems to have been normal 
organs.2 However, Sims did succeed in revolutionising 
medical ideas about infertility, and in the process ushered 
in a wave of technological innovation that contributed to 
the rapid emergence of the field of gynaecology. 
A number of societal trends following the Civil War 
resulted in a decreased birth rate, and as more women 
pursued higher education and careers, the people's views on 
the aetiolo~ of sterility centred on women's 'inappropriate' 
behaviour. ;s Harvard physician Edward H. Clarke's 1873 
"Sex in Education" argued that young women were 
educating themselves into sterility. He believed that young 
women should not be putting in long hours of studying 
difficult academic subjects, but should instead learn slowly 
and completely, and rest their minds during their menstrual 
periods. Education, he stated, had a "sterilizing influence" on 
young women and in another generation, "the race will be 
propagated from its inferior dasses".6 
By the end of the century, new ideas and evidence 
began to suggest that infertility, rather than resulting from 
women's refusal to bow to conventional behaviour, could 
be accounted for by more specific physiological disorders, 
particularly of the ovaries and fallopian tubes. Perhap the 
most important single factor in accomplishing this change 
was the dramatic alteration of medical views of 
gonorrhea.2 As practitioners began to accept gonorrhoea 
as a cause of sterility, they were forced to give more 
attention to the existence of infertility in males. By the end 
of the century, the idea of semen examination took hold 
among a number of the field 's prominent practitioners 
(although it did not become a routine part of arriving at a 
diagnosis of infertility until the 1950's).2 The realisation 
that men could be sterile marked an important shift in 
attitudes among gynaecologists. 
The discovery of estrogen in 1923 and progesterone in 
1929, coupled with the newly discovered intricacies of 
ovulation and implantation, marked the beginning of a 
journey that led to the creation of the birth control pill, the 
infertility drugs pergonal and clomid, and successful in 
vitro fertilization. 5 Fertility (and infertility) in women 
could now be understood and, in some cases, treated. 
The period from the 1960's to 80's illustrates some 
new dimensions of some aspects of infertility. After 1965, 
birth rates would begin to plunge and larger numbers of 
couples would choose to be childless; at the same time, 
dramatic advances would occur in the ability to treat 
infertility effectively.2 Attitudes towards the infertile were 
also changing as antinatalist sentiments challenged the 
pronatalist consensus that had held sway among the post-
war generation. Instead of sympathy, in the 1970's women 
feeling anguish over their inability to have a baby might 
be reminded that pregnancy was unattractive or that the 
world was overpopulated anyway?·9 Such opinions did 
not, of course, diminish the desires of the involuntarily 
childless. And despite fears held by advocates of the 
'traditional' family, a feminist movement that enabled 
more women to attend university and succeed in careers 
did not inevitably create a generation of women 
antithetical to motherhood.2 
This change in attitude is perhaps best illustrated 
using in vi tro fertilization as an example: what was 
heralded to be a technological miracle in the 40's, was a 
morally questionable endeavour in the 60's and had 
become a veritable political minefield by the 70's? In fact, 
by the mid 70's the Right to Life movement had succeeded 
in shutting down American IVF experimentation . 2 
However, work continued in England where Cambridge 
University physiologist Robert Edwards and gynaecologist 
Patrick Steptoe performed at least 80 in vitro fertilizations 
before they effected the first successful implantation} thus 
heralding the ultimate separation of the sexual and 
reproductive acts. The first test-tube baby, Louise Brown, 
was born on July 25, 1978 in Bristol, England.2 
Present day technologies such as achieving pregnancy 
post-menopausally, the possibility of harvesting and 
freezing sperm post-mortem, and breaking the genetic tie 
between mother and child through the use of donor eggs, 
are among the practices that have made IVF controversial. 
In addition, the daunting prospect of cloning babies is 
now more than ever a possibility. Such new techniques 
have further subverted the link between sex and 
reproduction and challenged traditional verities. One 
must remember that the desire to use these techniques, 
like those employed in the past to assist infertile women to 
conceive, is socially and culturally conditioned . 
Employing a historical perspective contributes to one's 
understanding and evaluation of the assumptions about 
the roles of reproductive technology that underlie the 
controversy over its use. 
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UNWINDING THE SNAKES: 
REDISCOVERING THE TRUE SYMBOL 
OF MEDICINE 
While medicine has been associated with ~erpent symbolism since humanity began recording the art, most authorities agree that the Aesculapian 
staff is the true symbol of medicine. Although seen 
frequently, few people are aware of its historical origins, 
and its relation to the profession. If the Aesculapian staff 
(around which one serpent) is entwined is the correct 
symbol, why then is the caduceus of Hermes (around 
which two serpents are entwined), so frequently adopted 
as the symbol of medicine? And is the caduceus an 
appropriate symbol for the medical profession? This paper 
will explore these questions. 
AESCULAPIUS AND HIS STAFF 
Homer, in the flliad, mentions Aesculapius only as a 
skilful physician; in later times, however, he was honored 
as a hero and eventually worshipped as a god. The first 
mention of Aesculapius occurred in a Greek inscription 
recording the establishment of an Aesculapian shrine in 
Athens in 420 BC. Aesculapius was the son of Apollo, the 
primary god of healing in the Greek pantheon, and the 
maiden Coronis. During his lifetime, Apollo passed along 
his knowledge of medicine to Chiron, the son of Saturn. It 
was Chiron who later helped to raise and instruct 
Aesculapius in the art of healing using herbs, potions, and 
incantations. 1 Further to the legend, after Perseus had 
beheaded Medusa, Athene directed young Aesculapius to 
extract blood from her headless body. Blood from her left 
side was lethal to the touch, while blood from her right 
side possessed unique powers to resurrect the dead.2 With 
these new therapeutic resources, Aesculapius now 
achieved notable clinical successes, albeit in small non-
randomized control trials. 
Aesculapius became so proficient in healing that he 
soon surpassed his master. .Furthermore, his powers 
became so well-known that people came from all over 
Greece to see him . Aesculapius was frequ ently 
represented in statues standing dressed in a long cloak. 
His two most important attributes began appearing 
together towards the end of the 4th century BC in the form 
of the Aesculapian staff, with a single serpent coiled 
around it. And, unlike the caduceus, its meaning seems to 
have developed from a utilitarian standpoint rather than 
as a sign of position or authority. 
The snake itself has both a practical and metaphorical 
meaning. The snake has always been considered sacred 
and worshipped for its representation of wisdom. It also 
came to symbolize the gods of fertility and since it could 
shed its skin, it was thought to possess powers that 
enabled it to live forever . Physicians in earlier primitive 
cultures thus ate snakes, believing they would become 
more efficient healers.3 Aesculapius' later association with 
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the serpent resulted from an incident that occurred while 
he was in the house of a patient. Tradition states that 
while he was deep in thought, a snake coiled itself around 
his staff. He killed the snake and then another one 
appeared with an herb leaf in its mouth and restored the 
dead serpent to life. 4 As a result of this incident, 
Aesculapius kept non-poisonous snakes in temples to help 
heal the sick. In addition, the species of snake found on his 
staff, Elaphe longissima, became an integral part of the 
temples later built in his honour. Because of its natural 
diet of rats, the priests used it as a biological pest control. 
As they became a more prominent fixture, they began to 
play an important part in the rituals of the temples.5 
The staff, the other symbol associated with 
Aesculapius, was adopted as a symbol of sovereignty in 
Egyptian and Sumerian cultures. While it denoted power, 
the emblems attached to it were associated with the god 
under whose name it was cast.6 The staff symbolized plant 
growth and was associated with both death and 
resurrection of the dead. In this regard, the staff was very 
much like the snake shedding its skin. Both indicated that 
life was everlasting. The sturdy nature of the staff may as 
well be seen as the traveller's staff, reminding us of the 
long journeys of Aesculapius from his home in northern 
Greece throughout the Hellenic world. It thus symbolizes 
the inexhaustible willingness of the physician to travel 
long and wearisome journeys to help the sick.7 . 
Aesculapius became recognized as a god because, m 
ancient Greece, it was believed that anyone who recovered 
from an illness was regarded as being resurrected from 
the dead. On one occasion Aesculapius is said to have 
raised a man from the dead and delivered him from 
Hades, a privilege reserved for the gods. Because of this, 
Pluto accused Aesculapius of diminishing the number of 
souls in Hades. An enraged Zeus, fearing that Aesculapius 
might make all men immortal, slew him w~th _a 
thunderbolt.8 Before his death, however, Aesculap1us 1s 
said to have sired six children. Two of his daughters were 
Hygeia and Panacea. The beautiful Hygeia was the 
goddess of health and preventative medicine; Panacea 
assisted her sister in the temple rites and tended the 
sacred serpents. Aesculapius' two sons, Podalirius and 
Machaon, were both physicians to the Greek armies 
besieging Troy. (llliad II, 645-8) 
The cult of Aesculapius originated in Thessaly where 
he was worshipped as a healing saviour, and quickly 
spread throughout Greece . The healing practices of 
Aesculapius were passed down from father to son, each 
generation being recognized as Asklepiads or healing 
priests. The name itself is interpreted to mean "hea~g 
soothinF,lY and deferring the withering that comes w1th 
death." They practiced their skills in magrrificent temples, 
24 
------------------------ U. W .O. Medica/Journal 68 (1)1 999 
built in honour of Aesculapius . These temples are 
generally acknowledged as the origins of hospitals. In 
these temples, wounds were dressed and sanitation and 
preventative medicine were rcracticed and taught, 
intertwined with religious rituals. ° For the ancient Greeks, 
medicine and religion were inseparable. Over time more 
than 200 asclepia were built throughout Greece, the 
greatest at Epidaurus, where the theatre seated 20,000 
persons.11 
Obviously, Greek medicine was rooted more in 
m y thology and theology than in science. It was 
remarkable that the cult of Aesculapius was popular and 
influential throughout Greece for about 1,000 years. In the 
Roman Empire, the worship of Aesculapius was bitterly 
attacked as Christianity gained popularity, though the cult 
surv ived until the 6th century. 1 Secular medicine also 
began competing with ecclesiastical medicine in Greece. In 
his essay The Sacred Disease, Hippocrates, credited with 
the liberation of medical ethics, attacked the theory that 
illness is caused by the gods, and claimed that all diseases, 
including epilepsy, had natural causes. Even Hippocrates, 
however, occasionally advised prayer as an aid. 13 The 
Hippocratic oath begins with the words "I swear by 
Apollo the physician, by Aesculapius, Hygeia and 
Panacea, and I take to witness all the gods, all the 
goddesses .. . ", though some no longer ascribe to it. 
THE CADUCEUS 
The caduceus, the staff around which two serpents are 
entwined, ultimately came to be associated with the Greek 
god Hermes . Hermes was the son of Zeus and Maia, 
d a ughter of Atlas . Graceful and swift, he served as 
messenger to the other gods. Hermes was considered on 
various occasions the god of commerce and merchants, 
messengers, thieves and the underworld deity who 
conducted souls to Hades. The caduceus represents the 
w and of Hermes and connotes his patronage of peace, 
trade, commerce and communication. In the account of the 
origin of the caduceus, it was stated that Apollo gave his 
staff to Hermes as a reward for Hermes' invention of the 
lyre. According to Apollo, the staff had the power to unite 
all beings divided by hate. When Hermes travelled to 
Arcadia, he saw two serpents fighting. With dispatch, he 
threw the staff between them and they wound around it in 
a friendl y manner .14 Wings were later added to this 
emblem as a symbol of Hermes' speed and the caduceus 
w as born. Because Hermes was the messenger of the gods, 
his staff, which came to symbolize authority and peace, 
became the herald's wand in times of war. As warring 
combatants might do today with a white flag as a symbol 
of truce, the Romans expressed their desire fo r 
negotiations with enemies under the caduceus.15 
There are few actual references to healing functions 
attributed to Hermes, although he was a god of 
gymnastics and athletics, and was considered to be a 
guardian of health.16 Hermes played some medical roles in 
that he did assist in conducting the dead to the 
underworld and also received some credit for relieving 
plagues and epidemics in Asia Minor. In peacetime, 
however, Hermes and his caduceus became primarily 
associated with trade and prosperity, retaining their 
wa rtime roles in negotiation and communication . 
History of Medicine 
Throughout Europe before the last century, the caduceus 
was a purely commercial symbol without medical 
connotation. Hermes carried over into Roman mythology 
as Mercury. A good deal of our English language is rooted 
in the commercial connotations of Hermes' function. The 
words "commerce," "merchant," "market," "mercenary," 
and "mercantile" all come from Latin merx or mercis 
(goods) and mercer (to traffic). 
THE MIDDLE AGES AND THE ROOTS OF CONFUSION 
In determining which god more accurately represents 
the medical profession, most scholars agree that 
Aesculapius wins hands down.17 After all, he was the god 
of medicine, healing, and physicians. The caduceus, on the 
other hand, is the symbol of Hermes, who had little to do 
with medicine . Since the Renaissance, however, the 
emblem of Hermes has often been confused with the staff 
of Aesculapius in representing the profession. From this 
unrelated past, how did Hermes and medicine get to be 
bedfellows? 
As noted, although Hermes had little to do with the 
healing arts, his caduceus was adopted as a medico-
pharmaceutical emblem in the 3rd Century, as he became 
increasingly associated with astrology, magic, alchemy, 
theology, and philosophy.18 Meanwhile, the cult of 
Aesculapius fell into disrepute as Christianity gained 
influence and power. Throughout the Middle Ages, there 
was little if any reference to Aesculapius and his staff. 
Resurrection of the image and its adoption as a symbol of 
healing came with the Protestant Reformation and the 
development of humanistic attitudes towards medicine 
and an interest in ancient mythologic and historical 
themes.19 
Ironically, the caduceus was the first of the ancient 
symbols to resurface; it was independently chosen as an 
emblem by two printers of incunabula, Erhard Ratdolt in 
1486, and Johann Proben, who actually did some medical 
printing, in 1518. The caduceus also appeared in the coat 
of arms given to Sir William Butts, physician to King 
Henry VII, at his knighting. Other prominent physicians 
soon chose the caduceus as an emblem. One theory holds 
that the adoption of the caduceus as a medical symbol 
derived partly from the fact that in the 16th and 17th 
Centuries, the fields of pharmacy, chemistry and medicine 
were not clearly defined. The Royal College of Physicians 
of London also had an indirect influence in popularizing 
the caduceus as a medical symbol. John Caius, President 
of the College in 1556, presented ~o the college a small 
"caduceus" to be carried by the President as an ensign of 
honour by which he would be distinguished from other 
Fellows.20 Nevertheless, when the medical writings of the 
great Arab physician Avicennq were published in 1544, 
the frontispiece was decorated with a bust of Aesculapius. 
Other medical textbooks were also decorated with images 
of Aesculapius, but by the last part of the 18th century 
there was a decline in the use · of this symbol by 
publishers. 21 
The caduceus first appeared in North America -
appropriately enough- in an advertisement that appeared 
in the Boston Columbian Sentinel. Josiah Flagg, Jr. was one 
of the first native-born dentists in the United States; he 
used the caduceus in an advertisement on May 26, 1792, 
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and later embellished the caduceus with crossed 
toothbrushes.22 The staff of Aesculapius was first utilized 
by the US Surgeon General's Office in 1818, and wa also 
adopted by the British Medical Corps in the same year. 
Medical historians have questioned the worthiness of the 
caduceus as a logo for the medical profession. 23 Its 
acceptance as such in many parts of the world, especially 
in the United States, is said to have resulted from an 
omission on the part of the US Army in 1856. At that time, 
a symbol was required for medical personnel in the field, 
and as a result the caduceus was adopted by the US Army 
as the insignia for hospital stewards. The caduceus served 
well and in 1902 it was added to the uniforms of US Army 
Medical Corps officers as well. One explanation for this 
decision is that the caduceus is an administrative, not 
medical, symbol; it signifies the neutral, noncombatant 
"messenger" status of these personnel. It seems more 
probable, however, that the caduceus was simply 
confused with the Aesculapian staff which more properly 
symbolizes the healing profession. In 1871, the caduceus 
became the symbol for the US Public Health Service. This 
move legitimized the case of mistaken identity, diverting 
attention from the Aesculapian staff, and affirming the 
caduceus' erroneous association with medicine. As a 
result of such official use, many developing medical 
organizations at the turn of the century incorporated the 
caduceus into their crests. Hence, through the years, either 
the caduceus or the Aesculapian staff have been adopted 
as an emblem by numerous medical organizations. 
ONE SNAKE OR TWO? 
More than a century ago, there was but one symbol of 
the medical profession, and that had held true for 
millennia . However, while confusion between the 
caduceus and the staff as the proper medical symbols runs 
rampant in the US, it is reassuring to know tha t the 
Aesculapian staff outscores the caduceus as a true symbol 
of medicine in places outside the pervasive influence of 
the US Army Medical Corps. Most of Canada's medical 
institutions, including the Canadian Medical Association, 
appropriately incorporated Aesculapius ' staff in their 
emblems, and during the lOth Annual meeting of the 
World Medical Association held in 1956, the Aesculapian 
staff was internationalized. This resolution designated the 
symbol to be used exclusively by physicians and members 
of the medical staff who were not entitled to the protection 
of the Red Cross badge?4 Recently as well, the American 
Medical Association along with other h ealth 
organizations, not wishing to represent themselves with 
the wrong symbol, spurned the caduceus in favour of 
Aesculapius' staff.25 • 
A symbol is supposed to evoke recognition of 
something it is associated with, and the caduceus means 
medicine to much of the public, and- it seems-
increasingly to members of the profession. It may be 
possible that a symbol may modify the thing it is meant to 
symbolize and that medicine as a profession is just now 
catching up to the newer symbol that it had adopted 
within the past century, forsaking the longer heritage of 
Aesculapius' staff. 
In today's social, political, and economic climate, it 
seems that medicine has placed healing somewhere off 
center. The language of medicine is becoming increasingly 
filled with terms like affordable health care, health reform, 
cost control, malpractice, etc., and the list of terms keeps 
growing. As well, the business of medicine is assuming a 
larger importance in the preoccupation of each 
practitioner. In some parts of the US there are more legal 
than medical indications for procedures prescribed in the 
handling of health problems. Advertising is becoming 
almost as prominent now in "capturing" an ever 
increasing "market share" than it was for Josiah Flagg, Jr. 
Indeed, all of these ingredients fit well under Hermes' 
emblem for those trafficking in medicine. 
It is unlikely that the symbolic change induced a 
change in the profession, but it may have changed the way 
physicians view themselves as other pressures and society 
have changed the philosophy and methods by which the 
art of healing is practiced and its relationship to the 
society it serves. We have two significant serpent symbols 
now, and these symbols and the profession for which they 
stand are in competition. However, within the setting of 
increased competition, an image that harkens back to the 
foundation of modern medicine, an image that conveys 
commitment to the healing arts, which is essentially what 
the Aesculapian staff embodies, should be the preferred 
identity for all members of the medical profession. 
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PROMOTION AND PREVENTION 
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ESTROGEN RECEPTOR SELECTED 
MODULATORS (SERMS): 
Their Development, 
INTRODUCI'ION 
M enopause gives two signals to women-its onset marks both the end of their reproductive years and the beginning of potential, chronic health 
concerns. The detrimental health effects of menopause are 
due to concomitant hormonal changes, with the decrease 
in circulating estrogen levels (primarily 17~-estradiol) as 
the greatest threat to postmenopausal women's health 
status. Average circulating estrogen levels in these women 
can fall to less than 10% of premenopausallevels.1 Because 
of the importance of estrogen actions to the maintenance 
of the skeleton and protection of the cardiovascular 
system, such a dramatic decrease in circulating estrogen 
levels greatly enhances the risks for osteoporosis and 
coronary heart disease (CHD). 
Estrogen deficiency leads to increased osteoclast 
activity, through a yet unclear mechanism that is mediated 
by cytokines? Heightened bone resorption rate enhances 
bone turnover, which leads to a net loss of bone mineral 
density. And since breaking strength of bone is directly 
proportional to bone mineral density, decreased levels of 
estrogen increases bone fragility and the risks for bone 
fractures.3 Although various bone fractures can result from 
postmenopausal bone loss, hip fracture is the one of most 
concern because severely compromises the independence 
and quality of life of the affected and leads to increased 
socio-economic burdens. 
Besides enhancing osteoclast activity, low levels of 
estrogen also cause postmenopausal women to have a 
higher proportion of low density lipoprotein (LDL)-
cholesterol, increased fibrinogen and plasminogen 
activator inhibitor (PAI-l), which is an essential antagonist 
of fibrinolysis in humans.3 Such a profile elevates the 
chances for the formation of atherosclerotic plaques and 
blood clots, and conseqt~ently, an increased risk to CHD. 
In the Western world, CHD is the leading cause of death 
in postmenopausal women.4· 5 • 
In order to deal with these serious health implications, 
estrogen replacement therapy (ERT), the administration of 
estrogen or conjugated estrogens to increase circulating 
estrogen levels in postmenopausal women, was 
developed. Its effectiveness towards decreasing the risks 
of bone fractures has been demonstrated in various studies 
since the 1970's.3 However, major concerns arose with 
long-term ERT when unopposed estrogen consumption 
after menopause was shown to increase the risks of breast 
cancer, endometrial hyperplasia and endometrial cancer.1.3·4 
As a result, progestin was adopted as a compliment to 
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ERT because it was found to be able to markedly decrease 
the risks of endometrial hyperplasia and endometrial 
cancer. But concerns remained as the use of hormonal 
replacement therapy (HRT, the combination of estrogen 
with a progestin regiment) for 5 years has been recently 
associated with a 40% increased risk of developing breast 
cancer.6 Because of these associated risks with HRT, many 
physicians have been reluctant in prescribing it to 
postmenopausal women. 1 Given these factors that limited 
its therapeutic and preventative application, HRT required 
modifications and improvements to better manage the 
health problems associated with menopause. 
THE BIRTH OF SERMs 
The search for safer and more effective HRT led to the 
reevaluation of antiestrogens, a group of steroidal or non-
steroidal compounds designed to treat estrogen-
dependent breast cancer via an antagonistic effect to 
estrogen at the estrogen receptor (ER). The reason for 
more extensive research into antiestrogens was that some 
of them displayed tissue-specific agonist/ antagonist 
actions at the ER, as supposed to being pure antagonists. 
Consequently, some of these antiestrogens were 
reclassified as the "selected estrogen receptor modulators 
(SERMS)". Precisely, SERMs are antiestrogens that exhibit 
a mixed estrogen agonist/ antagonist profile1• 5• 7 The ideal 
SERM should be an ER agonist in bone and lipid profile, 
and an ER antagonist in mammary and uterine tissues. 
FIRST GENERATION SERMs 
The first antiestrogen that was termed a SERM is 
tamoxifen ( olvadex®), which belongs to a class of 
chemical compounds known as the triphenylethylenes.3 1ts 
usage in the treatment of breast cancer began in the 1970's 
and is now a part of standard adjuvant therapy.1• 7 The 
tissue-specific estrogen effects of tamoxifen are well 
documented in various clinical trials that assessed its 
potency in preventing and treating mammary carcinomas. 
The agonistic, or estrogen-like, effects of tamoxifen are 
similar to those seen with traditional HRT therapy. Several 
studies involving postmenopausal low-risk breast cancer 
patients, women receiving adjuvant tamoxifen for 
treatment of early s tage breast cancer, and healthy 
postmenopausal volunteers provided evidence that 
tamoxifen has a beneficial effect on bone mineral density 
in the hip and spine.s-10 Tamoxifen also shows favorable 
influences on the lipid profiles of postmenopausal women. 
28 
------------------------ U. W .O. Medica/Journal 68 (l) 1999 
P r omot i o n and Preven ti on 
Table 1. Summary atd Comparison of First Geeration SERMs 1• 7• 11 
1st Generation SERMs 
Tamoxifen 
1st Generation SERMs 
(T 11110xifen Allalogs} 
Original Usage 
-treatment of estrogen-
dependent breast canc:er 
CheMical Structure 
Relative to T 11110xifen 
Estrogea Actions 
-antagonist in breast, 
bone 
-partial agonist in uterine 
tissues 
- agonist in lipid profile 
IIKI'eased Risks 
-endometrial polyps, 
hyperplasia, and cancer 
- liver tumors in rats 
COIIpCirisons willl TCIIIOxife~ 
Toremifene - ethyl side chain chlorinated 
analog of tamoxifen 
-reduced antiestrogenicity and antitumor potenc:y 
-reduced ability to induce rat liver tumors 
ldoxifene 
1st Generation SERMs 
(Derivatives of Tc.oxifee 
Metaboltes} 
-4-hydraxylated 
analog of tamoxifen 
- ability to inc:rease HDL cholesterol 
- inc:reased ontiestrogenicity 
- may hove less carcinogenic potential 
Relative Cllemical Stnctwe eo.p.isolls with Tc.oxift11 
Aside from the antagonistic 
effects of raloxifene in endometrial 
tissues, its actions on mammary 
tissues, skeleton, and lipid profile are 
very similar to those of tamoxifen. 
Investigations using ovariectomized 
rats demonstrated that raloxifene 
preserves bone density of the axial 
and appendicular skeleton, and is 
able to lower total and LDL-
cholesterol. 12· 13 One randomized, 
double-blind, phase II study 
involving 251 healthy 
postmenopausal women treated with 
conjugated estrogen or raloxifene 
found that raloxifene treatment was 
equally effective as conjugated 
estrogen in decreasing bone turnover, 
and significantly lowered total and 
LDL-cholesterol levels. Although 
raloxifene treatment did not increase 
HDL-cholesterol levels as the 
TAT 59 -derivative of 4-
hydroxytamoxifen 
conjugated estrogen did, it 
suppressed endometrial proliferation 
based on results of histological 
grading of biopsy material obtained 
before and after treatment. 14 Another 
- reduced antiestrogenicity and antitumor poten<y more recent, double-blind, placebo 
study that involved 601 
Droloxifene -derivative of 3, 4-
dihydroxytamoxifen 
- no induction of rat liver tumors postmenopausal wOI;nen confirmed these findings. 15 As for actions within 
mammary tissues, there is strong -low bioovailobility upon oral administration 
Like estrogen, it lowers total and LDL cholesterol, but has 
little effect on HDL cholesterol?· 10 
evidence from various investigations 
that raloxifene presen ts an 
antiproliferative effect on estrogen receptor-dependent 
mammary carcinomas. 16• 17 
The unique antagonistic effect of raloxifene 011 uterine 
tissues makes it one of the more promising SERMs. By 
conferring no detectable risks to gynecologicpl cancers, it 
allows the possibility of preventing osteoporosis and 
coronary heart disease in all postmenopausal with the 
bonus of breast cancer prevention. It eliminates the need 
Unfortuna tely, despite the beneficial effects of 
tamoxifen, it remains a partial agonist in the 
endometrium, which increases the risks of endometrial 
hyperplasia and cancer. 1'4' 7' 11 Another concern with 
tamoxifen is its potential to indu ce hep atocellular 
carcinoma. Al though there is no human data that 
demonstra tes the hepatocarcinogenicity of tamoxifen, studies have shown that tamoxifen .....;;..._ ____________________________ _ 
produces DNA adducts in rat liver.1• 7 Table 2. Sunnary of Agolist/Aitagonists of Different Estrogen Receptor Ugands•·H 11• 1' 
As a consequence to these real and 
potential adverse effects of tamoxifen, SERMs 
new analogs of tamoxifen that confer 
less carcinogenecity (Table 1) and 
second generation SERMs have been 17~-estradiol 
developed. 
SECOND GENERATION SERMs 
The representative of this class of 
SERMs is raloxifene, which is a 
benzothiophene with the profile of an 
ideal SERM. It is an estrogen 
antagonist in mammary and 
endometrial tissues, but exhibits 
estrogen-like effects on the skeleton 
and lipid profile in postmenopausal 
women. 
Pure estrogen 
antagonists 
{ICI-1 64,384, 
1(1-182,780) 
1 st generation 
SERMs (tamoxifen 
& its derivatives) 
2nd generation 
SERM (raloxifene) 
Profile in Bone 
agonist 
antagonist 
agonist 
agonist 
Profile on Cholesterol 
Metabolism 
agonist 
antagonist 
agonist 
agonist 
Profile in Uterus 
agonist 
antagonist 
partial agonist 
antagonist 
Profile in Mammary 
ftSsue 
agonist 
I 
antagonist 
antagonist 
antagonist 
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to restrict SERM treatment, as in the case for tamoxifen, to 
those whose high risks of breast cancer outweigh the 
increased risks of endometrial cancer. 11 Nonetheless, 
raloxifene has its drawbacks. The presence of 6- and 4-
hydroxyl groups makes it ~ighl_Y vulnerable . to 
glucuronidation within the gastromtestinal mucosa, which 
limits its systemic bioavailability upon oral 
administration. 11• 18 Because of this, further research has 
yielded the discovery of a ~on-st~roida! SE.RM that 
embraces the ideal SERM profile, while havmg mcreased 
potency. This new compound, currently known as CP-
336156, is undergoing clinical trials in postmenopausal 
women. 18 
GENERAL MECHANISMS OF SERMs 
Classical Estrogen-Mediated Activity of the ER 
The ER is a ligand-activated nuclear transcription 
factor . Upon ligand binding, . ER . un~ergoes 
conformational changes that allow 1t to dimenze. The 
dimeric form of the activated ER then binds to an estrogen 
response element (ERE), which is a specific DNA sequence 
located in the promoter region of an ER-regulated gene, to 
activate the expression of that particular ~en~. 1 ' 4 A(B ~d 
E domains on the ER represent the transcnption activation 
functions AF-1 and AF-2, respectively, while the C 
domain is the DNA-binding domain that mediates the 
binding between these transcr~ption act.iva~on ~cti<;>ns 
and DNA.1• 4 E domain is also mvolved m ligand bmding 
with F domain, and it facilitate the binding of receptor 
specific ligands, nuclear localization, and dimerization. 
Current Understanding of SERM-Mediated Activity of 
theER 
The mixed agonist/ antagonist effects of tamoxifen 
and raloxifene are partly attributed to fact that these two 
SERMs, when bound to the ER, induce different ER-ligand 
conformations than estrogen. These different ER-ligand 
conformations lead to a varied effect on AF-1 and AF-2, 
which may modify the DNA-bindingyr<;>ce.ss of. t~e 
ligand-bound ER and result in different mtrms1c actiVl~ 
on gene transcription. Results fr<;>m McJ?onnell et al. 0 
support this explanation for the ffilXed actions of SERMs. 
McDonnell et al.20 observed, through varied susceptibility 
of different ER-ligand complexes to protease degradation, 
that different ligands induced structurally different ER-
ligand complexes. The results of a more recent 
investigation that studied the crystal. structtu:es .of the ~R 
complexes with estrogen and raloxifene comCldes with 
those of McDonnell et al. 20 • It observed that different 
agonists and antagonists of the ER have ~fer~nt binding 
modes, resul ting in distinct conformations m A.F-~ .21 
Another crystallization study ~eported simll~r 
observations. Levenson and Jordan observed that tf 
amino acid 351 (aspartate) of the ER is replaced by 
tyrosine, raloxifene would lose its antiestrogenic activity 
and become an ER agonist like 17~-estradiol. They 
determined that amino acid 351, located within the ligand-
binding domain (LBO) of the ER, is ~eeded to ~ydrog~n 
bond with the nitrogen in the alkylammoethoxy stde cham 
of raloxifene to give raloxifene its antiestrogenicity, and 
that there is no such hydrogen bonding between 17~­
estradiol and the LBO. Consistent with these 
aforementioned studies, while focussing on tamoxifen, is 
the finding that tamoxifen-binding to the ER affected AF-1 
and AF-2 differently than estrogen-binding.1 
Another explanation for the tissue-specific activi~e~ of 
SERMs came from studies that observed an association 
between co-regulatory proteins and transcription activity 
of the ER. They showed that in addition to the direct 
binding to EREs, ERs may inhibit or enhance tr~ription 
by recruiting co-activator and co-repressor protems to the 
transcription initiation complex depend~ng on the cell 
type.23• 2 This observation helps to explam why SERMs 
have tissue-specific activities because different cells may 
have differing co-regulatory proteins in type and 
concentration. 23• 24 
More recent investigations suggest a third avenue by 
which SERMs exert their agonist/ antagonist effects. In a 
study by Yang et al.25 that compared the ability of estrogen 
and antiestrogens to induce transcription of. the TFG-~~' a 
bone matrix protein with antiosteoclashc properties, 
raloxifene-ER complexes were able to initiate TFG-~3 
transcription even when C domain, the ~~A-bi!'~ing 
domain, of the ER was mutated. Yang et al. Identified a 
distinct region on the TFG-~3 promoter that inte~acted 
with the raloxifene-ER complexes and called It the 
raloxifene response element (RRE). These results are in 
agreement with the earlier observation that tamoxifen 
stimulates transcription of genes with promoters that 
contain a non-ERE site, the AP-1 site, differently than 
estrogen. In this investigation, Webb et al.26 found that 
tamoxifen induced ER-mediated transcription at AP-1 
sites in cell lines of uterine origin, but not in cell lines of 
breast origin, a finding that reflected differential activities 
of tamoxifen in these two tissues. Thus, these results 
collectively point to the possibility that ERE-independent 
gene activation may be another way in ~hich SERMs 
present distinct agonist profiles in different tissues. 
Furthermore, the recent cloning of the second estrogen 
receptor, ER~, in rats, mice and humans added another 
level of complexity to the mechanism of SERMs .. Early 
implications of multiple ER subtypes ~n the ~~arusm of 
SERMs are available from several mveshgations that 
explored the differential response of ERn, the classical 
estrogen receptor, and ER~ to estrogen, antiestrogens, and 
SERMs . In summary, these s tudies collectively 
demonstrated that ERn and ER~ show distinct responses 
to the binding of the same ligands. Particular! y, 17~­
estradiol binding to mouse ERn stimulates transcription at 
the AP-1 site, while its binding to mouse ER~ has an 
inhibitory effect.27 The same study also found that both 
tamoxifen and raloxifene interaction with either ERn and 
ER~ did not induce AP-1 regulated transcription. The 
distinct responses of two ER subtypes are further 
exemplified in another investigation that probed the 
differential response of the ER sub types to SERMs . 
Barkhem et al.28 reported that 4-0H-tamoxifen, an active 
metabolite of tamoxifen believed to confer some of 
tamoxifen' s effects, tamoxifen and raloxifene all acted as 
agonists to human ERn, but were antagonists to h.w:n~n 
ER~. They attributed this observation to the posstbthty 
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that ER~ lacks a portion of the AF-1 that has previously 
been found to mediate the partial agonism of tamoxifen, 
but not that of 17~-estradiol. As well , an earlier 
investigation using mouse ER subtypes observed identical 
results with 4-0H-tamoxifen and suggested the same 
explanation for the observation.23 Consequently, the 
evidence from these studies raises the possibility that the 
agonist/antagonist profile of SERMs may be partially a 
result of the different responses that they elicit through 
tissue-specific distribution of ERa and ER~ . Also, the 
obse rva tion that ER~ can form homodimers and 
heterodimers with ERa upon ligand-activation has opened 
up two more potential pathways of estrogen signaling: 
signaling through their homodimer and heterodimer 
states.24 It is possible that ER~ homodimers and ERa-ER~ 
heterodimers may interact with novel co-regulatory 
proteins and response elements to produce various effects 
of ligand-activation of ERs.4, 23 
Although the aforementioned studies and various 
others have helped to unravel some of the mystery behind 
the mechanisms of SERMs, the current understanding of 
the ways by which SERMs stimulate or inhibit ER activity 
and their agonist/ antagonist profiles remains incomplete. 
Because most research conducted on the mechanism of 
estrogen, antiestrogen, and SERM signaling assumed the 
existence of one ER, there is a tremendous need to 
reevaluate those results and conclusions . The 
development of antibodies for ER~, ER~ knockout mice 
studies, and the phenotypic characterization of cells with 
activated genes that are transcriptionally regulated by ER~ 
may prov ide more precise information about the 
physiological role of ER~ and its importance in SERM 
signaling. 
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THINKING ON YOUR FEET 
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DOC, I HAVE T HI 5 
CASE PRESENTATION 
I n the early hours of the morning, the medicine intern on call receives one last page before heading off to the call room. A 54 year old female tobacco farmer from 
Tillsonburg presents to the emergency room w ith a 
history of a sore neck and fever. In the ER, you elicit a two 
day rapidly progressive history of fever, exquisitely 
painful neck and a red, hot, swollen right index finger. 
Past medical history includes chronic osteoarthritis in her 
cervical spine, knees, and DIP /PIP joints. 
On exam, you observe that the patient is febrile with a 
temperature of 39.00C, the right index finger is swollen 
from the DIP joint to the MCP joint with proximal red 
streaking along the dorsum of the hand. Heberden's and 
Bouchard's nodes are seen in both hands. The PIP joint 
appears particularly inflamed. There is also an 
erythematous and edematous lesion, i.e. cellulitis, on the 
dorsum of the right foot, which the patient was not aware 
of before examination. There are no obvious breaks in the 
skin to suggest a portal of entry for pathogens. 
Respiratory, cardiovascular, abdominal, genito-urinary, 
and neurologic exams were normal. 
CONSIDER THE FOLLOWING QUESTIONS: 
\ 
1. What are common causes of a red, hot swollen digit, 
i.e. dactylitis? 
2. Why is this patient's neck sore? 
3. What are common sources of bacterial emboli? 
4. How is septic arthritis treated? 
5. What are the common clinical signs of infective 
endocarditis? 
6. Is there any indication for an emergency surgical 
consult? 
7. What is your initial management of this patient? 
1. Dactylitis may result from either infectious or non-
infectious etiologies: 
a) Non-Infectious: 
on-infectious causes include trauma, sarcoidosis, 
seronegative spondyloarthropathies, and gout. There is no 
history of trauma. Dactylitis is occasionally a presenting 
sign of sarcoidosis.! Sarcoidosis can present either acutely, 
over a few weeks, or gradually over months. Acute 
presentation typically includes fever, fatigue, anorexia, 
weight loss, malaise and respiratory symptoms. 
Seronegative spondyloarthropathies, particularly 
psoriatic arthritis, Reiter's syndrome, and undifferentiated 
spondyloarthritis, are the most common cause of 
dactylitis.! It is rarely, however, the presenting symptom 
and is typically seen only in well established disease. 
PAIN IN MY NECK 1 
By Nimesh D. Desai, MEDS 2000 and Kathryn Webert, MD 
Gout and pseudogout are important causes to rule out 
by history, serum uric acid, x-ray findings 
(chondrocalcinosis seen in pseudogout), and joint 
aspiration looking for crystals .2 Gout presenting as 
dactylitis is invariably associated with other articular 
manifestations, including knee and ankle. 1 
b) Infectious: 
Infection of the flexor tendon sheath can result in 
dactylitis. 1 Infectious causes include gonococcal/non-
gonococcal septic arthritis, osteomyelitis, cellulitis, and 
bacterial embolization from a deep-seated infection or 
infectious endocarditis. Gonococcal arthritis typically 
presents with a prodrome of migrating polyarthralgias 
leading to tenosynovitis or furulent monoarthritis with a 
sparse, often pustular rash. It is uncommon over the age 
of40.3 
Osteomyelitis is a possibility, but usually has a slow 
progressive presentation with vague or evanescent local 
pain and few systemic symptoms.4 Cellulitis is a 
superficial diffuse spreading infection of the skin.3 The 
lesion is typically red and hot and classically, the source of 
bacteria is throu~h a break in the skin, although this is not 
always apparent. 
Deep-seated bacterial infections and infective 
endocarditis can shower emboli of bacteria into 
extremities leading to localized abscesses, cellulitis, and 
septic arthritis .4 Given that the patient is febrile, has no 
new murmur, and there are at least two visible foci of 
infection, one in the finger and one in the foot, a deep-
seated infection showering emboli is the most likely 
diagnosis. 
2. In the septic patient, bacteria tend to seed into joints 
which are already damaged, making them more 
susceptible.5 This patient's longstanding history of 
degenerative disease in the cervical spine may render 
them vulnerable to a intervertebral disc infection (discitis) 
or epidural abscess. A septic discitis leads to extremely 
severe pain with movement of any kind. 
A rapid onset of such pain with any indication of 
sepsis or elevated ESR requires diagnostic imaging. 
Suspected discitis should be evaluated with either a bone 
scan or, preferably, MR1.5 
3. Bacterial emboli can be showered from vegetations 
growing on heart valves, oropharyngeal abscesses, and 
intraabdominal abscesses. 4 Since antibiotics may not 
penetrate into significant deep-seated infections, a 
meticulous search for a source with af>propriate imaging 
and clinical signs should be conducted.2 Knowledge of the 
infecting organism may also delineate the source.2 
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4. Septic arthritis is a medical emergency. Therapy 
begins with immediate antibiotic therapy after blood is 
drawn for culture and sensitivity. The drug of choice 
depends on which organisms are most likely to be 
involved. A reasonable approach would include starting 
with an empiric therapy of a third generation cefalosporin, 
and penicillinase resistant penicillin, thereby providing 
extensive gram positive and gram negative coverage 
including S. aureus.3• 4 Once blood culture and sensitivity 
is completed, switching to a more organism-specific 
treatment is warranted. 
Septic joints should also be asf.irated and cultured 
daily to verify efficacy of treatment. Surgical incision and 
drainage is warranted when there has been poor response 
to appropriate antibiotics or there is difficulty aspirating 
joint contents, as in a relatively inaccessible joint such as 
the hip. 
5. Infective endocarditis (IE) is fatal if untreated so ruling 
this diagnosis out is crucial once empiric management is 
started. Classical signs of IE include a new or changing 
regurgitation murmur, fever, Osler nodes and painful 
nodular erythematous lesions with central pallor, Janeway 
lesions and macular, pustular, or purpuric lesions on the 
palmar and plantar surfaces, splenomegaly, petechiae, 
clubbing, Roth spots and oval retinal hemorrhages with 
central pallor, and splinter hemorrhages under the finger 
nails.6 
The most useful tests to diagnose IE include positive 
serial blood cultures and transesophageal echo, which has 
greater than 90% sensitivity for detecting vegetations. In 
comparison, transthoracic echo is about 65% sensitive for 
IE.6 There was no murmur or systemic manifestations seen 
in this patient. 
6. Yes! Deep hand infections can quickly spread between 
fascial compartments in the forearm, wrist, and hand, 
leading to irreparable damage.3 When deep hand 
infections are suspected, early involvement of plastic or 
orthopedic surgery services may prevent devastating loss 
of function from a spreading infection. 
7. A reasonable initial plan would include: 
i) Admit her. This patient is very ill and will need IV 
antibiotics. 
ii) Obtain blood for culture and sensitivity. Throat swab 
and urine for culture and sensitivity should also be 
taken. 
iii) Gain IV access. Begin empiric antibiotic therapy as 
soon as possible. 
iv) Perform lumbar puncture if neck stiffness is associated 
with meningeal signs (Kernig and Brudzinski signs) 
v) Review case with plastic / orthopedic surgery B joint 
aspiration or incision and drainage may be required 
immediately. 
vi) Treat any readily reversible concomitant conditions: 
antipyretics for fever and fluid/ electrolyte 
management. 
Thinking on your feet 
vii) Request a chest X-ray if one has not already been done 
and consider echocardiogram in the morning. In the 
absence of a murmur, you may wish to consult with a 
cardiologist before echocardiographic investigation. 
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MODERN MANAGEMENT OF THE 
Study) KING'S EVIL (An 
Scrofula is a cervical tumour that makes the lymph glands inflamed and scirrhous. The word is derived from the Latin, scrofa, related etymologically to the 
Greek word for pig-the disease was common in children 
in Hippocratic Greece; Aristotle records that sows were 
prone to the disease. The term scirrhous was invented by 
an unscrupulous pathologist during a game of Scrabble' in 
the 1950s and has no etymological origin. Robert Koch, in 
1882, was the first to demonstrate tubercle bacilli in 
scrofulous lymph nodes, but Mycobacterium bovis wa not 
universally accepted as a causative agent of cervical 
adenitis until much later.1 
For many centuries, it was widely believed that 
monarchs (as divine representatives) could cure 
tuberculous cervical adenitis by "royal touch". Clo is of 
France (481-511) was believed to be the first endowed with 
this ability, wishing to draw attention from the fact he had 
a comical name. Formal, public practice of the ceremonial 
rite can be traced to St. Louis (Louis IX of Missouri) and 
Edward III, who washed the diseased flesh with water and 
gave the sufferer a copper talisman in exchange for 
worthless gold pieces. According to the registry, Charles II 
touched 92,102 people during his 22-year reign. While an 
important source of royal revenue, claims of royal cure 
may have been widely accepted because scrofula usually 
represents a benign primary infection conferring 
immunity from pulmonary tuberculosis2 (an observation 
known as Marfan's law). Shakespeare describes the royal 
ceremony curing "the evil" in Macbeth (Act IV, Scene III) . 
The "good king ... solicits heaven" curing the "swol'n, and 
ulcerous, pitiful to the eye" from "the mere despair of 
surgery". Since millions of Frenchmen cannot be wrong 
(except during World Wars) and Shakespeare was a 
genius, it seems reasonable to conclude that male kings 
~cure "the King's Evil". There is little historical 
record of female kings curing scrofula, likely since 
medieval doctors were biased against women 
professionals. Since cure was thought possible due to 
theosophic proximity, it seems reasonable to conduct a 
study asking whether current surgical management of 
scrofula obtains better results than modern medical 
methods. 
Full of uric and acetic acids, we hypothesized that 
surgeons, having more God-like skills than in ternists, 
would have improved prognoses for scrofula. A literature 
search quickly revealed that "scrofula" is not mentioned in 
Harrison's or Rubin and Farber. Indeed, this disea e is 
rarely addressed in Ontario medical schools and 
represents a clear gap in the curriculum. Clearly it is no 
longer common-only 5% of active TB in Canada involves 
tuberculous adenitis. Also, M. bovis is much less common 
Ongoing 
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than M. tuberculosis, accounting for about 1% of Canadian 
cases (mainly among Indians and the Inuit, but 
increasing)3. It is also dear that isonizaid and rifampin are 
effective at dealing with many forms of tuberculosis. But 
when scrofula does arise, is this pharmaceutical approach 
more effective than an aggressive operation? A more 
conservative surgical approach? 
Two hundred patients, to the very best of your 
knowledge, were studied. Of these, one hundred patients 
were diagnosed with scrofula by first-year medical 
students who were told that "being able to stick out a 
rolled-up tongue is pathognomic" for the disease. The 
other group of one hundred patients showed no signs of 
adenitis, but claimed to have a deep, academic interest in 
scrofula, surveys and hyperchondria. 
Each cohort of 100 patients was divided into four 
equal groups. Thus, 25 patients were treated by aggressive 
debulking and 25 were treated surgically by more 
conservative measures. The third group was treated with 
isoniazid; the fourth group by placeboes of identical 
appearance to the drug, except shaped like Betty Rubble. 
Half of the 100 patients allegedly undergoing surgery 
were treated by orthopedic surgeons with an interest in 
scrofula; the remainder were treated surgically by cardiac 
or vascular surgeons. One-third of the patients who did 
not undergo surgery were given drugs by cardiologists, 
one-third were given medications by general internists, 
and one-third were given prescriptions by family doctors. 
In each case, the non-surgeon made sure to touch the 
patient in a comforting and non-provoca tive manner. 
Pathologists were permitted to examine any patient who 
expired during the course of the trial . 
Our results at this stage highly suggest a surgical 
approach is more effective, but these are preliminary with 
a P-value of P<0.05. (The P value, in this case, represents 
the statistical Power, calculated by the Reagan variation of 
the two-way ANOV A technique, which gives anecdotal 
results) . It dearly shows that orthopedic surgeons are the 
most able to manage scrofula, followed by cardiac 
surgeons, cardiologists, general internists, family doctors 
and pathologists. 
Orthopedic surgeons reported the best results, curing 
all of their patients regardless of whether they used 
aggressive approach (removal of the anatomical neck) or a 
conservative approach (removal of the surgical neck). 
They were said to enjoy the more aggressive approach 
more, though, since it involved much larger saws and 
more expensive reamers. Cardiovascular surgeons were 
also quite effective at curing scrofula, curing 86% using an 
aggressive approach (performing a neck bypass) but only 
61 % with a conservative approach (offering support, 
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reassurance and Snapple©), doing everything the 
cardiologists did, plus surgery. The cardiologists reported 
similar, but slightly lower figures . General internists 
reported lower cure rates and had a much higher 
incidence of complications such as sore tongue and 
pyridoxine deficiency, in part since they were able to 
recognize the six hand signs of sore tongue. They also 
concluded that, for any given patient, "their epidermis 
was showing". Family doctors reported higher rates than 
pathologists, who saw no living subjects, did . These 
results correlate well with a sister study4 that shows that 
although doctors are more effective at curing scrofula than 
social workers, they do not produce nearly as many "cool 
graphs" with "lots of arrows and shapes"5. 
Modern medicine does not know enough about 
scrofula, and it cannot be concluded that surgeons are 
more effective at curing adenitis because of di v ine 
abilities. Clearly, much more money and research is 
needed to make this conclusion . Make your donations 
payable to me (donations are fully deductible from your 
savings). 
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EDITOR: ZAKlR ESUFALI 
MEDICAL VOCABULARY 
This section is designed to test and expand your 
knowledge of medical vocabulary. How many items can 
you correctly define? 
Scoring: [13-15] = Excellent, 
[10-13] =Above average, 
[8-9] =Good, 
[5-7]= Fair, 
{1-5] =Poor 
1. False Pregnancy 
a) The presence of a positive pregnancy test in the 
absence of an embryo. 
b) Development of all the signs of pregnancy without the 
presence of an embryo. 
c) A pregnancy in which the fertilized ovum becomes 
implanted outside of the uterine cavity. 
d) Simultaneous intrauterine and extrauterine 
pregnancies. 
2. Menometrorrhagia 
a) Prolonged menstrual periods. 
b) Excessive uterine bleeding at and between menstrual 
periods. 
c) Painful periods. 
d) Excessive menstrual bleeding, occurring at intervals of 
greater than 21 days. 
3. Eclampsia 
a) A toxemia of late pregnancy, characterized by 
hypertension, preoteinuria, and edema. 
b) Ectopic pregnancy. 
c) Dilatation, expansion, or distension, as in the 
collecting ducts of the mammary gland. 
d) Convulsions and coma, rarely coma alone, occurring 
in a pregnant or puerperal woman, and associated 
with hypertension, edema, and proteinuria. 
4. Melasma 
a) An abnormally increased amount of melanin in the 
skin. 
b) Sharply demarcated, blotchy brown macules, usually 
in a symmetrical distribution on the cheeks and 
forehead, often associated with pregnancy. 
c) The passage of dark stools stained with altered blood. 
d) A condition' characterized by dark pigmentary deposits. 
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5. Mastopexy 
a) Surgical fixation of a pendulous breast, with removal 
of fat and lengthening of the nipple. 
b) Plastic reconstruction of the breast, to either augment 
or reduce its size. 
c) Excision of the breast. 
d) Atrophy of the breast. 
6. Vaginismus 
a) Failure by a female to attain or maintain lubrication 
and swelling, or to feel excitement, during sexual 
activity. 
b) Persistently low level of sexual fantasies and desire for 
sexual activity in a woman. 
c) Painful involuntary spasm of the vagina severe 
enough to prevent intercourse. 
7. Sheehan's Syndrome 
a) Oligo- or amenorrhea , anovulation, and hirsutism, 
associated with bilateral polycystic ovaries. 
b) Isolated gonadotropin deficiency, associated with 
anosmia. 
c) Destruction of the endometrium, usually associated 
with postpartum hemorrhage or therapeutic abortion 
complicated by infection. 
d) Postpartum pituitary necrosis, reulting in failure to 
lactate. 
8. Climacteric 
a) The transitional period of lessening ovarian activity. 
b) The period of changing ovarian activity prior to 
menopause and the first few years of amenorrhea. 
c) The period of time after menopause. 
d) The complete cessation of menses. 
9. Oligomenorrhea 
a) Dimunition of menstrual flow or duration. 
b) Temporary cessation of menstruation. 
c) Regular menses occurring at intervals of greater than 
35 days. 
d) Absence or abnormal stoppage of menses. 
10. Chadwick's Sign 
a) Softening of the cervix and vagina, a sign of 
pregnancy. 
b) Softening of the lower uterine segment; an indication 
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of pregnancy. 
c) Purplish-red, congested appearance of the vaginal 
mucosa, an indication of pregnancy. 
d ) Bluish discoloration around the umbilicus after 
intraperitonel hemorrhage, as may occur after rupture 
of the uterine tube in ectopic pregnancy. 
11. Phyllodes Tumour 
a) A large, locally aggressive, sometimes metastatic 
fibroadenoma of the breast. 
b) Carcinoma of the ovary, usually metastatic from 
gastrointestinal cancer, with areas of mucoid 
degeneration and the presence of signet ring-like cells. 
c) A fibroid-like ovarian tumour containing yellow 
(lipoid) areas derived from theca cells. 
d) A benign ovarian tumour causing masculinization, 
composed of lipoid vacuoles. 
12. False Labour 
a) Labour brought on by extraneous means, i .e . 
mechanically or with IV oxytocin. 
b) Labour in which contractions begin and then cease, 
the fetus being retained for weeks or months. 
c) The process in which a woman pretends she is in 
labour. 
d) Pains resembling labour pains, not accompanied by 
cervical dilatation. 
13. Stein-Leventhal Syndrome 
a) Familial early breast carcinoma associated with soft 
tissue sarcomas and other tumours. 
b) Oligomenorrhea or amenorrhea, anovulation, and 
hirsutism, associated with bilateral polycystic ovaries, 
but normal excretion of FSH and 17-ketosteroids. 
c) Compression of the ureter by an enlarged or varicose 
ovarian vein, usually in pregnancy. 
d) Lymphangiosarcoma secondary to severe 
lymphedema of the arm, after excision of the lymph 
nodes; typically after radical mastectomy. 
14. Define engagement (a s it relates to the bi r t h 
process!). 
15. Defi ne adenom y osi s, and s tate the method o f 
defini tive diagnosis. 
ANSWERS TO MEDICAL VOCABULARY 
1. False Pregnancy: b) The presence of all the signs of 
pregnancy without the presence of an embryo. (c) 
Ectopic pregnancy; (d) Combined pregnancy. 
2. Menometrorrhagia: b) Excessive uterine bleeding at 
and between menstrual periods. (a) Menostaxis; (c) 
Dysmenorrhea; (d) Hypermenorrhea. 
Vocabulary 
3. Eclam psia: d) Convulsions and coma, rarely coma 
alone, occurring in a pregnant or puerperal woman, 
and associated with hypertension, edema, and 
proteinuria. (a) Preeclampsia; (c) Ectasia. 
4. Melasma: b) Sharply demarcated, blotchy brown 
macules, usually in a symmetrical distribution on the 
cheeks and forehead, and sometimes on the upper lip 
and neck, often associated with pregnancy or other 
altered hormaonal state. Also known as chloasma. 
(a) Mlanoderma; (c) Melena; (d) Melanosis. 
5. Mastopexy: a) Surgical fixation of a pendulous breast, 
with removal of fat and lengthening of the nipple. 
(b) Mammoplasty; (c) Mastectomy; (d) Mastatrophy. 
6. Vaginismus: c) Painful involuntary spasm of the 
vagina severe enough to prevent intercourse . The 
cause may be organic or psychic. (a) Female sexual 
arousal disorder; (b ) Hypoactive sexual desire 
disorder. 
7. Sheehan's Synd rome: d) Postpartum pitu itary 
necrosis, reulting in failure to lactate . (a) Stein-
Leventhal Syndrome; (b) Kallman's Syndrome; (c) 
Asherman's Syndrome. 
8. Climacteric: a) The transitional period of lessening 
ovarian activity . (b) Perimenopa use; 
(c) Postmenopause; (d) Menopause. 
9. O ligomenorrh ea : c) Abnormally infrequent 
menstruation, with regular menses occurring at 
intervals of greater than 35 days. (a) Hypomenorrhea; 
(b) Menolipsis; (d) Amenorrhea. 
10. Chadwick's Sign: c) A dark-bluish or purplish-red, 
congested appearance of the vaginal mucosa, an 
indication of pregnancy. (a) Goodell's Sign; (b) 
Hegar's Sign; (d) Cullen's Sign. 
11. Phyllodes Tumour: a) A large, locally aggressive, 
sometimes metastatic fibroadenoma of the breast, with 
an unusually cellular, sarcoma-like stroma . 
(b) Krukenberg's Tumour; (c) Theca Cell tumour; (d) 
Lipoid Cell Tumour of the Ovary 
12. False Labour: d ) Pains resembling labour pains, not 
accompanied by cervical dilatation. (a) Induced 
Labour; (b) Missed Labour. 
13. Stein-Leventhal Syndrome: b) Oligomenorrhea or 
amenorrhea, anovulation, and hirsutism, associated 
with bilateral polycystic ovaries, but normal excretion 
of FSH and 17-ketosteroids. (a) Li-Fraumeni 
Syndrome; (c) Ovarian Vein Syndrome; (d) Stewart-
Treves Syndrome. 
14. Engagement: Descent of the biparietal diameter of the 
fetal head to a level at or below the pelvic inlet. The 
obstetrically important anteroposterior diameter of the 
pelvic inlet is the distance between the promontory of 
the sacrum and the symphysis pubis. 
15. Adenomyosis: The presence of endometrial glands 
and stroma within the myometrium . Definitive 
diagnosis is by histologic examination of the uterus at 
hysterectomy. 
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BREASTFEEDING: 
Part of the Care Continuum 
INTRODUCTION 
There is little dispute that breastfeeding is an important conclusion to the reproductive cycle. Few other methods of preventative medicine have such 
extensive benefits for mother, baby, and society as a 
whole . The American Academy of Pediatrics (AAP) 
recognizes the importance of breastfeeding and 
recommends that women breastfeed their infants 
exclusively for the first six months of life. 1 They go on to 
advise women to continue breastfeeding their infants for 
at least twelve months, and longer if desired.1 Managing 
the breastfeeding patient requires a multidisciplinary 
approach between lactation consultants, nurses, and 
physicians. This article is meant to serve as a basic 
introduction to the clinical management of breastfeeding. 
BENEFITS OF BREASTFEEDING 
Human milk provides the ideal nutrition for infants. It 
is species specific, easily digestible, and provides a 
multitude of health benefits to the infant. 1 There is a 
decrease in the incidence and severity of lower respiratory 
infections, 2 otitis media / urinary tract infections, 4 
diarrhea,5·6 bac teremia / bac terial meningitis / and 
necrotizing enterocolitis8 among breastfed infants. Se eral 
studies also show breastfeeding to be protective against 
sudden infant death syndrome,9"10 allergic diseases, 11"12 
Crohn's d.isease, 13. 14 ulcerative colitis,13 insulin dependent 
diabetes mellitus, 15 ll mph oma, 16 and other chronic 
digestive diseases. 17"1 Cognitive development is also 
enhanced in the breastfed infant.19-21 
Breastfeeding has many benefits for the mother. 
Decreased postpartum bleeding, faster involution of the 
uterus, lactation amenorrhea and an earlier return to 
prepregnancy body weight are commonly reported .1• 22 
Research demonstrates that women who breastfeed have 
increased bone mineralization postpartum, fewer 
postmenopausal hip fractures, and a lower incidence of 
ovarian and premenopausal breast cancer.23•27 Many 
women also enjoy the convenience of breastfeed.ing (the 
milk is always ready and the right temperature) along 
with the strong bond it forms with the newborn. 
The societal benefits of breastfeeding are potentially 
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enormous. Healthier babies means lower health care costs 
and decreased work absenteeism.1.28 It has been estimated 
that annual health care savings in Canada could top seven 
billion dollars in an exclusively breastfed population.2 
The direct cost savings to the family are also significant, as 
it costs about half as much to feed a breastfed infant as it 
does one fed formula.1 
BREASTFEEDING BASICS 
Breastfeeding literature has put much emphasis on the 
importance of a good latch because of its correlation with 
breastfeeding success.29-30 Surprisingly, attaining a good 
latch may not be instinctive for mother and babl,, and may 
require some initial education and support.29-3 Not every 
physician needs to become a technical expert in 
breastfeeding providing they understand the bas ic 
concepts. It is, however, important to know how to refer 
women to a lactation specialist when required. 
Correct positioning is the first step to successful 
breastfeeding .33 Both mother and in fant should be 
comfortable and relaxed.33 Although the possible positions 
for breastfeeding are multiple, the two most common are 
the cross cradle and the football hold (figure 1). Side lyin£ 
is also popular, especially after a cesarean delivery. 
Regardless of the position chosen, the infant's head should 
be supported at the level of the breast with the breast 
positioned level with the infant's mouth. 33•34 A pillow 
positioned on the mother's lap often makes nursing more 
comfortable. 
Figure A. Figure B. 
Figure 1: A . Cross Cradle Position 8 . Football Hold 
To initiate a Bood latch, the infant's mouth needs to be 
opened widely . .JJ-34 To facilitate this, the mother may 
stimulate the infant's rooting reflex by stroking her nipple 
across the baby's lips. The entire breast should be offered 
once the mouth is ~ened wide by quickly bringing the 
infant to the breast. ;:n.34 The baby will take up to an inch 
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and a half of areolar tissue with a good latch . 
Breastfeeding requires co-ordination of the tongue and 
jaw to rhythmically compress the sinuses; starting at the 
tip of the tonw.e and rolling back to the palate in a wave-
like motion. This compresses the lactiferous sinuses 
under the areola and ejects the milk so that it can be swept 
to the back of the mouth to be swallowed.33 An audible 
swallow may follow every suck, or may occur after 
several sucks. A good latch is one in which the infant's 
mouth is wide open with the lips fanged back, the tongue 
is under the areola, and the baby is taking slow deep 
sucks (figure 2} .33-34 A good latch does not hurt; 
breastfeeding should not be painful.30.35 If the latch does 
not appear to be right, the mother should carefullls 
remove the infant from the breast, and begin again .JJ. 5 
Once mother and infant are experienced, initiating a good 
latch takes little or no effort. 
Figure 2: 
N ursing infant w ith a good latch. 
THE PHYSICIAN'S ROLE 
The significance of breastfeeding in disease 
prevention has moved many health care agencies to stre s 
the physician's role as a breastfeeding advocate. 1.32.36 In 
order to fulfill this role, physicians require adequate 
education and clinical training.J7-40 Many researchers have 
found serious shortcomings in the breastfeeding 
knowledge and clinical skills among medical students, 
residents, and primary care physicians. 37-40 This is 
unfortunate as studies have shown that primary care 
physicians play an important role in a woman's decision 
to initiate and continue breastfeeding.40 Historically, 
physicians unfamiliar with the appropriate management 
of breastfeeding have failed to advocate breastfeeding for 
their patients, and have had a tendency to recommend 
formula feeding as a solution to any problems that arose.23 
It is now recognized that this approach is completely 
inappropriate. 
MANAGING THE BREASTFEEDING PATIENT 
Most women who breastfeed make the choice to do o 
while they are still pregnant.40 Therefore, prenatal visits 
are an opportune time to discuss breastfeeding, and 
should become a routine part of prena tal care . 
Feature Art i cles 
Breastfeeding should be recommended for all infants, 
including premature and sick newborns. u 2 The only 
exceptions to this are: infant galactosemia, illegal druB 
use, active tuberculosis, and positive HIV status. 1•41 -
Some drugs are also contraindicated while breastfeeding, 
however, listing these is beyond the scope of this article. 
If the decision to breastfeed has been made it should 
begin as soon as possible after delivery, ideally within one 
hour .1•23•32 In cultures where breastfeeding is more 
prevalent than in orth America, infants are left on the 
mother's abdomen after delivery until they initiate their 
own latch.31 It is believed that this increases the likelihood 
of establishing a good latch (the correct sucking 
technique), preventing the need for correction later.31 The 
newborn should remain with the mother throughout the 
recovery period, w ith procedures that interfere with 
breastfeeding or traumatize the infant kept to a 
minimum. 1.32 Rooming-in should be encouraged both in 
hospital and after discharge. 1.32 
All newborns should be nursed on demand. 1 Signs of 
hunger include increa ed alertness or activity, mouthing 
and rooting. 1 It is important to understand that crying is a 
late sign of hunger. ewborns need to be nursed until 
satiety eight to twelve times within a 24-hour period, and 
should be roused to nurse if four hours have elapsed since 
the previous feeding.1.23.32 At each feed the infant should 
be allowed to nurse at the first breast until satisfied, and 
then be offered the second.23 
Several task forces have devised recommendations to 
increase the success rates of breastfeeding. Research 
recommends that no supplements (water, formula, etc.) be 
given to newborn infants unless medically indicated, and 
bottles (with expres ed milk) and pacifiers be avoided 
until breastfeeding is well established, if used at all.1.32.4J 
Infants require only breastmilk (i.e., no other nutrition) for 
approximately the first six months of life.1 Breastfeeding 
should continue for at least the first twelve months, or 
longer if mutually de ired.1 If a mother chooses to wean 
before twelve month the infant should receive iron-
fortified infant formula (not cow's milk) until one year of 
age. 1• 44 Iron-enriched foods should accompany the breast 
milk diet during the econd half of the first year. 1 
ew mothers need to be made aware of the 
breastfeeding support that is available in their 
community, before they leave hospital. It is also 
recommended that all women have a follow-up home visit 
with a health nurse or lactation consultant within 48 to 72 
hours after discharge.1•23 The primary care physician 
should see all newborns at three to five days of age.1.23 An 
assessment of general health and infant weight should be 
accompanied by an evaluation for evidence of successful 
breastfeeding. The newborn should be assessed for 
adequate hydration, urination (six per day) and 
elimination (three to four stools per day), and should be 
assessed for jaundice.1 The topic of breastfeeding should 
be supported at each well baby visit, and women should 
be advised to return to their physicians for a complete 
breast examination once breastfeeding has been 
terminated. 1 
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TROUBLE-SHOOTING 
Breastfeeding can be effortless and enjoyable for 
some, and a difficult struggle for others. It is important to 
have the skills and knowledge necessary to deal with the 
difficult situations that may arise. Most problems occur 
within the first six weeks, and with perseverance, most 
infants and women become very proficient at it.35 
Slow Weight Gain 
In an otherwise healthy newborn, the most likely 
cause of slow weight gain is insufficient milk intake.34-35 A 
poor latch is likely the underl~g problem and needs to 
be evaluated and corrected.n. 5 Nursing the infant more 
frequently (at least eight times within 24 hours) may also 
help.23 No additional supplements (formula, juice, water, 
etc.) should be recommended.34-35 The infant and mother 
should be followed carefully until successful 
breastfeeding has been established. Note that it is essential 
to rule out any organic cause of slow weight gain before 
assuming inadequate intake.23 
Inadequate Milk Supply 
Breastfeeding works on supply and demand.23 More 
frequent nursing almost always increases the milk supply 
sufficiently.23 Using a breast pump immediately after a 
feed may also be helpful in bolstering the milk supply. 
Nipple Soreness 
Breastfeeding should not be painful, yet nipple 
soreness is common and the most likely cause of early 
breastfeeding failure. 3:>-35 Nipples can become sore, 
cracked, and may bleed. The most common cause is a 
poor latch.34-35 New mothers tend to endure the pain of a 
faulty latch because the infant appears to be feeding well. 
Appropriate treatment should be based on educating the 
mother and facilitating healing.34-35 Women need to be 
reassured that the nipples will adapt to the nursing 
experience naturally, but that efforts can be made to ease 
the discomfort (table 1}. 
Candida Albicans 
Candida has been called the hidden deterrent to 
breastfeeding and is likely an underdiagnosed cause of 
early weaning.45 Persistently red and sore nipples after the 
first two weeks of breastfeeding should raise a red flag 
and make the health care professional think about 
Candida. 45 Candida albicans is a normal fungal organism 
Table 1. Treating Nipple Discomfort 
Check position and assure that infant has a good latch 
Manually expreSs some milk before feeding to soften breast 
Apply warm compresses before nursing 
Begin nursing on the least sore side 
Allow breast milk to air dry on nipple area after feeding 
Leave nipples exposed to air 
A void nipple shields 
Do not allow infant to fall asleep at the breast 
Use Lansinoh® if ointment is used 
A void soaps and drying agents 
Table 2. Signs and Symptoms of Thrush 
Mother: 
Red nipples and areola 
Nipple itching 
Persistent sore nipples 
Burning/shooting pain in breast during and/or after 
feeding 
Cracked nipples that do not heal 
White patches 
Infant: 
White patches on oral mucosa and tongue 
Diaper rash 
Refuses to nurse, or pulls away repeatedly during 
nursing 
Slow weight gain 
Gas 
Fussiness 
Recent antibiotic use 
found in the flora of mouth, skin, intestinal tract, and 
vagina. However, when present in increased amounts, it 
can cause oral thrush (and therefore nipple thrush) and be 
a tremendous source of discomfort for both mother and 
infant.45 Thrush has several classic symptoms (table 2) but 
patients can be asymptomatic.45 The most likely route of 
infection is vaginal delivery .45 Therefore, the mos t 
effective treatment is prevention, by treating pregnant 
women with yeast infections during their third trimester. 
Lactating women should be made aware of the symptoms 
of thrush so they can seek medical attention. Treatment 
includes antifungal treatment for mother and infant, with 
mandatory follow-up. 45 Frequent hand washing, using 
disposable nursing pads, washing bras daily and 
sterilizing breast pumps, pacifiers, bottles and toys for 20 
minutes helps to prevent reinfection.45 
Breast Engorgement 
Nursing mothers will likely experience discomfort 
due to engorgement at some time. They should be 
reassured that because their milk supply is driven by 
demand, the breasts usually adjust quickly. Comforting 
measures include: warm compresses, nursing frequently, 
varying nursing positions, initiating let-down before 
feedings, and massage the breast toward the nipple before 
and during nursing. For severe breast fullness, a good 
quality breast pump can be used after nursing followed by 
cold compresses. 
Mastitis 
While mastitis is not nearly as common as it once was, 
it can still be a result of early weaning.23 Mastitis usually 
presents with sudden, intense, unilateral pain and flu-like 
symptoms.23 A lobe of the breast is usually red, hot and 
swollen, and the patient is febrile. 23 The patient should be 
advised to continue to nurse on both breasts, but to begin 
each feed on the affected side.23 The affected breast needs 
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to be _em~tied thoroughly at each feed by nursing or 
pumpmg. Bed rest is mandatory.23 An antibiotic that can 
be tolerated by infant and mother should be prescribed, 
with a course of at least 10 to 14 days.23 Ice packs or warm 
packs can be applied for local relief, and acetaminophen 
can be taken for pain. 23 
CONCLUSION 
The health and social benefits of breastfeeding are 
now well established in the scientific literature. Breast 
milk provides the ultimate nutrition for infants with the 
best health, developmental, and psychosocial outcomes. It 
is our job as health care professionals to become 
knowledgeable and skilled in the clinical management of 
breastfeeding in order to become enthusiastic 
breastfeeding advocates for our patients. 
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RESTORATION OF SELF 
RECONSTRUCTION OF 
THROUGH 
FORM: 
A Conceptual Review of Breast 
for the Postmastectomy 
Reconstruction 
Patient 
INTRODUCTION 
Breast Cancer: Still a Major Health Concern 
D espite ongoing research efforts and advances in oncologic therapy, carcinoma of the breast currently remains a major threat to women. (Figure 1.) It is 
estimateq that 19,300 new cases will be diagnosed in 
Canada during 1998,1 securing carcinoma of the breast as 
the female cancer with the greatest incidence, next to 
malignancies of the skin. 1.2 Of even greater concern is that 
5,300 Canadian females will succumb to the disease by the 
year's end,' making it the second leading cause of cancer 
mortality (lung cancer being first) .1.2 Indeed, a female born 
in North America today has approximately a one in nine 
chance of developing a primary breast tumour during her 
lifetime.3 But, in addition to the psychological devastation 
of living with the disease, coping with the physical results 
of surgical treatment often adds insult to injury. It should 
therefore not be surprising that breast cancer and its 
associated illness experience are firmly entrenched at the 
forefront of women's current healthcare concerns. Today, 
several approaches are available in the attempt to restore 
the body to normal form after disfiguring breast cancer 
surgery. However, essential for a more profound 
appreciation of breast reconstruction is an understanding 
of the treatment of breast malignancy, the significance of 
the breast to society, and the psychosocial consequences of 
the loss of a breast. This review explores these topics, and 
examines the surgical management options of breast 
reconstruction for the postmastectomy patient. 
Relevant Highligh ts of Treatment for Carcinoma of the 
Breast 
The TNM staging system by the American Joint 
Committee on Cancer classifies patients with breast cancer 
into different groups based on prognostic criteria. 
Information regarding the size and invasiveness of the 
primary tumour {T), regional lymph node involvement 
(N), and existence of distant metastasis (M) determine 
what stage grouping is appropriate.2 Stages are classified 
from I to IV, increasing according to the severity of 
disease. 
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Figure 1. Carcinoma of the breast. This case is taken from 1976 to 
illustrate an advanced tumour. Today, it is much less likely to see 
breast cancer present in this marmer. 
Tumour excision is an integral part of managing 
carcinoma of the breast. Surgical procedures include either 
total mastectomy (resection of entire breast) or 
lumpectomy (removal of cancerous tissue with 
pathologically negative margins). Although the role of 
surgery is better documented for patients with early stage 
disease, 4 where complete tumour excision is more 
probable, total mastectomy with adjuvant radiation and 
chemotherapy may be of therapeutic benefit for patients 
with late stage disease as well.5 
Although lumpectomy offers a superior cosmetic 
result when compared to mastectomy, initial concerns 
were that the procedure might not be as effective because 
of the decrease in tissue removal, and hence the decrease 
in probability of removing all malignant cells.4 However, 
numerous studies indicate that breast conserving surgery 
results in similar survival rates when compared to 
mastectomy.6,7,s,9 The medical community now generally 
believes that, in properly selected patients, lumpectomy is 
the appropriate surgical course of action.4 Nevertheless, at 
least one third of patients may not be acceptable 
candidates for the procedure.4 Contraindications for 
lumpectomy include extensive primary tumours, inability 
to obtain pathologically negative margins, occurrence of 
multiple primary cancers, or the presence of a carcinoma 
so large that there is no cosmetic benefit when compared 
to mastectomy.10 Today, despite the compelling evidence 
against the need for radical breast excision in many cases, 
women often choose mastectomy based on the perception 
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Figure 2. Before and after radical mastectomy. 
of a more favourable prognosis. Although the frequency of 
lumpectomy is increasing, mastectomy remains the most 
often performed surgery for breast cancer.2 (Figure 2.) 
Significance of the Breast 
The female breast has been a powerful symbol of 
feminini ty throughou t h istory. It represents fertility, 
comfort, and sexuality11 and is considered to be the most 
important marker of a woman's gender.U As such, ~any 
women have body image concerns after the amputation of 
a breast. The postmastectomy patient commonly feels 
mutilated and reports lower self-esteem. 13•14 She is likely to 
experience depression12•14 and studies ~ave s~own that the 
majority of women report a decrease m desue for sexual 
intimacy, often resulting in the cessation of sexual 
intercourse. 13•15 Furthermore, the loss of a breast is often a 
disfiguring reminder of the cancer diagnosis which 
invokes fears of recurrence, adjuvant therapy, and most of 
all, death . 15 People more likely to suffer greater 
psychological trauma include single or younger ~omen, 
patients who were critical of their breasts previous to 
mastectomy, and those whose self-esteem is primarily 
rooted in physical beauty. 12' 14'16 
BREAST RECONSTRUCTION 
Background 
After mastectomy, women are typically extremely 
unsatisfied with the option of using an external prosthesis 
to simulate the breast mound. External prostheses do not 
improve body image, 17 _an~ often serve_ to co_nstantlYs 
remind women of theu hfe threatemng disease . 
Consequently, there has been considerable interest in 
breast reconstruc tion . Top motivations reported by 
women to pursue breast reconstruction are to regain 
attractiveness, and to reclaim the sense of wholeness that 
they perceive the disease has taken away. 19 Often , 
reconstruction is perceived as an affirmation of the desire 
to keep living; a symbol of the commitment not to give in 
to the disease.20 However, the surgical community was 
initially concerned over the possibility of wor~enin~ the 
prognosis of breast cancer through reconstruction; either 
via altered tumour biology or through increased risk of 
wound complications. They theorized that tumour 
biology might be altered by stimulating or masking cancer 
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recurrence, or that the operation could weaken the 
immune system. 4 Also, an increa_se in w~>U_nd 
complications could potentially delay adJuvant radiation 
or chemotherapy.4 Fortunately, numerous studies have 
failed to show significant differences in tumor biologi1.22 
or in wo u nd complications23•24 between pa tients 
undergoing mastectomy wi th recons truction and 
mastectomy alone. 
There are two main conceptual approaches to modem 
breast reconstruction. One involves silicone gel- or saline-
filled prosthetic implants, and the other uses au togenous 
tissue flaps. Both methods have inherent advantages and 
disadvantages. 
Implant-based recons t ruction holds less short-term 
operative risk, but comes at a cosmetic and possibly a 
long-term p rice 
The usefulness of implants is to rep lace lost breast 
volume. An implant placed deep to the pectoralis maj~r 
muscle may be used immediately after mas tectomy If 
adequate skin is available. However, if a skin sparing 
mastectomy does not occur, then tissue expansion is used 
to ensure adequate skin coverage for eventual 
accommodation of the prosthesis. The insertion of an 
implant or tissue expander typically takes less th~ one 
hour, and is hence an attractive form of reconstruction for 
the patient that has risk factors associated with surgery.25 
Despite tha t advantage however, implants carry a high 
failure rate due to infection, rupture, extrusion, or capsular 
contraction.25 In addition, tissue expansion requires gradual 
inflation (4 to 6 months) of the soft-tissue mastectomy 
envelope to achieve a breast volume of about twice that of 
the contralateral breast. This commonly results in 
complaints of discomfort. 25 Su bsequ ently, anc:>ther 
operation is performed to remove the expander and msert 
the implant. Although attemp ts have been made to 
elimina te the need for two procedu res by the use of 
combination devices, further revisions are often neede<! 
thereby invalidating the potential benefit from their usage.25 
In addition, tissue expansion requires many follow-up 
visits and, as such, may be more successful in the highly 
motivated patient.26 Cosmetically, many surgeons feel 
silicone gel-filled implants provide a better approximation 
of breast tissue than the saline-filled type. When compared 
to silicone gel-filled implants, the shortcomings of s~e­
filled implants include a tendency for fullness or wavmess 
in the superior half of the breast mound, and a decreased 
natural breast contour in the upright position.27 
Controversy remains over w he ther the use of 
implants is connected to a wide variety of non-spe~ific 
symptoms and deficiencies of immune system function. 
Although data do not curren tly indica te a causal 
relationshi~ between implan ts and au toimmune 
disorders/ ·29•30•31 •32 the lack of lon g-term data raises 
concerns for implant safety. In addition, li ttle is known 
about the life span of implants beyond 20 years. For these 
reasons, many women continue to be anxious over the 
utilization of implants for reconstruction, and this should 
therefore be viewed as an additional disadvantage for 
their usage.25 (Figure 3.) 
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Figure 3. Implant-based reconstruction. Slight asymmetry is 
unnoticeable when the patient wears a brassiere. 
Autogenous Tissue Reconstruction, Often the Procedure 
of Choice 
Modern autogenous breast reconstruction is 
performed using myocutaneous flaps. The procedure 
involves the replacement of lost breast volume and skin 
envelope via the transfer of one's own muscle and kin 
layers from a suitable region that retain their original 
vasculature. The principal benefit of this type of 
procedure is the avoidance of the potential complications 
associa ted wi th foreign body implantation of internal 
prostheses. Since documentation of the use of latissimus 
dorsi myocutaneous flaps for breast reconstruction began 
over 20 years ago, many other flap transfer procedures 
have been described. Cosmetically, myocutaneous flaps 
better approximate the quality of breast tissue when 
compared to implants, resulting in more natural breast 
contour and improved symmetry with the contralateral 
breast.27 Although this type of reconstruction is more 
complex and is associa ted with increased operative risk, 
autogenous reconstruction is more durable over the long-
term than implantation.25 
Today, the flap most commonly utilized for 
autogenous breast reconstruction is the transverse rectus 
abdominis myocutaneous (TRAM) flap. 33(Figure 4.) 
Specifically, the main advantages of the TRAM flap 
underlying its popularity are that the abdominal donor 
site is frequently of generous quantity to provide ample 
tissue for reconstruction, and that the patient often 
benefits cosmetically from an abdominal lipectomy at the 
same time. In addition, ad ances in microsurgery have 
successfully allowed free flaps (a flap detached from a 
donor site for microvascular anastomosis at the recipient 
site), such as the free TRAM flap, to be a common 
selection of autogenous breast reconstruction in many 
centres.27 
Selection of Technique 
Because of the tremendous variability of implant type, 
shape, and multiple adequate donor sites for autogenous 
procedures, there are numerous reconstructive 
possibilities, and as such, each case is unique. However, it 
is important to keep in mind that not every patient desires 
such a procedure, and therefore inadvertent coercion 
should be avoided. However, if interest in reconstruction 
is expressed, then the patient's health status is ascertained, 
and weighed against what is technically feasible as 
determined by body habitus.26 Elderly women or patients 
with comorbid disease are best treated with less invasive 
procedures such as prosthetic implantation, possibly with 
tissue expansion as well.4 Moreover, reconstruction with 
autogenous tissue is preferable in the otherwise healthy 
patient, if her body habitus is suitable.4 When multiple 
options are approfria te, the patien t may select the 
operative technique. 
Immediate versus Delayed Reconstruction 
Historically, it was advised for the patient to delay 
reconstruction for a time after mastectomy to determine if 
the malignancy would return. However, this is no longer 
the case as numerous studies have concluded that 
immediate breast reconstruction is safe for selected 
patients. 21 .2Z.35.36 In addition, it has been thought that a 
woman must live with the mastectomy defect for a time to 
appreciate her new breast. This view is not currently 
accepted either, since immediate breast reconstruction, 
when appropriate, has been shown to decrease the 
psychological trauma associated with mastectomy.37 It is 
generally felt that patient selection for immediate 
reconstruction should be based on an understanding of 
the reconstructive options, stage of the carcinoma, amount 
of previous radiation therapy, and the surgical technique 
planned for mastectomy.4 
Implant-based reconstruction, especially those 
involving tissue expansion, involves multiple office visits 
and can require subsequent revisions. Consequently, it is 
necessary for the woman to be well informed about her 
reconstructive options and be realis tic regarding the 
outcomes of each, so that she may be better prepared for 
complications. In patients with advanced disease, where 
postmastectomy radiation of the chest wall is an integral 
part of therapy, a delayed reconstruction is indicated to 
avoid the risk of radiation necrosis in th e newly 
constructed breast.4 Radiation therapy before mastectomy 
Figure 4. Before and after TRAM flap reconstruction. TRAM 
flaps often provide a generous amount of tissue for 
reconstruction. 
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may also hinder the reconstructive process by decreasing 
the probability that a local flap will take successfully, 
decreasing tissue elasticity, and affecting the viability of 
the pedicle of regional tissue reconstruction along with the 
vasculature needed for microsurgical reconstruction.4 If 
the patient is at an increased operative risk due to 
prolonged anaesthesia, then a delayed reconstruction may 
also be appropriateY Obese patients, smokers, and people 
w ith marked comorbidity such as diabetes mellitus, 
uncontrolled hypertension, and cardiovascular disease are 
also less ideal candidates for immediate reconstruction as 
the y have an increased risk of developing 
complications. 38.39 
Reconstruction of the Nipple and Areola 
Current methods of nipple reconstruction include 
either taking a composite graft from the contralateral 
nipple or using small local flaps to elevate tissue from the 
breast mound . Areolar reconstruction can be 
accomplished by grafting techniques or by tattooing. 
ipple and areolar reconstruction can result in higher 
levels of patient satisfaction not achieved by improving 
physical contour alone.40 (Figure 5.) 
Psychological Outcomes 
Most women feel positive about their reconstructive 
results. They often feel that the new breast represents a 
commitment to the future; a desire not to give in to the 
disease.41 However, although improvements in technology 
and technique have enabled breast reconstructive results 
to be more aesthetically pleasing today than ever before, 
some women report disappointment that it did not return 
them to their premastectomy state.42 To help overcome the 
risk of this potential distress , the patient should 
understand the purpose of reconstruction, and be realistic 
regarding her outcome. In light of this, it should be 
strongly encouraged that reconstruction not be presented 
as a cosmetic triumph, but rather as an aid to restore her to 
a sense of wholeness. 
Figure 5. Reconstruction of the nipple and areola. 
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SUMMARY 
As surgery often leaves women suffering from breast 
cancer disfigured and depressed, reconstructive 
procedures of the breast have evolved with the purpose of 
improving form . Reconstructive techniques typically 
involve implants or autogenous tissue flaps, and the 
choice of method depends on factors including overall 
health, body habitus, and patient preference. In the 
otherwise healthy patient, autogenous reconstruction is 
generally preferred because of the decrease in 
complication risks and concerns associated with implant-
based reconstruction, often providing a cosmetically 
s uperior result a s well. Presuming realistic patient 
expectations, p sychological outcomes of breast 
reconstruction will tend to be extremely positive, showing 
that reconstruction of form in the postmastectomy patient 
can play a major role in a woman's psychological 
recovery. 
ACKNOWLEDGEMENT 
The author would like to thank Dr. Brian Evans and 
Dr. Ron Holliday for their suggestions pertaining to this 
article and for the use of their case photographs. Dr. Evans 
is a plastic surgeon at London Health Sciences Centre, 
University Campus, and Dr. Holliday is a general surgeon 
at London Health Sciences Centre, South Street Campus. 
REFERENCES 
1. National Cancer Institute of Canada: Canadian Cancer Statist ics 1998, 
Toronto, Canada, 1998. Internet : World Wide Web : 
http://www.cancer.ca/stats/egb010.1rtm 
2. Carlson GW, Wood WC. Primary treatment of breast cancer. In: Aston Sf, 
Beasley RW, Thome CHM , eds. Crabb and Smith's Plastic Su rgery (Stir 
edition). Plriladelplrin: Lippincott-Raven, 1997: 759-762. 
3. Statistics Canada: Canadian Statistics - Lifetime probability of developing 
and dying from cancer, 1998. Internet : World W ide Web: 
http://u.nmu.statcan.ca:80/englislr/Pgdb/People/Health/lrealtlr25a.Jrtm 
4. Burk Ill R W, Grotting }C. Conceptual considera t ions in breast 
reconstruction. Clinics in Plastic Surgery. 1995; 22(1): 141-151. 
5. Swain SM, Lippman ME. Locally advanced breast cancer. In: Copeland EM, 
Bland Kl, eds. Tire Breast: Comprehensive Management of Benign and 
Malignant Diseases. Plriladelplria: WB Saunders, 1991: 843-862. 
6. Bliclrert-Toft M , Brinker M , Andersen }. A Danish randomized trial 
compared breast-preserving therapy with mastectomy in mammary 
carcinoma. Acta Oncol. 1988; 27: 671 . 
7. Lichter A, Lippman M , Danforth D. Mastectomy vers!IS breast-conserving 
therapy in tire treatment of stage I and II carcinoma of tire breast: A 
randomized trial at tire National Cancer Institute. }. C/in. Oncol. 1992; 10: 
976. 
8. Sarrazin D, Le M, Arriagada R. Ten-year results of a randomized trial 
comparing a conservative treatment to mastectomy in early breast cancer. 
Radiother. Oneal. 1989; 14: 177. 
9. Veronesi U, Banfi A , Salvadori B. Breast conservation is the treatment of 
choice in small breast cancer: Long term results of a randomized trial. Eur. f . 
Cancer. 1990; 26: 668. 
10. Eberlein Tj, Crespo LD, Smith BL, eta/. Prospective evaluation of immediate 
reconstmction after mastectomy. Ann. Surg. 1993; 218: 29. 
11 . Grossman R. Psychological and psyclrosexua/ aspects of augmentation 
mammaplasty. Clinics in Plastic Surgery. 1976; 3(2): 167-170. 
12. Coin }, Coin M. Breast reconstmction after mastectomy. In: Coin}, Coin M, 
eds. Changing tire body: Psychological effects of plastic surgery. Baltimore: 
Williams and Wilkins, 1981: 163-189. 
U. W.O. Medical Journal 68 (1)1999------------------------ 45 
Feature Articles 
13. Daniel R, Maxwell G. Breast reconstruction following mastectomy. 
Advances in surgery. 1983; 16:49-73. 
14. Schain W , jacobs E, Wellisch OK. Psychosocial issues in breast 
reconstruction: Intrapsychic, interpersonal and practical concerns. Clinics in 
Plastic Surgery. 1984; 11(2): 237-251 . 
15. Maguiere P. The psychological and social sequelae of mastectomy. In : 
Howells jG. Modern perspectives in the psychiatric aspects of surgery. New 
York: Brunner/Mazel, 1976: 390-421 . 
16. Valanis B, Rumpler C. Helping women to choose breast cancer treatment 
alternatives. Cancer Nursing. 1985; 8(3): 167-175. 
17. Bostwick f. Patient rehabilitation and support. In: Harris J, Hellman 5, 
Henderson I, Kinne D, eds. Breast Disease. New York: j.B. Lippincott Co., 
1988: 632-698. 
18. Bostwick f. Breast reconstruction following mastectomy. Cancer journal for 
Clinicians. 1989; 39(1): 40-49. 
19. Spencer K. Significance of the breast to the individual and sociely. Plastic 
Surgical ursing. 1996; 16(3): 131-132. 
20. Matheson G, Drever JM. Psychological preparation of the patient for breast 
reconstruction. Annals of Plastic Surgery. 1990; 24(3): 238-247. 
21. Noguchi M , Fukushima W, Ohta N , eta/. Oncological aspect of immediate 
breast reconstruction in mastectomy patients. f. Surg. Oncol. 1992; 50: 241. 
22. Patel RT, Webster OJ, Mansel RE, et a/. Is immediate postmastectomy 
reconstruction safe in the long-temz? Eur. f. Surg. Oncol. 1993; 19:372. 
23. Noguchi M, Earashi M, Ohta N , et a/. Mastectomy with and without 
immediate breast reconstmction using a muswlocutaneous flap . Am. f. 
Surg. 1993; 166: 279. 
24. O'Brien W, Hasselgren PO, Hummel RP, eta/. Comparison of postoperative 
wound complications and early cancer recurrence between patients 
undergoing mastectomy with or without immediate breast 
reconstruction. Am. f. Surg. 1993; 166: 1. 
25. Singletary SE, Kroll 55 . Skin-sparing mastectomy with 
immediate breast reconstruction. Advances in surgery. 1996; 
30:39-52. 
26. Maxwell GP, Hammond DC. Breast reconstruction following 
mastectomy and surgical management of the patient with high-
risk breast disease. In: Aston Sf, Beasley RW, Thorne CHM, 
eds. Grabb and Smith 's Plastic Surgery (5th edition). 
Philadelphia: Lippincott-Raven, 1997: 763-784. 
27. Corral CJ, Mustoe TA. Controversy in breast reconstruction. 
Surgical Clinics of North America. 1996; 76(2): 309-326. 
28. Schusterman MA , Kroll 55, Reece GP, et a/. Incidence of 
autoimmune disease in patients after breast reconstruction with 
silicone gel implants versus autogenous tissue: A preliminary 
report. Ann. Plast. Surg. 1993; 31: 1. 
29. Fisher JC. The silicone controversy- when will science prevail? 
N . Engl. j. Med. 1992; 326: 1696-1698. 
30. Kessler DA . The basis for the FDA 's decision on breast 
implants. N. Engl. f. Med. 1992; 326: 1713-1715. 
31 . Shons AR, Schubert W. Silicone breast implants and immune 
disease. Ann. P/ast. Surg. 1992; 28:491-501 . 
32. Varga J, Schumacher HR, jimenez SA. Systemic sclerosis after 
augmentation mammoplasty with silicone implants. Ann . 
Intern . Med. 1989; 111:377-383. 
33. Hartrampf CR Jr . Breast reconstruction with a transverse 
abdominal island flap . Perspect. Plast. Surg. 1987; 1: 123-135. 
34. Reath DB, Stromberg BV. Plastic Surgery: Diseases of the Skin 
and Soft Tissue, Face, and Hand . In: Lawrence PF, ed . 
Essentials of Surgical Specialties. Baltimore: Williams and 
Wilkins, 1993: 127-176. 
35. johnson CH, van Heerden JA , Donl111e JH, et a/. Oncological 
aspects of immediate breast reconstruction following 
mastectomy for malignancy. Arch Surg. 1989; 124: 819. 
36. Kroll 55, Ames F, Singletary SA , et a/. The oncologic risks of skin 
preservation at mastectomy when combined with immediate reconstruction 
of the breast. Su rg. Gynecol. Obstet. 1991 ; 
172: 17. 
37. Dean C. Chetly U, Forrest APM. Effects of immediate breast reconstruction 
on psychosocial morbidily after mastectomy. Lancet. 1983; 1: 459-462. 
38. Dowden RV. Selection criteria for successful immediate breast 
reconstruction. Plast. Reconstr. Surg. 1991; 88: 628. 
39. Hartrampf CR, Bennett GK. Autogenous tissue reconstruction in the 
mastectomy patient. Ann. Surg. 1987; 205: 508. 
40. Goin MK. Goin JM. Growing pains: The psychological experience of breast 
reconstruction with tissue expansion. Annals of Plastic Surgery. 1988; 
21(3): 217-222. 
41 . Matheson G, Drever JM. Psychological preparation of the patient for breast 
reconstruction . Annals of Plastic Surgery. 1990; 24(3): 238-247. 
42. Hart D. The psychological outcome of breast reconstruction. Plastic Surgical 
Nursing. 1996; 16(3): 167-171. Q 
Creating and delivering innovative health 
care solutions enabling people to live 
longer, healthier and more active lives 
46 
------------------------ U. W.O. Medical Journal 68(1) 1999 
Feature Articles 
THE ROLE OF 
MANAGEMENT 
ULTRASOUND IN THE 
OF BREAST CANCER 
Introduction 
Breast cancer is the most common malignancy affecting women in Canada, and currently is the second leading cause of cancer-related female death. 
The expected incidence per annum in Canada is 
approximately 18,500, with approximately 5,000 expected 
deaths. 1 As such, it is an illness of significant proportion. 
While the prevalence of this disease is great, survival has 
been improving in recent years. This trend is thought to be 
due to a combination of both improved diagnosis and 
treatment. 
A key improvement in the diagnosis of breast cancer 
has been the recognition of the importance of imaging 
modalities in screening. More specifically, numerous 
studies have provided clear evidence that regular 
mammography in conjunction with careful physical 
examination can significantly decrease mortality due to 
breast cancer. In fact, the combined data show a reduction 
in mortality of at least 30%.2 This information lead to the 
development of the Ontario Breast Screening Program in 
the late 1980's. Current Canadian screening guidelines 
include mammography at least every two years for all 
women age 50-69. Regular mammography is also 
recommended for those age 40-49 in high risk groups such 
as those that have had a previous breast cancer or those 
with a family history of breast cancer in first degree 
relatives.3 
Mammography has thus been established as an 
importan t imaging modality for breast cancer both 
experimentally and clinically. Because of its success in 
reducing mortality, an obvious question arises as to the 
role of other imaging modalities in the management of 
breast cancer. One modality which has been extensively 
investigated is ultrasound. 
In fact, there are multiple reasons why the breast may 
be the most ideal organ in the human body for 
examination by ultrasound. Its relatively small size allows 
examination with high-frequency, high-definition probes. 
Also, air and bone which can interfere with sonography 
are not present in the breast. Finally, there is sufficient 
variance in the sonic impedences of the tissues in the 
breast that one can use this modality to differentiate 
glandular tissue, fat, fascia, lymph nodes, and normal 
sized ducts from one another. 4 Ultrasound can 
demonstrate the skin, subcutaneous fat, breast 
parenchyma, retromammary fat, pectoralis muscle, ribs, 
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and anterior chest wall.5 An advantage of ultrasound is 
the capability for real-time scanning of the breast. This 
quality is important in correlating images with physical 
findings, as well as in biopsy and interventional 
techniques.6 Ultrasound also does not share the significant 
albeit small radiation risk associated with x-ray use in 
mammography . As a result of these characteristics, 
ultrasound has become established as an important 
imaging adjunct in the diagnosis and management of 
breast disease. 
Is there a role for ultrasound in screening for breast 
cancer? 
For ultrasound to be considered a useful imaging tool 
for primary screening of breast cancer, it must display an 
efficacy equal to or greater than the current 
mammography program. At this point, there is no 
research available to s upport such an efficacy. 5•7•8 
Ultrasound simply does not detect all cancers that are 
visible mammographically.8 Studies with high frequency, 
real-time equipment in examination of known breast 
cancers have shown false negative rates for ultrasound 
ranging from 0.3% to 47% (mean 20 .7%).8 There are a 
number of reasons for this. Firstly, a significant number of 
breast cancers are isoechoic with fat or breast tissue, and 
thus difficult or impossible to visualize sonographically.5 
Secondly, ultrasound has poorer resolution than 
mammography for solid lesions . Ultrasound cannot 
reliably detect solid lesions <1 em in diameter? In fact, in 
one stud!' of 12 cancers <1 em, ultrasound failed to detect 
11(92%). Finally, microcalcifications are not consistently 
visible sonographically.7•9 Mammography, however, can 
consistently detect suspicious microcalcifica tions 
regardless of location. Many of these microcalcifications 
can be <O.Smm in diameter.10 Mammography is better in 
both resolution and contrast, and thus is a better screening 
tool. 
While mammography is the accepted imaging 
modality for breast cancer screening, ultrasound may yet 
have a role. Recently, there have been a few retrospective 
reports of malignant breast masses being initially detected 
only by ultrasound after negative high-quality 
mammograms and negative clinical examination.5 For 
example, Gordon and Goldenberg at UBC reviewed 12,706 
cases of breast ultrasound performed between 1989 and 
1994 for evaluation of a palpable abnormality or a 
nonpalpable, mammographically detected mass. 11 Of these 
cases, 1575 "sonographically incidental" masses were 
detected that had not been palpable nor seen on 
mammography. Of these incidental masses, 44 (2.8%) 
were surgically confirmed as malignant. A recent 
prospective study presented by Kolb et al. at the 
Radiological Society of North America Meeting in 
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October, 1996 examined 2,300 women w ith 
radiographically dense breas ts, negative findings on 
mammography, and a negative clinical examination.5 
Ultrasound on these women revealed a breast cancer 
detection rate of 4 per 1000. This is a significant rate for a 
screened population. 
In summary, combined evidence shows that 
ultrasound alone is an inadequate imaging modality in 
comparison to mammography in the role of primary 
screening for breast cancer. The main reasons include the 
inability to depict microcalcifications, difficulty in imaging 
fatt y breast, inability to differentiate benign from 
malignant solid masses, and unreliable depiction of solid 
masses smaller than 1cm? Evidence has shown, however, 
there may be a role as a secondary screening technique in 
high-risk women. These include those women w ith a 
strong famil y history of breas t cancer, those wi th a 
personal history of breast cancer, or those with suboptimal 
mammography.5 Further prospective research is needed to 
better clarify this role. 
What is the role of ultrasound in the diagnosis of breast 
disease? 
The primary and most important role for ultrasound 
in evaluating breast disease is the differentiation of the 
cystic vs. solid nature of a mass found by either palpation 
or mammography (Figure 1).5•7• •9 This differentiation 
reduces the need and therefore the trauma and cost of 
surgical biopsies . The significance of this is revealed in 
that more than 500,000 benign breast biopsies are 
performed per annum in the USA.12 It is not unreasonable 
to assume a similar relative prevalence in Canada . 
Ultrasound is reported to be 95-100% accurate in 
diagnosing a lesion as a cyst if all criteria are strictly met.5 
These criteria include a lesion which on ultrasound has no 
internal echoes, smooth and sharp margins, and a round 
or oval shape . Reactive shadowing at the edges and 
posterior acoustic enhancement may also be present. If 
these criteria are met on assessment of a mass, mos t 
radiologists would consider it diagnosticY.B Sonographic 
signs suspicious for malignancy include a hypoechoic 
mass and margin irregularity. It is important that for any 
Figure la: An example of a simple cyst diagnosed through breast 
ultrasound 
suspicious solid lesion, or any lesion not strictly following 
the classic cyst pattern on ultrasound, a biopsy must be 
considered to confirm a diagnosis. 12 
This capability is even more valuable in the evaluation 
of a palpable breast mass in a woman younger than 30. 
These women are not regularly screened b y 
mammography and have an extremely rare incidence of 
breast cancer. They are also more sensitive to radiation 
than older women. For these reasons, many recommend 
ultrasound as the primary imaging modality for palpable 
masses in this age group.7,8 If the mass is a cyst, no 
further evaluation is required. If not, then one would 
obtain a mammogram and then a biopsy. While 
ultrasound has a unique role for this age group, it should 
be stressed that for women older than 30, it is 
recommended to begin imaging with mammography, 
using ultrasound as an adjunct when indicated. 
A second diagnostic indication for ultrasound is in the 
investigation of women where mammographic sensitivity 
is low. These conditions include radiographically dense 
breasts, near prostheses, at the breast periphery in rare 
cases of mammographic inaccessibility, in surgically 
altered breasts, or in the breasts of pregnant or lactating 
women. Ultrasound is not an alternative to 
mammographic screening of these women, but is an 
adjunct to be used when mammography is 
contraindicated or of unacceptable quality.5•7.s 
A third major role for ultrasound in diagnosis is as a 
guidance mechanism for interventional procedures.13•14 
Classically, open surgical biopsy has been the gold 
standard for the diagnosis of a breast lesion. This can be 
costly and traumatic as the standard of care has been 
lesion removal by lumpectomy to both diagnose and 
provide definitive treatment concurrently. More recently, 
surgical intervention to this extent has been widely 
replaced by fine needle aspiration (FNA) or core needle 
biopsy (CNB), so as to reduce trauma for benign disease. 
While the efficacy of these procedures compared to 
surgical biopsy has never been studied in a randomly 
controlled trial, a retrospective study has reported false 
negative rates as low as 0.04%·14 For readily palpable 
lesions, these procedures can be guided by physical exam. 
Figure lb: A solid mass proven to be malignant by ultrasound-
guided core biopsy 
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For non-palpable lesions discovered through 
mammography, however, imaging gu id ance is 
imperative. As well as ultrasound, needle biopsies have 
been successfully guided via mammography, CT, MRI, 
and nuclear medicine studies. The efficacy of FNA and 
CNB appears to be independent of the imaging guidance 
system if properly done.14 Ultrasound, however, has the 
advantages of being relatively cheap, a traumatic, and real-
time. It is currently a favored modality.13•15 
What is the role of ultrasound in therapy fo r b reast 
disease? 
While ultrasound is primarily a diagnostic modality, it 
does have some therapeutic indications. Ultrasound-
guided cyst aspiration is performed not only for 
diagnostic purposes, but is also indicated for the relief of 
symptoms such as pain .14 The real-time nature of 
ultrasound is beneficial for these indications as one can 
visualize cyst reduction.9 Similarity, ultrasound can be 
utilized for the therapeutic drainage of an abcess. 9 
For solid masses, definitive treatment most often 
in volv es surgery. Ultrasound plays a useful role in 
imaging the pre-operative needle localization of a 
malignancy.8 By using the pre-placed needle as a guide, 
the surgeon can then confidently excise the mass with 
minimal trauma and disfigurement. This procedure is 
especially useful for non-palpable masses. 
What is the future of ultrasound in the management of 
breast cancer? 
With technological development and increasing 
resolution ultrasound may eventually have a role in breast 
screening as previously described. While it is unlikely to 
ever replace mammography for primary screening, it may 
eventually be a suggested adjunct for more efficacious 
screening programs. 
Better technology ma y also enable better 
differentiation between solid masses. While ultrasound at 
present is excellent in differentiating cystic from solid 
lesions, it is not yet acceptable in distinguishing benign 
from malignant states. Some authors have described 
different characteristics of a solid mass which suggest 
malignant vs. benign pathology .16 Malignant 
characteristics include spiculation, angular margins, 
marked hypoechogenicity, shadowing, calcification, duct 
extension, a branching pattern, and rnicrolobulation. More 
benign patterns include an absence of these malignant 
findings, intense hyperechogenicity, an ellipsoid shape, 
gentle bi- or trilobulations, and a thin , echogenic 
pseudocapsule. Stavros et al. go on retrospectively to say 
that for solid masses with classic benign characteristics on 
ultrasound the negative predictive value is over 99%.16 
Furthermore, they state that these cases can be managed 
with close follow-up imaging rather than biopsy. It is 
important to note that there are no prospective data to 
support this statement.5 The current standard of care is to 
biopsy any non-cystic lesion, at least via FNA, to obtain a 
more accurate tissue diagnosis. This information does, 
however, raise the possibility that perhaps with improved 
technology and further research, ultrasound may account 
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for a vast reduction in the number of unnecessary 
biopsies. 
Doppler ultrasound is another technology that may 
develop further. The rationale for its use is the fact that 
many cancers appear to have far greater blood flow 
through neovascularization than do benign lesions. In one 
study, Cosgrove et al. state that 96% of benign breast 
changes had no color Doppler signals. They state that 
vessels were detected in 57 of 58 cancers. 17 According to 
their study, one could conclude that "color Doppler 
signals in a lesion otherwise thought to be benign should 
prompt a biopsy, while the absence of signals in an 
indeterminate les ion is reassuring" 17• While this 
conclusion has little clinical implication at present, it does 
suggest that with future technology Doppler may have a 
role in differentiating benign from malignant lesions. 
Conclusion 
Currently, mammography is the imaging modality 
most widely associated with the management of breast 
cancer. Ultrasound is an adjunctive modality which also 
should be considered. While at present it has little value in 
screening for breast cancer, it does have value in other 
roles. Diagnostically, its most important uses include 
differentiating cys tic from solid lesions, as well as in 
guiding fine needle aspiration and core needle biopsy. 
Therapeutically, ultrasound is useful in cyst drainage and 
in needle localization of non-palpable masses for surgery. 
Due to its many attractive features, fur ther technological 
development may expand the role of ultrasound, and 
ultimately improve the management of this prevalent and 
serious disease. 
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THE CLINICAL BREAST EXAMINATION 
INTRODUCTION 
A s a third year medical student given the task of performing a full physical exam on a female patient over the age of 55, it struck m~ that a "full 
physical" excluded a clinical breast exam: ~s .Pro~p.ted 
an investigation into medical student trammg m Clinical 
Breast Exam (CBE) skills, which suggested that the breast 
examination does not receive sufficient emphasis in the 
current curriculum and that more effective ways of 
teaching it could be employed. . 
My research includes a review of literature concemmg 
the importance of the Clinical Breast Exam and .the ~o~t 
effective ways of teaching it and of ensurmg It IS 
performed on all eligible patients. As well, I conducted a 
brief survey of the UWO Medical School Cl~ss of 20~0 
three weeks prior to the commencement of therr clerks~p 
in order to assess their level of training and degree of skill 
and comfort with respect to the CBE. As the pelvic and 
rectal exams are also excluded from "full physical exams" 
I asked students to exclude these exams when comparing 
the CBE to other components of the physical exam. One of 
the main purposes of the survey was to determine if the 
increased number of times students performed other 
clinical skills as well as the increased opportunity for 
observation and feedback would make the students feel 
more comfortable and proficient with them. A skill such as 
auscultation of the heart is performed on virtually every 
patient seen in the Phase II or second-year Clinical 
Methods Curriculum. It may be unreasonable to attempt 
this level of exposure to the CBE as it is more invasiv~ of 
patient privacy, however, this in itself argues for ensurmg 
the CBE is emphasized in the curriculum in other ways. 
At the University of Western Ontario Faculty of 
Medicine, pre-clerkship training on th~ clinic~! bre~st 
exam consists of one three hour self-leammg sesswn usmg 
a model of a female breast. There is no formal training on 
patients, either actual or standardized. Students may reach 
their clerkship without having performed a CBE. The 
literature clearly demonstrates that this training is not 
sufficient. A retrospective analysis using clinical clerks at 
two different US medical schools showed that over 50% of 
students had not had a single CBE supervised during the 
course of their clerkship.10 
RELEVANCE OF THE CLINICAL BREAST EXAM 
Breast cancer is the most common malignancy and the 
second leading cause of death among Canadian women 
over the age of 55. Breast cancer accounts for 30% of all 
new cancers in Canadian women.1 While both genetic and 
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environmental factors have been implicated as etiologic 
factors, the cause remains unknown. 
Breast cancer screening consists of a three-tiered 
strategy which includes breast self-exa~ (BS~) by the 
patient and clinical breast exam (CBE) and rmagmg of the 
breast through either ultrasound or mammogr:aphy by the 
physician. Current screening recommendations are for 
women between ages 50-69 to perform a monthly breast 
self-exam and to receive a l.earl~ clinical breast ex~ .and 
a bi-armual mammogram. The rmportance of physiCians 
performing a clinical breast exam in addition to 
mammography has been underscored in a stu~y of the 
two modalities' sensitivity for cancer detectiOn. The 
sensitivity for cancer detection is 24% with CBE alone and 
62% with mammography alone while the sensitivity of the 
two methods combined is 75%.3 Furthermore, women may 
learn how to perform a self-exam of the br~ast by 
watching their physician. Alternately, havmg the 
physician perform the exam may underscore to them the 
importance of palpating the breast and thus encourage 
them to monitor their breasts monthly. 
Data in both Canada and the United States suggest 
that physicians and students are not following the current 
screening recommendations. 4 In fac~, the numbe~ of 
women who report having a CBE at therr armu~ ~hysical 
is decreasing.5 Studies investigating why p~ysiCian:' do 
not perform clinical breast exams on all eligible patients 
frequently cite a lack of physician comfort and skill as the 
causal factor.5•10•11 A study of 398 physicians in Minnesota 
found that less than one third of them reported their skill 
at performing a CBE as excellent and less than half of 
them described themselves as "very comfortable" 
performing the exam. Also of note was ~a.t in comparison 
to their male counterparts, female physicians were more 
comfortable and more likely to assess their skills as 
excellent in numbers which reached statistical 
significance.5 Another study by the same authours f?und 
that in addition to being more comfortable performmg a 
CBE, female physicians also performed the exam .on more 
eligible patients than their male counterparts.6 This echoes 
the results of another study which documented that 
patients of female physicians were significantly more 
likely to be screened by a clinical breast exam than 
patients of male physicians and that neither group 
screened all eligible women.3 From this data, the lesson 
can be drawn that first, there is a deficit in screening with 
CBE. Second, physicians are less likely to perform CBE if 
they are uncomfortable performing the skill. Third, t~e 
reasons why female physicians are more comf?~tabl~ With 
and more likely to perform a CBE must be elicited m the 
hope of eliminating this gender disparity. . 
Unfortunately the trend of decreased screemng 
numbers and gender disparity in physician comfort level 
exists at the student level as well. For example, a 
retrospective chart review of 111 women eligible f~r CBE 
seen by internal medicine residents at George Washington 
University Medical Centre showed that only 35 of them 
received a clinical breast exam? An assessment of primary 
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care residents from seven training program noted 
performance deficiencies in breast examination skills and 
lump detection sensitivity. There were significant 
differences in the performance abilities of residents from 
different training programs. The programs with poorer 
performance in Clinical Breast Exam were also the 
programs where the CBE was not emphasized in the 
curriculum and the residents described the training they 
received as "poor to fair" .8 
A survey of students currently entering their clinical 
clerkship at UWO posed the question "Relative to other 
clinical skills (but excluding pap and rectal exam) how 
adequate is the instruction you have received through the 
Clinical Methods Curriculum?" Students were asked to 
rate it as "Excellent, Good, Fair or Poor" Of 57 
respondents, 50 (89%) considered it "Poor", 6 considered it 
"Fair" and 1 considered it "Good". A second question 
posed was "Relative to other clinical skills (but excluding 
pap and rectal exam) how comfortable / relaxed do you 
feel performing a clinical breast exam? " Of 57 
respondents, 36 answered "Poor" and 14 answered "Fair". 
Only 6 students answered either "Good" (n=4) or 
"Excellent" (n=2). In response to the question "Relative to 
other clinical skills (but excluding pap and rectal exam) 
how confident do you feel about your ability to detect a 
breast pathology by performing the CBE?" 38 respondents 
said "Poor" and 16 said "Fair" and 3 said "Good". No 
students felt their ability to detect pathology was 
"Excellent" relative to their other clinical skills. This data 
argues strongly for placing greater curriculum emphasis 
on theCBE. 
TEACHING THE CLINICAL BREAST EXAM 
The most effective way to teach current and future 
practitioners the CBE and to ensure they perform it on all 
eligible patients has been addressed in a number of 
studies with success. The medical school curriculum at the 
University of Western Ontario could benefit greatly by 
adapting successful strategies for teaching clinical breast 
exam. The outcome would be more competent and 
comfortable future physicians. 
A compelling argument can be made that to improve 
both the level of comfort and skill of medical students in 
performing CBE need not be a time-consuming measure. 
The impact of even one training session or intervention to 
teach Clinical Breast Exam has been documented in 
several studies. A study that used an office-based training 
program targeted at primary care physicians improved 
their ability to correctly detect lumps in a silicone breast 
model. The mean number of correct lump detections in a 
model With 5 lumps increased from .66 before to 3.2 after 
instruction and the improvement was sustained at a six 
month follow-up . 
Utilizing standardized patients is an alternative 
method by which some schools teach the CBE. A study 
conducted using medical students compared the 
performance of a control and experimental group. Both 
groups received "traditional" instruction consisting of a 
thirty minute videotape on the breast exam and assigned 
readings immediately prior to commencing their clinical 
clerkship. In addition, the experimental group received a 
single 70 minute teaching program nu(by Standardized 
Patients (SP's) in which they performed a CBE, received 
feedback and then practiced the CBE on the Standardized 
Patient while receiving ongoing feedback . The 
experimental group scored significantly for both skill level 
and professionalism at an OSCE station for CBE in a 
follow-up at the end of the twelve month clerkship.10 
CONCLUSION 
The conclusions to be drawn from this are clear. The 
Clinical Breast Exam is a necessary part of women 's 
healthcare which should be performed on all women 
according to current screening recommendations. There 
exists among both current and future physicians a 
phenomenon of sub-optimal screening rates, skill level 
and comfort level. This has been documented at UWO by 
a student seU-assessment survey. Interventions to teach 
the CBE can be simple and effective and thus curriculum 
modification need not be extensive. It could mean 
replacing the three hour self-learning session with a 
supervised viewing of the video followed by supervision 
of the CBE on the current model breast. Alternately, access 
could be provided to the more sophisticated breast models 
employed in the Breast Cancer Clinic. It may even be 
possible to arrange for students to attend a pre-operative 
clinic for women with carcinoma of the breast. As a 
responsive and responsible medical school, the University 
of Western Ontario should strive to address any and all 
curriculum deficits. It is in the interest of women's health 
and physician competence to enlarge the role of CBE in 
the pre-clerkship curriculum. 
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THE LINK BETWEEN ORAL 
CONTRACEPTIVE USE 
CANCER 
AND BREAST 
INTRODUCTION 
Breast cancer is a serious, prevalent disease affecting women around the world. This is a health issue of particular interest to researchers, since the incidence 
of breast cancer in women has been increasing.1 A number 
of researchers have investigated the possible link between 
estrogen and the pathogenesis of breast cancer. More 
specifically, research has been conducted to investigate the 
relationship between oral contraceptive use and breast 
cancer in women. This article is a review of recent research 
on this topic. 
ESTROGEN AND BREAST CANCER 
It has been well established that hormones such as 
estrogen play key roles in the development of breast 
cancer. 1 It is thought that these hormones increase risk of 
breast cancer via effects on cell division in breast 
epithelium. Research suggests that "the cumulative 
frequency of ovulatory cycles is a primary determinant of 
breast cancer risk." 1 For instance, it has been found that 
women with breast cancer tend to have shorter menstrual 
cycles, earlier age of regular menstrual cycles, and later 
age of menopause, than controls.1 There is also substantial 
laboratory evidence that suggests that estrogen is related 
to breast cancer risk. For instance, mice and rats exposed 
to exogenous estropens have increased incidence of 
mammary tumours. In humans, breast cancer patients 
have been found to have up to four times as much free 
estriol as controls. 
Overall, there is strong evidence of a link between 
estrogen exposure and breast cancer. Since such a link has 
been established, there is reason to believe that oral 
contraceptives, or other exogenous estrogens, ma y 
increase one's risk of breast cancer.1 This is an important 
area of investi9ation, since a number of women use oral 
contraceptives. This leads to the next section, which will 
review the research findings to date on the relationship 
between oral contraceptives and breast cancer. 
ORAL CONTRACEPTIVE USE AND BREAST 
CANCER 
In a review of research on oral contraceptive (OC) use 
and breast cancer, it is reported that the majority of 
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epidemiological research that was published prior to 1984 
did not find evidence of OC use related to increased risk 
of breast cancer.3 However, since 1984 there have been a 
number of studies that suggest that some sub-groups of 
women who use OCs have an increased risk of breast 
cancer, along with several studies finding no such 
association, resulting in contradictory, and difficult-to-
interpret findings . 
When studying women who have ever versus never 
used OCs, research has failed to find a relationship 
between ever use of OCs and breast cancer risk.3 A group 
of researchers have suggested that "ever" use of OCs is 
likely too crude of a measure to reveal a link, if one exists.3 
They suggest that researchers consider sub-groups within 
OC users, since positive links between OC use and breast 
cancer are more often found in studies which focus on 
particular subgroups of women. For instance, most of the 
studies that have investigated OC use in women 
diagnosed with breast cancer at a young age (under age 
45) have found that OC use does increase the risk in this 
subset of women. 3 In a meta-analysis of such studies, 
researchers found an overall RR of 1.5 for young women 
in one review of research, 4 and a summary RR value of 1.4 
was found in another review. 5 Also, it appears that long 
duration of OC use before full term pregnancy is 
associated with increased risk of breast cancer, with 
summary risk estimates being 1.7,4 and 1.4.5 
A prospective cohort study was recently conducted to 
investigate the breast cancer risk associated with OC use 
in a number of sub-groups of women. 6 This study 
involved the Nurses' Health Study in the US, which 
included 114 880 women. Of these women, 3 383 had 
breast cancer. The researchers found a marginally 
significant increase in breast cancer risk in women who 
had last taken OCs within the past five years (RR = 1.20; 
95%CI = 1.00 - 1.44). As the authors reported elsewhere,6 
they also found increased risk of breast cancer associated 
with current OC use (RR = 1.53; 95%CI = 1.06- 2.19). There 
was no relationship between breast cancer risk and OC 
use prior to first pregnancy, even when analyses only 
included the sub-groups of women by age and parity. 
Also, no relationship was found between duration of OC 
use and breast cancer.6 
There are a number of strengths of this study. First of 
all, this has been the largest prospective study to date on 
this topic . Since the investigation was prospective in 
nature, there was little likelihood of selection or recall 
bias. 6 Secondly, the researchers controlled for many 
possible breast cancer risk factors in their analyses (e.g. 
age, BMI, age at menarche, etc.) . In addition, the OC users 
and non-users in this study were similar on most of these 
risk factors. Finally, there were high follow-up rates of the 
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study participants (at least 90%).6 
A weakness of this study is that there was limited 
power in some analyses, since there were few cases in 
some of the sub-groups.6 For instance, there were only six 
OC users with breast cancer in the 30-34 year age group, 
and 27 OC users with breast cancer in the 35-39 year age 
group. The limited power here may explain why this 
study did not confirm other studies' findings that OC 
users under the age of 45 are at increased risk of breast 
cancer.6 The studies that found such a relationship tended 
to be case-control studies, which had more cases, and thus 
increased power. 
In summary, these investigators found that current 
and recent OC use is associated with increased risk of 
breast cancer, a finding that has also been reported in 
reviews and meta-analyses. 6 They did not find any 
increases in breast cancer risk due to long OC use, or OC 
use prior to first pregnancy, which is also consistent with 
other recent studies. Finally, their one finding that was not 
consistent with other research findings (lack of increased 
risk for OC users under age 45) should be interpreted with 
caution, since there was limited statistical power for this 
particular analysis. Overall, the findings of this study were 
consistent with the view that any relationship that may 
exist between breast cancer and OC use is a short-term 
effect only. 
A large case-control study that was conducted fairly 
recently found relationships that were consistent with the 
findings of the previously discussed study.6 This was a 
population-based case-control study, with 6751 cases and 
9311 controls? As with the previously discussed study, in 
this investigation a number of potential confounding 
variables were controlled. The researchers found that 
recent use of OCs (within past 5 years) for women aged 
35-44 years was associated with increased breast cancer 
risk (RR = 2.0; 95%CI = 1.1 - 3.9). However, the authors 
did not find a relationship between breast cancer risk and: 
current use of OCs, age at first use of OCs, or long 
duration of OC use? 
Newcomb et al's case-control study has a numb r of 
strengths .6 Firstly, they had more power than did 
Hankinson et al's cohort study, 7 for they had twice as 
many cases . Secondly, they had high questionnaire 
response rates (80.7% for cases, and 84.2% for controls). 
Furthermore, their questionnaire was quite reliable, for 
when they retested it 6-12 months later, the Spearman 
correlation coefficients ranged from r = 0.89 to r = 0.98. 
Finally, they found that the recent cancer cases who were 
0C users in their study were less likely to have undergone 
mammography than the cases who were former users, 
which allowed them to rule out the possibility that their 
positive findin~s were due to increased surveillance in 
recent OC users. 
Overall, Newcomb et al found that recent OC u ers 
who were aged 35-44, and / or had low BMI, were at 
increased risk of breast cancer? However, duration of use 
was not a risk factor. The researchers considered two 
possibilities for their findings of an increased breast cancer 
risk in recent OC users. Firstly, this finding could be 
merely due to the fact that young women are more likely 
to have used OCs recently, and they seem to be more 
prone to OC effects. Secondly, the results could suggest 
that OC effects on breas t cancer risk are due to 
promotional effects on existing tumours, rather than due 
to triggering effects? 
In summary, research that was reviewed by Malone et 
al generally found that OC use for a long duration prior to 
first pregnancy increases a woman's risk of breast cancer.3 
However, two large studies since then have not 
corroborated these findings.6•7 What has been found in 
most recent studies is that recent and/ or current OC use is 
a risk factor for breast cancer.6•7 This, combined with lack 
of evidence for a relationship between long-term OC use 
and breast cancer, suggest that OCs may play a small, 
short-term promotional effect on existing cancer 
tumours.6•7 
CONCLUSION 
There are a number of aspects of the research that are 
in support of a link between OC use and breast cancer. 
First of all, carcinogenic effects of OCs on the breast is 
biologically plausible, given experimental evidence. 
Secondly, prospective cohort studies and case-control 
studies have found a link between OC use and breast 
cancer. Thirdly, findings that OCs play a role in breast 
cancer is consistent with the descriptive epidemiology of 
cancer, since breast cancer incidence is increasing as OC 
use increases. However, there are a number of weaknesses 
with the research to date. First of all, the research in this 
area lacks consistency. Secondly, the strength of the 
association in studies with positive findings tends to be 
quite low. Finally, although the quality of research seems 
to have improved, recent research still lacks enough cases 
to have high enough statistical power for analyses of sub-
groups. The only conclusion that can be made thus far is 
that OCs seem to have a small, promotional effect on 
breast cancer in some sub-groups of women, such as those 
who are young and are currently using OCs. There does 
not appear to be evidence of long-term effects of OC use 
on breast cancer risk. 
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NAUSEA AND 
PREGNANCY: A 
INTRODUCTION 
Nausea and vomiting during pregnancy (NVP), better known as "morning sickness," affects upwards of 50% of pregnancies.1-1 1 It is thought to 
occur more frequently among nulliparous women in 
Western populations and tends to recur in subsequent 
pregnancies.3•12•13 In the majority of these cases, NVP is 
clustered in the first trimester, but not necessarily during 
the morning hours?·9 Its occurrence is so pervasive that 
VP is considered a hallmark of pregnancy. The 
experience of NVP may include fatigue, irritability and 
sleep disturbances . Although research has failed to 
produce definitive conclusions regarding the aetiology of 
VP, many believe it to be a normal physiologic 
occurrence which results the sudden and substantial 
physiologic changes which characterize the first few 
weeks of pregnancy.12 Often, NVP subsides, without 
residual effects, near the end of the first trimester. 
In a small proportion of VP cases, however, 
vomiting is so severe and prolonged that it interferes with 
the woman's fluid intake and nutrition. This can translate 
to significant weight loss (>5% of body weight) and 
electrolyte and acid-base imbalances which often bring 
about hospitalization.3 The prevalence of this condition, 
known as hyperemesis gravidarum (HG), is estimated to 
range from 0.5 to 10 per 1000 pregnancies.8•14•15 While some 
may dismiss NVP as not being a legitimate medical 
concern, research findings suggest that the experiences of 
VP and HG affect the quality of women's lives. For 
example, data from a Swedish survey indicated that in 
12% of pregnancies, NVP was so severe that it precluded 
continuous employment.7 Alarmingly, data from the 
Motherisk program at the Hospital for Sick Children, 
corroborated by the findings of Jarnfelt-Samsioe, indicate 
that a significant number of women decide to terminate 
their pregn<l!lcies as a result of their experience with NVP 
and/ or HG?·16 There are, however, many methodological 
issues regarding the Motherisk study which are deserving 
of mention. The first concern is how representative the 
study sample is of the general populace, as women who 
were enrolled as participants had voluntarily responded 
to advertisements placed in Canadian and American 
newspapers, magazines and electronic media. It could be 
that women who responded to the advertisement were 
motivated, for whatever reason, to share their story. Thus, 
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VOMITING IN 
BRIEF REVIEW 
By Tammy Clifford 
these results may not generalize to the general population 
of pregnant women. Secondly, the study's retrospective 
design may have biased some findings, as women who 
elected to terminate their pregnancies may have been 
searching for a reason and, upon reflection, the experience 
of NVP was an easy reason to give. This is not to say that 
these results are untrue but that caution should be used 
when interpreting study results and that future works 
must address these methodological deficiencies in order to 
facilitate understanding of NVP. It is not doubted that, as 
researchers from the Motherisk program suggest, this 
finding is an "unacceptable combination." 16 It is evident, 
then, that much work remains to be done in order to 
improve our understanding of VP and HG and to 
minimize its effects on the lives of pregnant women and 
those around them. 
DIAGNOSIS 
Although NVP and HG can be thought to represent 
opposite ends of a continuum, both are diagnoses of 
exclusion; before establishing a diagnosis of NVP or HG, 
clinicians must first rule out other potential causes of 
nausea and/or vomiting, such as gastroenteritis, 
cholecystitis, peptic ulcer, food poisoning, etc. The 
experience of NVP is, undeniably, bothersome but is 
usually a self-limiting condition. On the other hand, the 
experience of HG can, if left untreated, be potentially life-
threatening. Clinical features of HG include intractable 
vomiting which can lead to significant weight loss, severe 
disturbances of electrolytes , depletion of mineral stores, 
and hypovolemia. Laboratory findings indicate ketonuria, 
hyponatremia, hypokalemia, hypochloremia, metabolic 
alkalosis with paradoxical aciduria and elevations in urine 
specific gravity, hematocrit, and blood urea nitrogen.6 
OUTCOMES 
Substantial reductions in maternal mortality have 
been made over the past few decades, owing to improved 
understanding of the effects of HG and aggressive 
treatment strategies which aim to restore maternal fluid 
and electrolyte balances. Left untreated, complications of 
HG include Wernicke ' s encephalopathy, 17•18 coma, 
hepatorenal failure and death. 
Historically, NVP was thought to be a positive 
predictor of pregnancy outcome, specifically with respect 
to birth weight and gestational age. 13•19 Recent findings 
uphold the suggestion that the experience of VP is 
associa ted with a reduced risk of miscarriage, stillbirth, 
fetal mortality, preterm delivery, low birth weight, 
perinatal mortality or growth retardation. 7•9•20 The 
outcome of HG, however, is not so definitive. While most 
studies report no substantial deleterious effects of HG on 
maternal and fetal outcomes/ ·9•13.21•23 several studies report 
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associations between severe HG and negative outcomes 
such as fetal growth retardation, pre-eclampsia and small-
for-gestational age births.8.21.24-26 Other reports have hinted 
at an elevation in CNS and skeletal malformations in 
children whose mothers experienced HG.8.21.26.27 It has also 
been suggested that maternal ketonemia, whether due to 
HG or a metabolic disorder, adversely affects the 
neuropsychological development of the infant. 28•29 It is 
important to note, however, that the limitations associated 
with the designs of these studies make it impossible to 
infer a causal relationship. Additionally, it is expected that 
prompt and appropriate treatment to address maternal 
weight loss and electrolyte imbalances will reduce the 
likelihood of adverse outcomes.2 
AETIOLOGY 
In keeping with the established trend of uncertainty 
and despite concerted research efforts over the past few 
decades, the exact mechanisms underlying NVP and HG 
are still unknown. Recently proposed mechanisms include 
Helicobacter pylori infection,30 vitamin B deficiency/1.32 
endocrine imbalances/ 3-36 alterations in serum steroid 
hormone levels,11 .26.37-J9 and psychological disturbance .3' 41}. 
50 While each of these hypotheses has been studied 
clinically, none has been proven definitively. 
For example, an association between HG and human 
chorionic gonadotropin (hCG) is plausible, given that the 
incidence of HG in pregnancies of multiple gestation is 
elevated, as is the concentration of hCG. The fact that the 
onset of HG corresponds to the time at which hCG levels 
reach their peak lends further support to this hypothesis. 
Research findings, however, have been contradictory, 
weakening the possibility of a causal association.3•11.38.51-55 
In terms of psychology, some researchers have sugge ted 
the NVP and HG may stem from a "protest" reaction 
against the pregnancy and/ or attempts by the woman to 
elicit attention and sympathy from family and friends 
while addressing hostility toward the father of the 
baby.40•41 •4 The absence of definitive research findings, 
despite concerted efforts, may be attributable, in part, to a 
failure to see NVP and HG as manifestations of an 
interplay of biological, psychological and social factors . 
Additionally, most studies have examined nausea and 
vomiting as a single entity. This could introduce bias into 
the research, particularly in retrospective works, since 
nausea, as a subjective entity, is more difficult to recall 
than vomiting. Future research must address these 
limitations and utilize sound study designs if our 
understanding of these condi tions of pregnancy is to 
improve. 
TREATMENT 
The management of VP in mildly symptomatic 
women typically involves reassurance, dietary 
modifications and, in some cases, drug therapy. 
Pharmacological measures may need to be considered for 
the treatment of women whose NVP continues, even after 
receiving reassurances and after modifying her diet. 1.2.16 In 
light of the thalidomide experience, however, it is 
understandable that both physicians and their patients 
continue to express concern over the safety of 
pharmacological agents, including anti-emetics, 
administered during early pregnancy. Caution is 
reasonable and it is accepted that medications be used 
during pregnancy only when absolutely necessary. While 
there are a number of options available to physicians, at 
this point in time, Dilectin (doxylamine succinate + 
vitamin 86) is the only medication approved by Health 
Canada for use as an anti-emetic in the treatment of 
NVP.56 
For women who experience HG, timely treatment 
must address hypovolemia, electrolyte imbalances and 
ketosis. Results of one study, which indicated that, relative 
to controls, the mean dietary intake of most nutrients for 
women with HG was less than 50% of the recommended 
daily allowance, 57 highlights the fact that these patients are 
at high nutritional risk. Nothing should be given by 
mouth until dehydration is corrected and vomiting is 
controlled.58.59 If the episode is prolonged, consideration 
should be given to vitamin supplementa tion, via the 
parenteral route .60•61 ' 62 Emotional support, perhaps 
including psychological therapy, is especially important 
throughout this time.63•64 
PREVENTION 
From all perspectives, prevention is always better than 
cure. In the case of NVP and HG, however, the absence of 
a causal model translates into tremendous difficulty in 
reducing the incidence of these conditions. Nevertheless, 
results of a randomized, double-blind controlled trial of 
periconceptual vitamin and mineral supplementation, 
initiated to demonstrate the effect of these supplements on 
the incidence of neural tube defects, indicated that these 
supplements also reduced the incidence of NVP and HG.65 
Although this appears to be "good news," this hypothesis 
remains to be proven in prospective randomized trials 
initiated specifically to examine this particular research 
question. 
CONCLUSIONS 
A wide variety of disorders have been implicated in 
the aetiology of NVP and HG. Future research must 
address the likely interplay of biological, psychological 
and social factors in the aetiologies of NVP and HG and 
utilize prospective methods in representative, sufficiently-
large samples which would permit detailed examination 
of a number of factors in multivariable models. 
Until the scientific community can elucidate the causal 
mechanism(s) underlying NVP and HG, clinicians must 
ensure that patients are provided with prompt and 
appropriate treatment(s) , thereby ensuring optimal 
outcomes for mother and child. 
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THE LONG TERM CONSEQUENCES 
OF POLYCYSTIC OVARY SYNDROME 
Polycystic ovary syndrome (PCOS), also known as Stein-Leventhal syndrome, is the most common endocrine disorder in women of reproductive age. 1 
In fact, it is the leading cause of pathologic amenorrhea in 
premenopausal women and is one of the leading causes of 
female infertility.2 Approximately 75% of women with 
PCOS have fertility problems.3 
PCOS is a heterogeneous syndrome characterized by 
an increased LH:FSH ratio (>2.5), elevated androgens, and 
anovulation.4.s Normally, LH stimulates ovarian theca cells 
to produce androgens such as 17-hydroxyprogesterone, 
androstenedione, and testosterone from cholesterol via 
cytochrome P450c-17 alphahydroxylase. Ultimately, these 
androgens undergo aromatization by the FSH-stimulated 
granulosa aromatase.6 However, in women with PCOS, 
the high LH levels cause ovarian theca cell hyperplasia, 
resulting in excess of these androgens and thereby halting 
follicular development within the ovary. Since a dominant 
follicle is not being formed, multiple cysts occur on the 
ovary, eventually causing impaired estradiol production.2 
This abnormal secretion of estrogen results in chronic 
anovulation, which may be manifest as amenorrhea, 
oligomenorrhea, or dysfunctional uterine bleeding. In 
addition to these symptoms, acne, hirsutism, and / or 
male-pattern baldness may be present due to androgen 
excess? 
Androgen excess in PCOS may also occur due 
to the adrenal glands, resulting in increased 
levels of dehydroepiandrosterone (DHEA) and 
dehydroepiandrosterone sulfate (DHEAS), the latter 
hormone being a substrate for ovarian testosterone 
synthesis.6 Although the exact role that adrenal androgens 
play in PCOS and the mechanisms involved have not yet 
been fully established, investigating the source of 
androgen excess in any individual patient is important in 
managing the symptoms of the androgen excess. 
The prevalence of PCOS in the general population has 
been estimated to be about 5-10%. It is interesting to note, 
however, that a recent study of healthy women found that 
22% of these women had ultrasonic evidence of polycystic 
ovaries and 94% of these "normal" women with polycystic 
ovaries had at least one other symptom indicative of 
PCOS. 7 Yet, the importance of PCOS lies not in simply 
diagnosing cystic ovaries but in also understanding the 
associated long term consequences, including infertility, 
insulin resistance, non-insulin dependent diabetes 
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mellitus (NIDDM), cardiovascular disease, and 
endometrial cancer. 
INFERTILITY 
PCOS is often undetected until a woman experiences 
difficulty in conceiving.3 The improper secretion of 
estrogen associated with PCOS causes cessation of 
follicular development and thus, lack of ovum release. 
PCOS is also a risk factor for repeated early spontaneous 
abortion related to the high LH levels and obesity.9 About 
50% of women with PCOS are obese.4 In fact, obesity and 
hyperandrogenism contribute significantly to infertility 
via increased peripheral conversion of androgens 
(primarily, androstenedione and testosterone) to estrone 
within adipose tissue, thereby adding to the already 
abnormal estrogen secretion and menstrual disturbances 
present in PCOS patients.10 Fortunately, diet modification 
and weight loss have been shown to improve these two 
contributing factors and thereby improve cycle regularity, 
ovulation, and fertility rates.11 •12 
INSULIN RESISTANCE AND NIDDM 
Women with PCOS have a greater likelihood of 
having hyperinsulinernia and insulin resistance.7 The exact 
mechanism responsible for insulin resistance is still under 
investigation. However, recent studies have shown that 
peripheral insulin resistance in adipocytes from PCOS 
patients may be due to decreased expression of the 
insulin-mediated glucose transporter protein GLUT -4. 13•14 
Although insulin resistance would be expected to be more 
prevalent in obese women with PCOS, it was actually 
found to be independent of obesity. 14 Interestingly, 
patients with PCOS have double the risk of having 
subclinical bulimia and it has been postulated that this 
may also play a role in the insulin resistance in PCOS 
patients.5• 1 ~ 
Insulin resistance, common to most women with 
PCOS, is important in the development of NIDDM, the 
prevalence of which is seven times higher in PCOS patients 
than in the control population. 16 Moreover, NIDDM 
develops at an earlier age in women with PCOS (third to 
fourth decades) than in the general population (sixth to 
seventh decades).1 Hyperinsulinernia is also a contributor 
to infertility since suppression of insulin concentrations by 
the use of metforrnin has been shown to improve fertility 
rate. 12 As well, it is an independent risk factor for 
cardiovascular disease due to its pro-atherogenic effects, 
including promotion of lipid plaque formation, smooth 
muscle proliferation, and growth factor production.6 A 
recent study has shown that weight control and dietary 
intervention can increase insulin sensitivity (up to 93%) in 
obese women with PCOS and thus potentially decrease the 
risk of NIDDM or cardiovascular disease. 17 
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CARDIOVASCULAR DISEASE 
A number of risk factors for cardiovascular disease are 
present in women with PCOS. PCOS patients tend to have 
higher me~ serum triglyceride levels as well as lower 
HDL levels compared to controls.18'19 As discussed earlier, 
women with PCOS are prone to developing insulin 
resistance, hyperinsulinemia, and I or NIDDM, all of 
which increase the risk for cardiovascular disease. Based 
on the low HDL levels in women with PCOS and the 
correlation between low HDL levels and cardiovascular 
risk in the Framingham study, one author has estimated 
that women with PCOS have a relative risk of about 3 for 
cardiovascular disease compared with the general 
population. 20 However, s ince these risk factors of 
increased triglyceride levels, low HDL levels, obesity, 
hyperinsulinemia, insulin resistance, and NIDDM tend to 
cluster in women with PCOS, it would be reasonable to 
predict that the actual cardiovascular risk may be much 
higher, although no prospective study has yet quantified 
this risk. 
ENDOMETRIAL CANCER 
The risk of endometrial cancer is also increased in 
women with PCOS due to several factors: 1) lack of 
progesterone, 2) obesity, 3) hyperandrogenism, and 4). 
hyperinsulinemia . The lack of cyclical progesterone 
secretion results in unopposed estrogen effects, including 
endometrial hyperplasia . These effects may indeed be 
worsened in obese women with PCOS due to conversion 
of androgens to estrone within adipose tissue? It has been 
found that obese women with an upper body fat 
distribution have a 5.8-fold higher risk of endometrial 
cancer than non-obese women or women with a lower 
body fat distribution .21 Thus, both obesity and the 
distribution of body fat are important in assessing the risk 
of endometrial cancer for women with PCOS. 
H yperandrogenism may further contribute to the 
unopposed estrogen effect by ~oviding additional 
substrate for conversion to estrone. The relation between 
hyperinsulinemia and increased risk of endometrial cancer 
may occur through production of excess androgens. 
Increased levels of insulin cause decreased sex hormone 
binding globulin (SHBG) production, resulting in higher 
circulating levels of androgens.10•23 High levels of insulin 
also cause a decrease in circulating levels of insulin 
growth factor binding protein 1 (IGFBP-1), thereby raising 
the levels of IGF-1. In response to LH, IGF-1 stimulates the 
ovary, resulting in increased activity of cytochrome 
P450c-17 alphahydroxylase, the enzyme responsible for 
production of androgens. Thus, with the decreased SHBG 
levels and increased IGF-1 levels, ultimately increased 
estrone production occurs, thereby compounding the 
unopposed estrogen effect on the endometrium and 
promoting the risk of endometrial cancer.24 
SUMMARY 
PCOS is a relatively common female endocr ine 
disorder tha t should be considered in all women 
presenting with menstrual dis turbances, infertili ty, 
and / or hirsutism. It is associated with an increased 
cardiovascular risk due to obesity, insulin resistance or 
diabetes, high triglyceride levels, and low HDL levels . 
Further, unopposed estrogen contributes to the menstrual 
disturbances, anovulation, and infertility as well as to the 
increased risk of endometrial cancer in these w omen. 
Thus, the treatment and management of women with 
PCOS focuses on preventing the long-term consequences 
of PCOS by reducing obesity, decreasing androgen action, 
normali z ing the endometrium, and correcting 
anovulation. 
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UNDERSTANDING PREMATURE 
OVARIAN FAILURE 
Premature ovarian failure (POF) is a condition that is characterized by elevated gonadotropins, hypoestrogenism and amenorrhea occurring in a 
woman who is younger than 40 years of age.1 POF is not a 
rare condition; indeed, the incidence of POF before the age 
of 40 is estimated to be 1 in 100.1 Despite the rela tive 
frequency of POF, there has yet to be found a definitive 
cause for its occurrence. Many theories have been 
proposed and researched as potential mechanisms for 
POF, and in some cases, specific causes have been found. 
However, for the most part, the etiology of POF remains 
obscure. The following article is intended as a summary of 
current theories used to describe POF. 
WHATISPOF? 
In the early research into causes of POF, it was 
believed that the condition is a true "failure" of the ovaries 
in the sense that it is irreversible.1 However, it later 
became evident that this is not the case. Follicle function 
appears to be at least intermittently maintained in most 
POF pa tients. 1 Studies have shown that follicles are 
present on pelvic ultrasound; as well, some POF patients 
have even become pregnant. 1 Thus, POF is not a complete 
termination of ovarian function. Rather, it is a condition of 
termination of normal ovarian function. 
Clinically, a set of guidelines help to identify a patient 
as having POF. The patient must present with amenorrhea 
before age 40.2 Laboratory criteria specify that amenorrhea 
should be present for more than or equal to 4 months, and 
that 2 serum FSH values of more than 40 miU I mL are 
obtained at least 1 month apart from the patient.2 Of 
particular note is that the progesterone withdrawal bleed 
test is not diagnostic in POF. This is due to the fact that 
some patients with POF may still intermittently produce 
enough estrogen for a withdrawal bleed to take place.1 
CAUSES OF POF 
A convenient way to examine potential causes of POF 
is by dividing the condition into two categories: i. patients 
with follicle depletion, thus resulting in POF; ii. patients 
with follicle dysfunction, thus resulting in POF. 
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I. Follicle Depletion 
If the normal contingent of follicles attributed to an 
ovary were somehow abnormally rapidly depleted, a 
patient may present clinically with amenorrhea and POF. 1 
Some potential causes of follicle depletion include: 
• abnormally low initial follicle endowment (as in cases 
of Turner's Syndrome or gonadal dysgenesis) 1 
• accelerated follicle atresia (determined in some cases 
to be due to balanced translocations of the X 
chromosome; two genes, POF1 and POF2 have been 
proposed) 1' 3 
• enzyme deficiencies such as galactosemia (deficiency 
in galactose-1-phosphate uridyl-transferase) which 
lead to accelerated follicle atresia, as above1 
• chemotherapy, irradiation, or exposure to 
environmental toxins1 
II. Ovarian Follicle Dysfunction 
The category of 'ovarian follicle dysfunction' includes 
those patients with adequate gonadotropins, and follicles 
and oocytes that appear histologically normal yet they fail 
to have normal ovarian function. 1 This group consists of 
many cases of unknown etiology. However, some patient 
groups have been studied, leading to the discovery of a 
growing number of specific causes of POF in patients. 
These include: 
• enzyme deficiencies, as related to defects in the 
17a-hydroxylase enzyme, cholesterol desmolase, 
17-20 desmolase and aromatase enzymes 1 
• signalling defects (defects in gonadotropins or 
gonadotropin receptors)1 
• immune-related dysfunction (association with 
autoimmune diseases, antiovarian antibodies, steroid 
cell antibodies, zona pellucida antibodies or 
oophoritis)1 
MANAGEMENT OF KARYOTYPICALL Y NORMAL 
PATIENTS WITH POF 
For patients that present with POF and who are 
karyotypically normal, there are a number of things that 
the managing physician can do to help the patient 
understand and cope with her condition. A general plan is 
to: i) Inform; ii) Counsel; iii) Replace; and iv) Follow-up.1 
i. Infonn 
When diagnosed with POF, the patient should be 
provided with accurate and up-to-date information. The 
patient should be told that spontaneous remission of POF 
can occur, but that there is currently no known treatment 
forPOF. 1 
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ii. Counsel 
The patient who is concerned about having children 
should be first advised to wait for the possibility of 
spontaneous remission. Adoption or a change in life plans 
should be offered as an alternative to couples. As well, a 
couple may be counselled to consider ovum donation after 
an appropriate waiting period.1 
iii. Replace 
In all cases of POF, there are definite indications for 
hormone replacement therapy to be implemented.1 Full 
hormone replacement will not only reduce the patient' s 
risks for osteoporosis and heart disease, but will also 
alleviate symptoms (such as vasomotor symptoms, 
vaginitis, dyspareunia and urinary frequency) .1 
iv. Follow-up 
There has been some evidence correlating POF to 
autoimmune disorders and adrenal insufficiency.1 
Therefore, it is necessary to maintain a careful follow-up 
schedule with patients with POF. 1 
THE FUTURE OF POF 
As molecular techniques are continuing to evolve, 
new avenues into POF research are appearing on the 
scientific horizon. Immunotherapies have been proposed, 
as well as studies into the role of apoptosis (programmed 
cell death) in POF.1 Furthermore, new developments in 
the field of assisted reproductive technologies may 
increase options for couples with POF.1 Current research 
at the University of Western Ontario is exploring the role 
of intercellular communication through gap junctions in 
the growing follicles in cases of follicular dysfunction (Dr. 
G.M. Kidder, Departments of Physiology and Obstetrics 
and Gynaecology) . Interestingly, knockout mice models 
have been developed that are deficient in certain gap 
junctions expressed in the follicle or oocyte-resulting in 
fe male mice that are infertile, and express ovarian 
histology similar to that of women with POF.4• personal 
cornmunicationa from C. Ackert and G.M. Kidder 
Premature ovarian failure is a fairly common 
condition that patients may present with both to the 
fa mily physician and to the gynaecologist. Study into 
causes of POF are continuously bringing to light new data 
and theories. Hopefully, this brief review will help put 
forth to medical professionals some of the current theories 
of POF and information to pass on to patients. 
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ASPECTS OF FEMALE INFERTILITY 
INTRODUCTION 
I nfertility is a devastating problem for many couples. It is defined as a couple ' s unsuccessful attempt at conception after one year of unprotected intercourse. 
Primary infertility is a diagnosis that describes an infertile 
couple that has not previously achieved pregnancy, while 
secondary infertility denotes a couple that has achieved 
pregnancy prior to the onset of infertility. 
Most industrialized countries report the combined 
incidence of primary and secondary infertilitf to be 
10-15% of couples in their reproductive years. Many 
couples are delaying conception, which results in 
increased risk of age-related infertility factors. There is 
also a rising incidence of sexually transmitted disease, 
which can result in tubal dysfunction. For these reasons, 
there appears to be an increasing trend of infertility. 
However, advancing technology, both diagnostic and 
therapeutic, as well as decreasing access and availability 
of alternatives, such as adoption, may prove this apparent 
rising trend to be factitious, or at least exaggerated. 
There are numerous factors that may contribute to the 
etiology and pathogenesis of infertility in either or both of 
the partners. Initial evaluation by the Family Physician 
with appropriate and timely referral to a specialist may 
help the couple feel more comfortable with the process 
and prepare them for the possibility of further 
investigation or assisted reproductive technology.2 The 
investigation, diagnosis and management of infertility can 
be difficult and frustrating for both the couple and the 
physician. 
PHYSIOLOGY OF CONCEPTION 
Numerous factors contribute to success ful 
achievement and maintenance of pregnancy. 
Considerations for conception include both male and 
female issues, such as anatomy, endocrinology and 
metabolism, genetics, immunology, psychology and 
behaviour. Based on the collective effect of these factors, 
the statistical probability of conception in a given month is 
estimated at 20-25% in the normal population of child-
bearing age.3 
Male contributions to effective conception include the 
capability of vaginal intercourse and ejaculation of an 
adequate number of motile sperm. Therefore, 
requirements are normal spermatogenesis, semen 
production, as well as functional erection and ejaculation. 4 
In order to conceive, females must achieve normal 
folliculogenesis for development of a mature oocyte, 
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ovulation and production of gonadotropin-releasing 
hormone (GnRH), luteinizing hormone (LH), follicle-
stimulating hormone (FSH), estradiol and progesterone in 
adequate quantity. These hormones regulate oocyte 
maturation, ovulation, proliferation and preparation of the 
endometrium for pregnancy, as well as amount and 
quality of cervical mucus. Therefore, female requirements 
for conception are proper hormone production and 
response, patent and functional fallopian tubes, 
appropriate uterine anatomy and effective oocyte-sperm 
interactions.4 
Consequently, infertility may be the result of an 
isolated problem with any one physiological or anatomical 
element, or a combination of factors, and may involve 
either partner of the couple or both. 
ETIOLOGY OF FEMALE INFERTILITY 
Based on the assessment of contributory factors to 
successful conception, it is apparent that there are diverse 
causes of infertility. Common causes of female infertility 
are summarized in table 1. Several important topics have 
been selected for elaboration: 
Table 1- Etiology of Female Infertility' 
Mechanism Condition 
Absent gonadal tissue Turner's syndrome 
Pure gonadal dysgenesis 
Impaired gamete Hypogonadotrophic hypogonadism 
production and function Hypothalamic anovulation 
Hyperprolactinemic anovulation 
Androgen insensitivity 
Polycystic ovarian syndrome 
Premature ovarian failure 
Resistent ovarian syndrome 
Ovum retention 
Oocyte factor' (aged oocyte) 
Cytotoxic drugs 
Other drugs 
Irradiation 
?smoking 
Impaired gamete Malfunction of ovum capture and 
transport cilia mediated transport 
Tubal infertility 
Endometriosis 
Cervical factor 
Antisperm antibodies 
Impaired conception Polycystic ovaries 
Smoking 
Abnormal sperm adhesion molecules 
RecurrentnUscanriage Chromosomal aberrations 
Oocyte factor' (aged oocyte) 
Coagulation disturbances 
Polycystic ovaries 
Gross uterine anomalies 
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Disorders of Ovulation 
Dysfunction of ovulation is involved in 15 to 30% of 
cases of couple infertility.4 Hypothalamic disorders result 
in anovulation and amenorrhea due to an abnormality of 
pulsatile secretion of GnRH, which impacts upon normal 
LH and FSH secretion. Approximately 20% of women 
with amenorrhea are found to have a pituitary 
abnormality, such as a prolactinoma.4 Other endocrine 
disorders which can potentially lead to infertility are 
thy roid dysfunction and adrenal gland disorders, 
including congenital adrenal hyperplasia, adrenal tumour, 
Cushing's disease and Addison's disease. 
Ovarian dysfunction may result in anovulation. 
Polycystic ovary syndrome is commonly associated with 
infertility. Aside from the anovulatory disturbances, this 
condition is associated with hirsutism, obesity, 
d ysfunctional uterine bleeding and endometrial 
carcinoma. Investigations reveal elevated LH, normal or 
low FSH and slightly elevated testosterone levels. Ovaries 
contain multiple follicles arrested at 0.5 to 1.0 em 
diameter. Resistant ovary syndrome, which results from 
decreased sensitivity to FSH leading to failure of 
maturation of primordial follicles, primary ovarian failure 
and other ovulatory disorders are potential factors in 
infertility . The 'oocyte factor ' 1 or ' reluctant ovum 
syndrome'4 refers to the aging oocyte's reduced capacity 
to be fertilized and undergo normal division. Lower 
pregnancy rate, higher abortion rate and rising incidence 
of fetal chromosomal abnormality is associated with 
increasing maternal age.1.4 
Disorders of Transport 
Impaired function or blockage of the fallopian tubes 
have strong associations with pelvic inflammatory disease 
(PID), tubal ligation, pelvic surgery, previous ectopic 
pregnancy and endometriosis. Tubal factors are relevant 
in 12-20% of infertility cases. 4 PID is caused by an 
infection of the upper genital tract . Specific sexually 
transmitted infections, such as Chlamydia trachomatis or 
Neisseria gonorrhoeae are implicated in 60-80% of cases.5 
The symptoms include pelvic pain, vaginal discharge, 
fever, vomiting and abnormal bleeding. Signs include 
cervical motion and adnexal tenderness, palpable mass, 
fever, and cervical discharge. Pathology frequently shows 
cervicitis, endometritis, pelvic peritonitis, and, most 
relevant to fertility, salpingitis . For each episode of 
infection, there is a 10% or greater risk of tubal infertility 
and each subsequent infection represents a cumulative 
risk. For example, the risk of infertility is 35% with a 
second infection and 75% with three or more episodes.5 
Damage related to PID accounts for between 20 and 56% 
of ectopic pregnancies, which can be a compounding risk 
factor for infertility.6 
Endometriosis is a common cause of infertility . 
Although controversial, estimates of the incidence of 
endometriosis among females of infertile couples range 
from 20 to 50% and there is clearly a reduced rate of 
conception among these women.7 Even mild 
endometriosis may result in reduced fertility by leading to 
pelvic adhesions, ovarian or tubal damage. Mechanisms 
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proposed for infertility include direct obstruction of the 
tubes, prostaglandin-induced tubal dysfunction resulting 
in decreased transport capacity, ovulatory dysfunction 
and luteinized unruptured follicle syndrome, as well as 
cell-mediated immune system alterations and increased 
leucocytes in the peritoneal fluid that may alter 
conception and implantation.7 
Cervical mucus of inadequate quality and quantity or 
containing antisperm antibodies may interfere with 
mucus-sperm interactions and transport, although this 
remains controversial as an isolated factor in infertility.8 
Disorders of Implantation 
Uterine pathology is a rare cause of infertility.9 Uterine 
abnormalities, such as bicornuate uterus or uterus 
subseptus, Asherman's syndrome, intrauterine adhesions 
endometrial ossification, leiomyoma and adenomyosis 
constitute some of these etiologies. Hormonal disorders 
causing decreased endometrial receptivity are other 
potential mechanisms resulting in infertility. 
Chromosomal Abnormalities 
Although not initially presenting with infertility, 
phenotypic females with chromosomal abnormalities such 
as gonadal dysgenesis, including Turner's syndrome, and 
androgen insensitivity, are sterile. Habitual abortion, 
recurrent loss of 3 or more pregnancies, is experienced by 
0.5 % of the population. Investigations have shown that in 
10-20% of these couples one partner will have a 
chromosomal abnormality, such as 47,XXX, 47,XXY or a 
balanced translocation.10 
Of spontaneous abortions occurring in the first 8 
weeks of gestation, 50% are due to chromosomal 
abnormalities of the fetus. Trisomy, polyploidy and 45,XO 
are common karyotypes that may result in lethal 
conditions. 10 Many women are not aware of the 
pregnancy, and this may be perceived as failure to 
conceive. 
Behavioural and Psychological Factors 
From a careful history , sexual behaviours and 
misconceptions can be ascertained. Education regarding 
normal pregnancy rates, timing of intercourse, adequate 
penetration and drug and alcohol use may be required . 
There is some evidence to suggest a delayed rate of 
pregnancy among women who smoke.1 Effects of other 
lifestyle issues are less clear. 
Psychological factors can have a great impact on 
infertility. Whether or not they actually cause infertility is 
controversial, but it is clear that they definitely contribute 
to it. Questions regarding impotence, premature 
ejaculation and decreased libido are important for the 
male partner. Female issues include stressful life events, 
anorexia nervosa, depression, anxiety, decreased libido 
and vaginismus. 
Unexplained Infertility 
Idiopathic infertility is a diagnosis of exclusion that 
applies to patients whose investigations have not revealed 
a known etiology. With advances in diagnostic 
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techniques, the incidence of infertility that remains 
unexplained after appropriate diagnostic investigations 
has been declining since the 1950's, when it was reported 
at greater than 20% of infertile couples . II Current 
estimations of idiopathic infertility range from 10 to 
15%.12•4 Possible etiologies include subtle sperm function 
defects, subclinical endocrine abnormalities, 
immunological factors and infectionY Without treatment, 
there is a reported pregnancy rate of 60% within 3 years, 
which evokes the theory that there may be no abnormality 
at all, or one that resolves spontaneously.13 
Multifactorial Infertility 
Approximately 20% of couples experiencing infertility 
are shown to exhibit a combination of factors relating to 
their difficulties. 14 Infertility may be attributed to more 
than one factor in one partner or a combination of factors 
in both partners . Although not addressed in d e tail 
throughout this discussion, male factors contributing to 
infertility may include disorders such as those listed in 
table 2. 
DIAGNOSING FEMALE INFERTILITY 
Evaluation of a couple's diagnosis of infertility 
includes an attempt to determine the probable cause, 
education, support, counselling for the couple and a 
review of the treatment options. Both partners should 
participate in all aspects of the evaluation and decisions 
regarding treatment. This allows assessment of the 
couple's relationship, level of understanding and ability to 
cope. It is also an important indicator of the couple's 
support and commitment to each other. 
A thorough evaluation of the contributory factors to 
infertilitX will reveal a probable cause in 85-90% of 
couples . 4 The remaining 10-15% may have multiple 
combined causes or a more subtle cause of their infertility 
that leaves them with the frustrating diagnosis of 
unexplained infertility. 
The History and Physical Examination 
The history should focus on the factors required for 
successful conception. These factors include male and 
female determinants. Both partners should be assessed for 
factors involved in infertility. Onset, duration and primary 
versus secondary infertility should be determined from 
the history. The rest of the interview should be composed 
of a review of presenting and associated symptoms, 
previous obstetrical and gynecological history, including 
sexual history, menstrual history, attitudes towards sex, 
sexual practices (timing and frequency of intercourse, 
method of contraception), general medical and surgical 
history, medications and social history (smoking, 
nutrition, weight, exercise, drug and alcohol use). 
A complete physical examination must be done, 
focusing on the signs and physical findings of the causes 
of infertility. For example, polycystic ovary syndrome is 
associated with hirsutism, acne, obesity, and acanthosis 
nigricans. During the pelvic exam, enlarged or nodular 
ovaries, uterine or adnexal masses or tenderness and 
fixation of pelvic structures may be demonstrated in 
relation to specific suspected diagnoses. 
Table 2- Etiology of Male Factor Infertility 14 
Mechanism Condition 
Endocrine disorder Hypothalamic dysfunction (Kallmann's 
syndrome) 
Pituitary failure (tumor, radiation, 
surgery) 
Hyperprolactinemia 
Exogenous androgens 
Thyroid disorder 
Adrenal hyperplasia 
Anatomic disorder Congenital absence of vas deferens 
Obstruction of ejaculatory system 
Spermatogenesis Chromosomal abnormalities 
abnormalities Mumps orchitis 
Cryptorchidism 
Chemical or radiation exposure 
Varicocele 
Motility abnormality Absent cilia (Kartagener's syndrome) 
Varicocele 
Antibody formation 
Sexual dysfunction Retrograde ejaculation 
Impotence 
Decreased libido 
Table 3- Common Tests for the Evaluation of Female Infertility 4 
Test Factor Evaluated 
Pregnancy test Pregnancy 
CBC, Glucose Underlying medical conditions 
TSH Thvroid disorders 
Prolactin Prolactinoma 
Serum FSH, LH Polycystic ovarian syndrome 
Premature ovarian failure 
Testosterone Polycystic ovarian syndrome 
Ovarian tumor 
17-Alpha hydro.,. '1-''I.J);""'terone Adrenal hyperplasia 
Progesterone challenge Endogenous estrogen 
endometrial Qroliferation 
Post-coital test Cervical mucus 
Sperm motility 
Endometrial Biopsy Secretory endometrium 
Hysterosalpingography Genital tract anatomy 
Laparoscopy Tubal patency and anatomy 
Endometriosis 
Adhesions 
Hysteroscopy Intrauterine abnormalities 
Vaginal Ultrasound Polycystic ovaries 
Vaginal, cervical swabs Infection 
CBC=Complete Blood Count; FSH=Follicle Stimulating Hormone; 
LH=Leuteinizing Hormone 
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Investigation of Female Infertility 
Aggressive eva luation is indicated in patients 
presenting with abnormal uterine bleeding, amenorrhea, 
endocrinological symptoms, longstanding infertility or 
maternal age over 35 years. Pregnancy should be ruled 
out in amenorrheic presentations. Often a suspected 
diagnosis will present with the initial history . The 
approach is determined by the wishes and availability of 
the couple, the cost of the tests and the potential treatment 
options. Table 3 summarizes the major tests for evaluation 
of infertility and the factors being evaluated. 
IMP ACT AND IMPLICATIONS OF INFERTILITY 
Few couples consider infertility until their attempt at 
conception fails . In most cases, it is a diagnosis that is 
unanticipated and interrupts longterm planning. Many 
intense feelings may be associated with the realization 
that they may not conceive as planned. Feelings of guilt, 
grief, inadequacy and shame tend to dominate initially. 
Similar to individuals experiencing death of a loved-one, 
couples ma y cope with the diagnosis in progressive 
stages, including denial, bargaining, anger, grief and 
resolution. Anger can be accompanied by frustration, rage 
or jealousy and resentment of other couples' successes.14 
Dominant beliefs of society worldwide support the 
view of parenthood as imperative for " personal 
fulfillment, social acceptance, achievement of full adult 
s ta tus, religious membership, sexual identity and 
psychologic adjustment".15 There is a social stigma that is 
inflicted upon infertile couples for "failing to fulfill a 
cultural norm". 16 According to Miall/7 orth American 
society is procreative and upholds two fundamental 
philosophies: that married couples should have children, 
and that married couples should want to have children. 
Infertile couples can feel a sense of social isolation and a 
loss of identity. 
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Although some couples report difficulty in 
relationships with family and friends, Danulik's15 studies 
suggest that investigation and treatment of infertility may 
actually increase the level of trust, intimacy and 
communication perceived by the couple in their 
relationship. Similarly, sexual satisfaction and functioning 
were reported by Danulik15 not to have been negatively 
impacted by the diagnosis, or the investigations. Negative 
consequences of investigations, however, have been 
reported to be a loss of dignity and privacy.16 Other issues 
raised were the impacts of the results of testing. For 
example, perhaps the most frustrating diagnosis is that of 
unexplained infertility. ot only do couples not have a 
disease process to blame, they do not have a specific 
treatment plan. 
Most couples agree on the importance of feeling free 
to express their thoughts, fears, feelings and questions. 
Both partners should have access to counseling and 
support groups. Insight into feelings and behaviours can 
help prevent depression, while strengthening existing 
relationships. Many couples are comforted by hearing the 
feelings and experiences of others in similar situations and 
understanding that they are not alone . Counseling, 
support and education should be a primary goal of all 
infertility evaluations . There are various resources 
available for this purpose (Figure 1). 
MANAGEMENT OF FEMALE INFERTILITY 
Management of infertility includes medical or surgical 
therapy in conjunction with counseling and education. 
Choice of treatment options must be evaluated by the 
couple and the physician on the basis of the investigation 
results, diagnosis, time and effort commitment, treatment 
side effects, psychosocial issues, expense, and the couple's 
attitudes, experiences and wishes. Table 4 summarizes the 
recommended treatments for specific e tiologies of 
Figure 1 - Resources available for Support , Counseling and Patient Information 
What resources are available 
Support Groups 
Web Site 
Information 
1. Infertility Awareness Association of Canada (IAAC), Ottawa- Tel: 1-800-263-2929 or (613) 730-1322 
2. Infertility Self-Help Support Groups, London- Tel: (519) 668-3895 or (519) 672-7605 
3. Infertility Network, Toronto - Tel: (416) 691-3611 
4. Gamete Donation Advocacy and Support Group, Toronto- Tel: (416) 762-0103 
S.lnfertility/Adoption Helper, Toronto - Tel: (416) 690-9593 Email: helper@helping.com 
http: / /www.cdnfertility.com/ fertility 
Reading Materials 1. Surviving Infertility: A Compassionate Guide Through the Emotional Crisis of Infertility, by 
Linda P. Salzer. New York: Harper Collins, 1991. 
2. Making Babies - A Complete Guide to Fertility and Infertility, by Heather Pullen and Jocelyn 
Smith. Toronto: Random House, 1990. 
3. The Long-Awaited Stork: A Guide to Parenting After Infertility, by Ellen Glazer. Lexington, 
Massachusetts: Lexington Books, 1990. 
4. Without Child - Experiencing and Resolving Infertility, by Ellen Glazer and Susan Cooper. 
Toronto: 1988. 
5. Adopting After Infertility, by Patricia Irwin Johnston. Indianapolis: Perspectives Press, 1992. 
6. The Canadian Adoption Guide, by Judith Wine. Toronto: McGraw-Hill Ryerson, 1995. 
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infertility and the respective success rates. In addition to 
these conventional therapies, advanced techniques, 
referred to as assisted reproductive techniques (ARTs), 
may be considered. These procedures may be indicated, as 
determined by specialists, in such conditions as fallopian 
tube damage, endometriosis, cervical factor infertility, 
unexplained infertility, male factor infertility and failed 
conventional therapies.18 
In Vitro Fertilization (IVF) 
The current preferred method of in vitro fertilization 
and embryo transfer (lVF-ET) requires controlled ovarian 
hyperstimulation in order to induce follicle maturation for 
maximum potential yield of oocytes. Oocytes are removed 
from the ovary, fertilized in vitro, and returned to the 
uterus. This technique first resulted in the successful birth 
of a child on July 25, 1978, to the credit of the British team 
Steptoe and Edwards. 19 Since then, the success rate has 
dramatically improved and has gained world-wide 
recognition in the management of human infertility. The 
pregnancy rate is approximately 20% per embryo transfer 
per lVF cycle.20 To increase the potential for pregnancy, 
more than one embryo is transferred, and therefore, 
increases the risk of multiple gestations. 
Problems with IVF-ET include financial expense, 
complications of multiple gestations or ectopic pregnancy, 21 
as well as cancellation of cycles due to inadequate 
response to stimulation, premature LH surging and 
excessive hyperstimulation that promotes oocyte 
dysmaturity. Excessive stimulation has been associated 
with ovarian hyperstimulation syndrome, characterized 
by ascites, pleural effusions, hypercoagulability and pain 
secondary to ovarian enlargement. 
Gamete Intra-Fallopian Tube Transfer (GIFT) 
GIFT is a technology that uses the same techniques as 
IVF for hyperstimulation and harvest of oocytes. The 
oocytes are combined with capacitated sperm and 
replaced in the fallopian tubes for natural fertilization and 
development. Reported pregnancy rates of 20-30% per 
cycle tend to be slightly higher than those of IVF 
techniques, but normal tubal function is required. 20 
When to Refer to a Specialist 
Consultation by a specialist requires referral by a 
family physician, gynecologist or urologist. Family 
physicians should instigate initial evaluations. Surgical 
treatment and medical therapy beyond administration of 
clomiphene, bromocriptine and progesterone require the 
expertise of a specialist. In addition, physicians not 
comfortable in the role of counselor and educator should 
refer their patients to a specialist, social worker, 
psychologist or other professional 'trained in this capacity. 
Recognition of when to refer is important in order to 
minimize anxiety, discomfort and expense, as well as to 
maximize potential success. 
Table 4- Conventional Treatments for Infertility 1 
and their respective Success Rates ' 
Etiology of Infertility Treatments Success Rate 
Ovulatory factors Clomiphene 50-90% 
Gonadotropins 
Pulsatile GnRH 
Hyperprolactinemia Bromocriptine N/A 
Cervical factors Estrogen supplementation N/A 
Intrauterine insemination 
Tubal damage Tubal surgery 20-30% 
Adhesions Lysis of adhesions 50% 
Endometriosis Surgical ablation 35-60% 
Unexplained Clomiphene 3% 
Gonadotropins 
Intrauterine insemination 
GnRH=Gonadotropin Releasing Honnone 
The London Program for Treatment of Infertility 
The Department of Gynaecology and Reproductive 
Medicine at University Hospital Campus of the London 
Health Sciences Centre offers numerous services and 
programs for the management of infertility. In 1972, the 
Therapeutic Donor Insemination program was developed 
and since then, boasts more than 1200 pregnancies. The 
lVF program was established in 1985 and proudly reports 
over 850 births. The year 1993 saw the first baby born 
following embryo cryopreservation. Subsequently, in 
1994, the most recent addition to this internationally 
renown centre became the intracytoplasmic sperm 
injection (ICSI) program, for the treatment of male 
infertility. 
CO NCLUSION 
The diagnosis of infertility is a devastating one. It 
targets young, otherwise healthy individuals and strikes 
without warning. It is important that couples have access 
to accurate, updated information and adequate supports 
in order to make informed decisions regarding their 
futures. Research continues to make advances in the areas 
of infertility diagnosis and treatment. These advances 
promise better safety and improved success rates. 
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FEMA L E 
THE ROAD 
PHYSICIANS 
AHEAD: 
AS ROLE MODELS 
I n the first two years of the University of Western Ontario's medical undergraduate curriculum students are exposed to a variety of clinical discipline and 
professional teaching styles, which influence their choice 
of electives and research projects during their early 
medical education. Later, during the clinical clerkship, 
students base their career decisions partially on the 
contact they have had with clinicians from the various 
specialties. Exposure to women physicians at both of these 
stages is minimal, and female role models within 
academic medicine (particularly at the senior level) are 
lacking. Consequently, most students ' vision of their 
career forms without the inspiration and support of 
female leaders. The lack of female lecturers and clinical 
teachers reflects a marginal representation of women 
across the board in the Faculty of Medicine and Dentistry 
(Table 1). 
As third year students we recently completed the in-
class component of our training. We found exposure to 
women physicians to be minimal. The picture for the next 
two years of our education recapitulates that of the first 
two years: a dearth of female physicians as role models 
and mentors. While there is a high degree of female 
representation in the planning of the new curriculum, the 
outlook for first year students is not likely to vary from 
our experience. Course coordinators can only elect 
lecturers from the fund of women academics that exists at 
Western-a fund which is limited and increasingly 
overburdened.1.2 
The medical school at UWO has 17 women who are 
Full Professors. This follows the pattern of other major 
medical schools in North America, which ha e, on 
average, sixteen female full professors of clinical and basic 
sciences.3 At Western this figure compares to 259 full 
professors who are men. At the senior academic level of 
UWO, there is an eight to one ratio of males to females; at 
the junior academic level, the ratio of men to women is 
three to one (See Table II) . If the junior faculty progresses 
as expected along the academic path, the representation of 
women at the senior faculty level should eventually 
approach three:one as well. Unfortunately, research has 
shown that female physicians often fail to advance at the 
same rate as male physicians within academia. In a report 
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by Dickstein, it took an average of 20 years for women to 
advance to the position of full professor while for men, it 
took only 12 years.4 Similarly, a national U.S. study by 
Tesch demonstrated that, women are not as likely as men 
to attain the position of associate professor or full 
professor after approximately eleven years of faculty 
service.5 Even after adjustments were made within the 
study to account for the fact that women reported less 
academic productivity with respect to hours worked, 
articles published, and grants received they were still 
substantially less likely to be promoted than men.5 Relying 
on the slow movement of Western's junior academics up 
into the senior ranks may therefore not be the best 
solution to improving the representation of women on the 
Faculty. If junior women are not yet qualified for specific 
senior positions, which become available, an active effort 
should be made by recruiters to encourage applications 
Table 1-FEMALE vs. MALE REPRESENTATION IN MEDICINE AT UWO 
Specialty Male FetHie Specialty Male ftMie 
a. Anaesthesia 53 IS k. Ophthalmology 18 0 
b. Neurological Sciences 34 7 I. Otolaryngology 16 0 
c. Radiology & Nuc. Med. 64 9 m. Paediatrics so 27 
d. Family Medicine 115 52 n. Pathology 24 12 
e. Medicine 160 26 o. Psychiatry 108 32 
f. Obstetrics & Gynecology 41 4 p. Surgery 77 s 
g. Oncology 28 8 q. Physical Medicine 9 2 
h. Anatomy & Cell Biology 19 3 r. Biochemistry 34 s 
i. Epidemiology & Statistics 21 12 s. Micro. & lmmuno. 37 5 
j. Pharmacology & Tox. 19 2 I. Physiology 33 4 
from qualified women at other institutions. There is, 
however, a general consensus among members of the 
Gender Issues Committee and Dr. McMurtry, the Dean of 
Medicine and Dentistry, that this type of an affirmative 
action program at UWO would not benefit the status of 
women. If appointed in association with an affirmative 
action program, a woman may not be viewed as having 
earned a "right" to her position; in this way, her authority 
in the position may be undermined, as may be her ability 
to gamer collegial support.2•6 
T6 2 • fBMll vs. MALE REPRfSENJAmN AT 1115810R 101181«. LEVB. (I UWO 
Positio1 
Senior Faculty 
(full and Associate Professors) 
Junior Faculty 
(Assistant professors, Lecturers and Instructors) 
Male 
370 
281 97 
70 
------------------------ U. W .O. Medical Journal 68 (1)1999 
,-----------------------------------------------------------------~ - ----
A number of reasons have been presented to explain 
the under-representation of women in academic medicine. 
First and foremost is the issue of choice. Many women do 
not choose a career in academic medicine because of the 
demands on their time and quality of life. It is important 
to note that women physicians' choices are made from a 
limited set of opportunities? 
To root the rationale for Western's statistics solely in 
women's individual choices, attitudes, and productivity 
would be implying that education, recruitment and 
promotion systems are always fair and based on merit 
alone. As has been suggested by Dr. Nicole LeRiche, 
Director of Admissions, and Chair of the Medicine 
Admissions Committee, oftentimes a faculty selection 
committee identifies "merit" based on an outdated model 
crafted by men. Further, it is by and large men who sit on 
the election committees at Western. For example, there 
are currently two active selection committees. The 
Oncology committee consists of nine men and two women 
and the Physical Medicine and Rehabilitation committee is 
composed of twelve men and no women. 
In addition to accepting the need for a new definition 
of merit, we would do well to recognize that medicine is 
not a meritocracy and never has been. Choices for 
promotion and hiring are based on personality, gender, 
values, age, and sociocultural similarity to the inner circle 
of the specialty, the so-called "locker-room advantage." 
Similarity of a candidate's traits to those of the dominant 
group are perceived to create the most trustworthy 
colleague.7 
Since early in his term Dean McMurtry has strongly 
advocated recruiting and promoting female staff. He has 
also supported the activities of the Gender Issues 
Committee (GIC) . The GIC is a committee primarily 
concerned with policy and education issues related to 
gender. A budget exists for promoting and helping with 
activities of the GIC, but it has not been fully utilized in 
the past.6 Other initiatives from the Dean's office have 
included : the encouragement of physicians with sick 
children to remain at home with them; the abolishment of 
meetings held outside of work hours; and the recent 
establishment of job sharing. Once the opportunity to job 
share becomes widely known it will allow for careers in 
highly demanding specialties to become more feasible for 
women. 
Belle Potts, the resource person for the GIC and 
Counselor / Coordinator for the office of Student and 
Equity Affairs, recounted two ways in which the GIC has 
been active in the Faculty selection process. First, the GIC 
developed a list of questions designed to assess all 
candidates' sensitivity to gender issues. These questions 
were given to the selection committee members who were 
to interview candidates . Second, Dean McMurtry 
requested that a member of the GIC sit on every selection 
committee. 1 This GIC representation has proven difficult 
due to the fact that the number of selection committees 
frequently exceeds the number of GIC members . In 
addition, members of the GIC are stressed by other clinical 
and academic responsibilities. At some Canadian medical 
schools, such as the University of Ottawa, there is a faculty 
member who is appointed as Dean of Equity. Western's 
Faculty would also benefit from the appointment of a 
Feature Articles 
person whose unique mandate is gender issues. 
Working with selection committees to improve the 
hiring and promotions process is only one way of opening 
more doors to women in medicine. At the same time, the 
Faculty of Medicine and Dentistry should actively 
encourage contact between female faculty and medical 
students as it is vital to the way in which young women 
perceive their roles in medicine. Better contact can be 
achieved through increased involvement of women in 
clinical teaching and through mentoring. Little research 
has been done on the possible impact of increasing the 
exposure of women students to women consultants in the 
early years of medical training. On the other hand , 
mentoring has been a topic of discussion in the literature 
and there is evidence for its efficacy. 
Mentors are those individuals who have been ahead of 
u s on a given career, social or personal path. 
Consequently, they are able to act as guides on that path; 
they encourage, point out obstacles, reveal secret short 
cuts, and introduce one to fellow travelers. Overall, 
mentors can smooth the way for a newcomer and build a 
ense of belonging. In particular, mentors may be helpful 
to women because studies have illustrated that men and 
women approach career development differently. Lorber 
uggests that "Men are likely to have a sponsor during 
training and to fall into serendipitous training 
opportunities. Women tend to pattern themselves after 
role models, who give only indirect guidance, rather than 
active help."7 
Finding female mentors at Western may be a difficult 
for some students, due to the lack of exposure to female 
consultants on the lecture circuit and due to the limited 
numbers of women in leadership and chair positions. 
Historically, mentor-student relationships have been 
underutilized by women often owing to the complications 
of mixed-sex mentoring.8 In spite of the difficulties with 
mixed-sex mentoring, it is important that it continues. 
Mentor groups have been set up at the University of 
Western Ontario wherein a faculty member is grouped 
with several students from each year of medical school. 
Together they form a "mentor group". The mentor group 
does not always, however, provide one to one contact with 
a physician in a student's discipline of interest. An 
informal mentor group has also been set up among female 
consultants and residents in Paediatrics. The Organization 
for Medical Gender Awareness (OMEGA) was created in 
1995 and has now been changed to the Medical Education 
for Societal Awareness group (OMESA); this group of 
undergraduate medical students also sets up programs 
which bring female physicians into contact with female 
medical students. All of these programs are set up to 
facilitate mentoring. 
Without a past degree, or personal connec tions, 
students have their lectures, small groups, and career 
nights on which to base their early decisions regarding 
with whom to spend valuable elective and research hours. 
The question arises as to whether female students will 
view certain fields, and academic medicine itself, as a 
realistic choice when so few women are present in the 
cla room as well as the hospital teaching environment. 
For instance, there were no female lecturers in the entire 
second year Surgery block. It is difficult to imagine that 
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this absence of female physicians would not have impact 
on students, particularly female students in search of role 
models. 
Under-representation of female faculty at the lecturing 
and clinical teaching levels, creates a paucity of women 
role models for both female and male students. Although 
the goal of this article has not been to evaluate career 
choices and placement for residency training, our 
contention is that a lack of female role models may be 
discouraging to undergraduate female medical students. 
Women's concept of their role in medicine crystallizes in a 
relative vacuum of female leadership. It would be naive to 
sugges t that networking exists less in the medical 
profession than anywhere else. Thus, if advantages accrue 
in medicine they begin at the undergraduate level and 
blossom exponentially. This complex process of 
accumulated advantages and disadvantages underscores 
the importance of exposing medical school classes to both 
male and female professors. 
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This project on menstrual education has distant beginnings in the personal experiences of two of the authors. In their high school years, they formed a 
group with other young women to share their menstrual 
experiences and attempt to remove the secrecy that 
enshrouds the subject. A consensus was reached that 
many women and men seemed to have a very negative 
perception of menstruation in general. Four years later, 
the two authors introduced these ideas to a group of 
women in their first year medicine class at UWO. The 
group's enthusiasm for these ideas developed into an 
opportunity to do an honours PBL project, entitled 
"Sharing Information with Young Girls about 
Menstruation". 
The overall aim of our project was to communicate the 
experience, as well as the sociocultural and biological 
meanings of menstruation through the use of an 
integrated approach that embodied personal and 
collective experiences, comfort with self, empowerment 
and autonomy 1• We addressed this objective in three 
ways: evaluation of current menstrual education and local 
resources for young girls; creation of a workshop for 
young girls about menstruation; and creation of a 
workshop for medical students about menstruation. 
THE EVALUATION PHASE 
We devoted the first year of our project to the 
evaluation of current menstrual education and resources 
for young girls. To accomplish this, we took a variety of 
approaches, beginning with a survey of the resources 
available at the London Public Library and a review of the 
London Board of Education elementary school 
curriculum. We followed this with interviews with local 
schoolteachers regarding their views on menstrual 
education. We investigated available resources and 
programs offered through the London-Middlesex Health 
Unit in addition to interviewing local family physicians 
and a child psychiatrist regarding their approach to the 
topic of menstruation with young girls in their medical 
practices. Finally, we consulted the academic literature 
about the psychological framework of menstruation, the 
social context, and the cultural issues surrounding 
menstruation. 
ABOUT THE AurHORS 
The authors are in the class of Meds 2000 and wrote 
this article as they concluded a two year honours PBL 
project. They look forward to extending the project with the 
help of Meds 2001. 
By examining available public resources as well as the 
current public school curriculum and its implementation, 
we were able to obtain a comprehensive picture of 
menstrual education of young girls in London. While 
teachers and public health nurses work hard at enacting 
the curriculum, there remain the powerful influences of 
media and the subtle effects of culture which engender a 
negative attitude towards the menstrual experience. Thus, 
we concluded there was room for a positive, woman-
friendly approach to teaching menstruation beyond the 
traditional biological perspective. The reviewed research 
supported that young girls need positive, practical 
information on menstruation and, in fact, it has been 
shown that increased knowledge is correlated with a 
positive menarcheal experience2• Physicians and teachers 
alike were supportive of this approach and recognized the 
need. Our report also indicated that future physicians are 
not made aware of menstrual issues beyond biology 
through the UWO Faculty of Medicine curriculum. We 
concluded that heightening the sensitivity and awareness 
in these areas was in the best interest of all members of 
any health partnership . Based on the findings, we 
proposed innovative workshops for both young girls and 
medical students. 
THE MENSTRUAL WORKSHOP FOR YOUNG GIRLS 
In the second year of the project, we divided into two 
groups to tackle the further development and 
implementation of each workshop. The purpose of the 
interactive educational session for young girls was to 
communicate the integrated experience, sociocultural 
meaning, and biological meaning of menstruation in a 
positive, woman-friendly manner. Acting upon the 
suggestion of a community member, we contacted the 
Children's Aid Society (CAS) as a potential pilot group for 
the workshop. Laverne Foran, social worker at the CAS, 
recommended the "Pre-Teen Group", a counseling group 
for 11-13 year old girls who have been the victims of 
sexual abuse. While we were initially hesitant to 
undertake the workshop with a group of girls having a 
complex array of additional issues, after several 
discussions and the encouragement from the CAS, we 
decided to pursue the proposal. With the support of CAS, 
we intentionally did not alter the workshop to address the 
issues of sexual abuse; rather, we created a picture of 
menstruation as a normal, healthy process in every young 
woman's life. 
We conducted the workshop over two evenings with 
seven girls from the previously mentioned Pre-Teen 
Group and the CAS Pre-Teen Group coordinators. On the 
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first evening, we asked each girl to create and present to 
the group a paper collage from provided magazine 
materials depicting what menstruation meant to her. It 
was an excellent ac tivity to promote discussion of a 
commonly silenced topic. This led into an interactive 
discussion in which the girls identified the changes of 
puberty and subsequently added these changes to a 
feltboard model of a pre-teen girl. Through the discussion 
of secondary sex characteristic development and the 
biology of mens truation, this activity demonstrated 
several misconceptions held by the girls in the group. In 
fact, extra time was required to complete this activity in 
order to provide the girls wi th correct informa tion 
regarding the process of puberty and menstruation. With 
the knowledge base reinforced, we then discussed the 
practical issues of the experience of menstruation such as 
how a girl's period looks, feels, and smells. 
On the second evening, we addressed many questions 
from the previous session. Then we circulated a series of 
menstrual supplies including pads and tampons for the 
girls to examine. A step-by-step interactive demonstration 
was used for both pad and tampon use. This was followed 
by the viewing of a video in which the presenters were 
shown entering a drugstore and purchasing menstrual 
products . While the opportunity to ask anonymous 
questions had been provided, the girls felt comfortable 
enough to ask them outright. The session was concluded 
b y handing o ut a pamphlet that contained some 
frequently asked questions about menstruation (Table 1). 
After the workshop was completed, the presenters 
met with the CAS social workers for feedback . It was 
noted that initially many girls seemed reluctant to discuss 
menstruation in a group setting but tha t their comfort 
level visibly changed after they put together their collages. 
The openness and level of honesty of the presentation 
seemed respected by the girls in the group and enhanced 
the educational experience. In particular, the fact that 
misconceptions about the physiology of menstruation 
were revealed and dealt with was very helpful. The social 
workers felt that having the pads and tampons available 
for the girls to look at and touch helped prepare them for 
their menstrual experiences. Another interesting finding in 
the workshop was that many girls were unaware that they 
could speak to their physicians about menstruation and 
the encouragement of this dialogue seemed effective. The 
girls write in journals after every session and the social 
workers indicated that the entries reflected a valuable 
workshop . The social workers were pleased wi th the 
success of the worksh op and expressed in teres t in 
incorporating this kind of workshop into their regular 
program. We are curren tly working with members of 
Meds 2001 to bring this about for the 1999 spring session. 
THE MENSTRUAL WORKSHOP FOR MEDICAL 
STUDENTS 
We decided to create a workshop for medical students 
because we believed it was important to address the 
physician ' s role in educating young girls abou t 
mens truation . When reviewing the literatu re , we 
discovered several articles discussing the benefits of 
menstrual education in terms of the impact on a young 
Table 1 -MENSTRUATION PAMPHLET FOR YOUNG GIRLS 
Beginning to menstruate, or having your first period, is a natural event which 
women experience. It may seem scary, as it involves changes in your body, but 
knowing the facts con help you feel in control during this time of change. 
Wlte• will I get my period? 
Young women start menstruating at different ages, although many young 
women hove their first period between the ages of eleven and fourteen. It's 
normolthot some will hove their first periods earlier or Iuter. If you ore 
concerned about your liming, you con ask your doctor. 
Wht do periods feel like? 
While some women ore unaware thotthey are having their periods, others may 
feel a bit of blood leaving their vaginas. Women may feel cramps in their lower 
stomachs. These cramps con often be relieved by exercising, having a hot both, 
or using a hat water banle. 
How muciJ blood is lost? 
Not us much as it may look or feel like! Most women lose about o half a cup of 
blood. 
Wltat ltappens H you get your period at scllool? 
It's a good ideo to keep a pad or tampon in your desk and bog in case of on 
emergency. Your teacher or the office will hove supplies, if you hove run out or 
don 't hove money to buy them. It 's perfectly normal to hove very 
unpredictable periods early on - so be prepared!! 
Does it mean I am dirty wlten I menstr1111te? 
Absolutely not!! Menstruation is o not o dirty process. As long os you keep up 
with your normal doily hygiene (showering, changing pods every 4-6 hours 
etc.) there should be no strong odour. A linle odour, however, is normal. You 
don't need to use deodorant pods or tampons because they can cause rushes. 
Wlto can use tampons? Are tltey safe? 
All girls con use tampons, but many wait until they ore o bit older because 
using them tokes prodice. Remember, tampons cannot get lost or pushed up 
too for. It is impartontto change o tampon every 4-6 hours because there is o 
rare disease called Toxic Shock Syndrome that is associated with leaving 
tampons in too long. Tampons ore useful because you con wear swimsuits and 
swim while using one. You do not need to be sexually odive to use a tampon. 
Wltat is P.M.S.? 
P.M.S. or uPremenstruol Syndrome* is o mood change experienced by some 
young women just before they get their period. Some women feel happy, 
hungry, o bit sod, or just different. After lime, you will start to figure out what 
is normal for you, and you con letthot feeling be okay. 
If I ltave been abused, will tltat aHect my periods? 
Abuse con be o very complicated issue - we encourage you to speak to your 
doctor if you ore or hove been abused. They will hove information and 
resources ovoiloble to help you. 
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girl's menstrual experiences. Studies2 have shown that an 
increase in knowledge about menstruation will decrease 
the stress and trauma at menarche, a developmental 
milestone in the lives of young girls. Several surveys3 have 
demonstrated that girls and boys can develop negative 
views about menstruation at quite a young age. Even 
more disturbing is the fact that early menarche can serve 
as a roufh predictor for increased risk fo~ eating 
disorders . This seemed to reinforce the fact that grrls need 
support and positive reinforcement from their physicians 
about the facts of menstruation and the normality of the 
experience. 
The medical students' workshop was designed to 
heighten their awareness of menstruation as it presents in 
clinical practice with attention to the emotional, social and 
cultural contexts of menstruation. The workshop began 
with a case that included issues such as early menarche, 
exercising during menstruation, menstrual product 
options and body image. The students were asked_ to 
identify issues in the case and suggest ways of addressmg 
them. After this opening discussion, we outlined the scope 
of the honours PBL project and then cited some of the 
findings from our search of the literature. We discussed 
the psychological framework of the adolescent girl and the 
complexities that formed the foundation for menarcheal 
and menstrual experiences . The social context of 
menstruation was reviewed in terms of the media's 
presentation of menstruation in adv~rtising and co~on 
social myths. A collage of advertisements depleting 
various menstrual products was circulated to illustrate the 
common themes of: ideals of femininity, the promotion of 
cleanliness and conversely dirtiness of menstruation. 
We also mentioned some of the cultural and religious 
contexts of menstruation and how they can impact upon 
women's experiences. An example is the orthodox Jewish 
tradition of a ceremonial cleansing bath, the Mikvah. In 
addition we elicited from the students some of the myths 
they had heard about menstruation such as women not 
being able to swim during their periods. We also spent 
some time talking about girls who undergo early 
menarche, experience dysmenorrhea or premenstrual 
syndrome symptoms. The session was concluded by a 
summary of what girls need to know about menstruation 
from their physicians (Table 2) . At the end of the 
workshop, we handed out the same pamphlet that the 
young girls received so that the medical students could 
use it as a reference for their patients. 
We received a lot of positive feedback from the 
medical students in Meds 2000 and Meds 2001 who 
attended the workshop. In particular, the male medical 
s tudents seemed to feel it was particularly beneficial to 
learn about some of the practical issues surrounding 
menstruation . They believed this would help them feel 
more comfortable talking to their female patients about 
menstruation. In the evaluation phase of our project, Dr. 
Barbara Lent, a family physician at the Victoria Medical 
Center, approached us about presenting the medical 
student workshop with family medicine residents. During 
one of the noon hour Family Medicine rounds at Victoria 
Medical Center, we presented the workshop and it was 
well received with active participation and discussion. 
Feature Articles 
Table 2 
What girls need to know about menstruation fr0111 their physicians 
• Menstrual physiology 
• Menstrual hygiene 
• The normality of menstruation - it must be distinguished from disease, 
injury, and uncleanliness 
• Feelings of fright and embarrassment girls experience at menarche must be 
acknowledged as normal 
• Negative aspects of menstruation (eg. PMS, menstrual cramps, inconvenience) 
need to be discussed in order to provide a balanced view 
• Girls need support and reassurance at the lime of menarche 
• Families need to be prepared to be informed, understanding, and accepting 
• It is important to find out where girls hove obtained their information about 
menstruation and question the accuracy of the source if necessary 
CONCLUSION 
For an idea that began as a high school experience, 
"Sharing Information with Young Girls about 
Menstruation" expanded into a project that encompassed a 
wide range of issues. There is evidence to support the 
impact of educational intervention on a girl's menstrual 
experiences. Armed with this information, we were able to 
develop an innovative workshop that had a positive 
impact on a group of young girls. Furthermore, we were 
able to encourage future physicians to engage in similar 
interactive discussions with their young patients. Given 
that the non-biological issues of menstruation are often 
overlooked in medicine, it is our hope that with this project 
and this article we may give more health care providers 
reason to consider them more carefully in their patients. 
REFERENCES 
1. Baugniet f, Calder L, Moore K, van Hooren K, Woo/houseS , Yuan M. 
Slmring information with young girls about menstruation: an honours PBL 
project. Summary of Background Research. Submitted to Dr. Silcox, April 
1997. 
2. Moore S. Girls' understanding and social constructions of menarche. Journal 
of Adolescence. 1995; 18:87-104. 
3. Golub S. Menarche: the beginning of menstrual life. "Lifting the Curse of 
Menstruation: A Feminist Appraisal of the Influence of Menstruation on 
Women's Lives". Women & Health. 1983; 8(2,3):17-36. 
4. Cauffman E, Steinberg L. Interactive effects of menarcheal status and dating 
on dieting and disordered eating among adolescent girls. Developmental 
Psychology. 1996; 32(4):631-5. Q 
U. W.O. Medical Journal 68 (1) 1999------------------------- 75 
Flexibility To Be Precise. 
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25 meg, 50 meg, 75 meg, 88 meg, 100 meg, 112 meg, 125 meg 150 meg, 175 meg, 200 meg,300 meg Tablets 
500 meg Injection 
THERAPEUTIC CLASSIFJCAnDN - Thyroid Hormone 
INDJCAnONS AND CLINICAL USE 
Synthroid (I.MJthyroxine sodium} is indicated: 
t. As repJacement or supplementallherapy in patients o1 any age or state (including pregnancy} with hypo-
thyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute 
thyroiditis; prmuy hypothyroifosrn resulting from thyroid dysfunction, primary atrophy, or partial or total 
absence of the thyroid gland, or from the effects of surgery, radiation or drugs, with or without the presence of 
goiter, Including subclinical hypothyroidism; secoodaty (pituitary} hypothyroidism; and tertialy (hypothalamic} 
hypothyroidism (see COIITRMIOICAJlOIIS and PRECAUTlOIIS}. Synthroid Injection can be used intJavenously 
wllen rapid repletion is required, and either intJavenously or intramuscutar!y wllen the oral route is precluded. 
2. As a pituitary lSH suppressant in the treatment or prevention of valious types o1 euthyroid goers, including 
thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's}. multinodular goiter, and in 
conjunction with survery and radioactive iodine therapy in the management of thyrotropin-dependent wei-
differentiated papillary or follicular carcinoma of the thyroid. 
COIITIWNDICAnONS 
Synthroid (I.MJthyroxine sodium} is contraindicated in patients with untreated thyrotoxicosis of any 
etiology, acute myocardial infarction, or an apparent hypersensitivity to thyroid hormones or any of the 
inactive product constituents. (Note: The 50 meg tablet is formulated without colour additives for patients 
who are sensitive to dyes.} There is no well-documented evidence of true allergic or idiosyncratic reactions 
to thyroid hormone. Synthroid is also contraindicated in patients with uncorrected adrenal insuffiCiency, as 
thyroid hormones increase tissue demands for adrenocortical hormones and may thereby precipitate acute 
adrenal crisis (see PRECAU110NS}. 
WARNINGS 
Thyroid hormones, e~her alone or together with other therapeutic agents. should not be used for the treat-
ment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective 
for weight reduction. larger doses may produce serious or even l~e threatening man~estatioos of toxicity, 
particularly when given in association with sympathomimetic arnines such as those used for their anorectic 
effects. 
The use of Synthroid (levothyroxine sodium} in the treatment of obesity, e~r alone or in combination 
with other drugs, is unjustified. The use of Synthroid is also unjustified in the treatment of male or female 
infertility unless this condition is associated with hypothyroidism. 
PRECAUllDNS 
GeNII I: 
Synthroid (levothyroxine sodium} should be used with caution in patients with cardiovascular disorders, 
including angina. coronary artery disease, and hypertension, and in the elderly who have a greater 
likefthood of occutt cardiac disease. Concom~t administration of thyroid hormone and sympathomimetic 
agents to patients with coronary artery disease may increase the risk of coronary insufficiency. 
Use of Synthroid in patients with~~ diabetes mell~us, diabetes insipidus or adrenal cortical 
insufficiency may aggravate the intensity of their symptoms. Appropriate adjustments of the various 
therapeutic measures directed at these concomitant endocrine diseases may therefore be required. 
Treatment of myxedema coma may require simuttaneous administration of glucocorticoids (see DOSAGE 
AND AO•IIISTRAnDN). 
T 4 enhances the response to anticoagulant therapy. Prothrombin time should be closely mon~ored in 
patients taking both Synthroid and oral anticoagulants, and the dosage ol anticoagulant adjusted accordingly. 
Tile ~lonaiiUility Df lnolllynxiN may ~iller to some utanl 1"""" ... - b ... 0.. llle 
)llllelllls staloillzH .. 1 Jllrlicallr bllll Dllnalllyraxioe sodlom, calti .. llloll<ll k uerdsH wlle1 1 
......, I•.,. proftcl nllll il lm,le•IIIH. 
It ila Nee ....... lllal ~iflen- II fannlilti- Df lnalllyro.liN, -He II iHIIIical COIIHI Ill 
ICiift intrttlietll, may k ISSOCiaiH wllll ~"'-- In lracli-1 pstroilllmiul ~~- T1ltse 
~iflere- may not k Nlerwed lllroltll••-llmelll Df tot.l T3 111d T4 serv111 llftls. ft Is lllelllore, 
,_melllietllllal )lllielllrwllo Ill nrildiH from - lnolllyrolille fomlliltion to 111C1111er M reiiiiiiH 
to llle Hslrttl lllynlitl hlncti.. . AcciiiCY In retillllioo cao Msl k lcllinn 11y nill sellliliwl 
,.,..,.,In _,._ 
The intestinal absorption of levothyroxine may be impaired in patients with atrsorption disorder; in such 
patients. higher dosage levels of Jevothyroxine may be required. 
Seizures have been reported rarely in association with the initiation of levothyroxine sodium therapy, and 
may be related to the effect of thyroid hormone on seizure threshold. 
LMium blocks the TSH-mediated release of T 4 and T 3. Thyroid function should therefore be carefuly 
mon~ored during l~ium initiation, stabilization, and maintenance. If hypothyroidism occurs during lithium 
treatmenL a higher than usual Synthroid dose may be required. 
lllfomllti .. far tile Poli111t: 
1. Synthroid is intended to replace a hormone that is normaly produced by your thyroid glivld. H is generaly 
taken for life, except in cases of temporary hypothyroidism associated with an inttammatioo of the thyroid gland. 
2. Before or at any time while using Synthroid you should tell your doctor ~ you are allergic to any foods or 
medicines, are pregnant or intend to become pregnanL are breast-feeding, are tal<ing or start taking any other 
prescription or nonprescription (OTC} medications, or have any other medical problems (especialy hardening 
of the arteries, heart disease, high blood pressure. or history of thyroid, adrenal or pituitary gland problems). 
3. Use Synthroid only as prescribed by your doctor. Do not discontinue Synthroid or change the amount 
you take or how often you take it, except as directed by your doctor. 
4. Synthroid, like all medicines obtained from your doctor. must be used only by you and for the condition 
determined appropriate by your doctor. 
5. H may take a few weeks for Synthroid to begin worl<ing. Unlit ~ begins worl<ing, you may not notice any 
change in your symptoms. 
6. You should notify your doctor ~ you experience any of the following symptoms. or ~ you experience any 
other unusual medical event chest pain. shortness of breath, hives or skin rash, rapid or irregular heartbeaL 
headache, irritability, neiVOusness. sleeplessness, diarrhea, excessive sweating, heat intolerance, changes in 
appetite, vomiting, weight gain or Joss. changes in menstrual periods, fever, hand tremors, leg aamps. 
7. You should inform your doctor or dentist that you are taking Synthroid before having any kind of surgery. 
8. You should notity your doctor~ you become pregnant while taking Synthroid. Your dose ol this medicine 
will r ly have to be increased while you are pregnant 
9. H you have diabetes, your dose of insulin or oral antidiabetic agent may need to be changed after starting 
Synthroid. You should mon~or your blood or urinary glucose levels as directed by your doctor and report any 
changes to your doctor immedia1ely. 
10. H you are taking an oral anticoagulant drug such as wartam. your dose may need to be chqed after starting 
Synthroid. Your coagulation status should be checked often to determine ~ a change in dose is required. 
11 . Partial hair loss may occur rarely during the first Jew months of Synthroid therapy, but I is usualy lempolary. 
12. Synthroid is the trade name for tablets containing the thyroid hormone levothyroxine sodium, manu-
factured by Knoll Pharma Inc. Other manufacturers also make tablets containing Jevothyroxine. Ne~r you 
nor your pharmacist should change to another manufacturer's product without discussing that change with 
your doctor first Repeat blood tests and a change in the amount of levothyroxine you take may be required. 
13. Keep Synthroid out of the reach of children. Store Synthroid away from heal light and moisture. 
Llboralory Tills: 
Treatment of patients with Synthroid requires periodic assessment of thyroid status by appropriate laboratory 
tests and clinical ewlualion. Selection of appropriate tests for the diagnosis and management of thyroid disorders 
depends on patient variables such as presenting signs and symptoms, pregnancy, and concom~t 
medications. A combination of sens~ive TSH assay and free T4 estimate (free T4 index, FT4 I} are recom-
mended to confirm a diagnosis of thyroid disease. Normal ranges for these parameters are age-specifoc in 
newborns and younger children. 
TSH alone or in~ may be useful for thyroid disease screening and for mon~oring therapy for primary 
hypothyroidism as a ftnear inverse correlation exists between serum TSH and free T 4• Measurement of total 
serum T4 and T3, resin T3 uptake, and free T3 concentrations may also be useful. Antithyroid microsomal 
antibodies are an indicator of autoimmune thyroid disease. P- microsomal antibody presence in an 
euthyroid patient is a major risk factor for the development of hypothyroidism. An elevated serum TSH in the 
presence of a normal T4 may indicate subclinical hypothyroidism. Intracellular resistance to thyroid hormone 
is quite rare, and is suggested by clinical signs and symptoms of hypothyroidism in the presence of high 
serum T 4 levels. Adequacy of Synthroid therapy for hypothyroidism of pitu~ or hypothalamic origin 
should be assessed by measuring free T 4, which should be maintained in the upper hall of the normal range. 
Measurement of TSH is not a reliable indicator of response to therapy for this condition. Adequacy of 
Synlhroid therapy for congen~ and acquired pediatric hypothyroidism should be assessed by measuring 
serum total T 4 or free T 4; these should be maintained in the upper haH of the normal range. In congen~l 
hypothyroidism, serum TSH normalization may lag behind serum T 4 normalization by 2 to 3 months or 
Jonoer. In rare patients, serum TSH remains relatively elevated des~e clinical euthyroidism and age-specifoc 
normal T4 or tree T, levels. (See Po4illrlc - -> 
11n11 Jmrocti-: 
The ma{.tlitude and relative dinical importance of the effects noted below are likely to be patient-specific and may 
vary by such factors as age, gender, race, interrurrent illnesses, dose of either agents, add~ concomitant 
medications, and timing of drug administration. Ant agent that alters thyroid hormone synthesis, secretion. dis-
tribution. effect on tarvet tissues, metabolism, or eliminalion may alter the optimal therapeutic dose of Synthroid. 
Levolflyroidne sodium absorption - The following agents may bind and decrease absorption of levothy-
roxine sodium from the gastrointestinal tract: aluminum hydroxide, cholestyramine resin. colestipol 
hydrochloride. ferrous sulfate, sodium polystyrene suHonate. soybean nour (e.g., infant formula}, sucralfate. 
Binding to serum proteins- The following agents may e~r in hiM Jevothyroxine sodium binding to serum 
proteins or atter the concentrations of serum binding proteins: androgens and related anaboiic hormones. 
asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorou~. furosemide, gluco-
corticoids, meclofenamic acid, mefenamic acid, methadone. perphenazine, phenylbutazone, phenytoin. 
salicylates, tamomen. 
Thyroid physiology- The following agents may atter thyroid hormone or TSH levels, generaly by effects on 
thyroid hormone synthesis. secretion, distribution, metabolism, hormone action, or elimination, or attered TSH 
secretion: arninoglutethimide. p-arninosalicylic acid. arniodarone. androgens and related anabolic hormones, 
complex anions (thiocyanate, perchlorate, pertechnetate}, antithyroid drugs, &-adrenergic blodcing agents, 
carbamazepine, chloral hydrate. diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids. 
heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodinH:ontaining compounds. 
levodopa. lovastatin, lithium. 6-mercaptopurine, metodopramide, mftotane, nitroprusside, phenobarbital, 
phenytoin, resorcinol, rifampin, somatostatin analogs, suHonarnides, suHonytureas, thiazide diuretics. 
AdrenOCQfticoids - Metaboiic clearance of adrenocorticoids is decreased in hypothyroid patients and 
increased in hyperthyroid patients. and may therefore change with changing thyroid status. 
Amiot/arone- Amiodarone therapy alone can cause hypothyroidism or hyperthyroidism. 
AntX:oagu/ants {Dr.ll}- The hypoprothrombinemic effect of anticoagulants may be potentiated, apparently 
by increased catabolism of vitamin K-dependent clotting factors. 
Antidiabetk; agents (IIISUiin, sulfonylureas) - Requirements for insulin or oral antidiabetic agents may be 
reduced in hypothyroid patients with diabetes menitus. and may subsequently increase with the initiation of 
thyroid hormone replacement therapy. 
8-adrenergir: bloc/ring agents - Actions of some beta-blocking agents may be impaired when hypothyroid 
patients become euthyroid. 
Cyto/cines (interferon, interleulcin) - Cytokines have been reported to induce bolh hyperthyroidism and 
hypothyroidism. 
Di{Jilalis g/yoosides- Therapeutic effects of dig~lis glycosides may be reduced. Serum dig~lis levels may 
be decreased in hyperthyroidism or when a hypothyroid patient becomes euthyroid. 
~tJmine - Mar'<ed hypertension and tachycardia have been reported in association with concom~nt 
administration of levothyroxine sodium and ketJmine. 
Maprotiline- Risk of cardiac arrhythmias may increase. 
Sodium iodide {'131 and "' 1). sodium pertechnetate Tc99m - Uptake of radio labeled ions may be 
decreased. 
Somatremlsomatropin- Excessive concurrent use of thyroid hormone may accelerate epiphyseal closure. 
Untreated hypothyroidism may interfere with the growth response to somatrem or somatropin. 
Tlreophyfline - Theophytline clearance may decrease in hypothyroid patients and returns toward normal 
when the euthyroid state is achieved . 
Tricyclic antidepressants- Concurrent use may increase the therapeutic and toxic effects of both drugs, 
possibly due to increased catecholamine sen~ivity. Onset of action of tricyclics may be accelerated. 
Sympathornimetk; agents - Possible increased risk of coronary insuffiCiency in patients with coronary 
artery disease. 
LIMIItary Tnt hotellctl-: 
A number of drugs or moieties are known to atter serum levels of TSH, T4 and T3 and may thereby influence 
the interpretation of laboratory tests ol thyroid function (see Drv1 llllelldioos}. 
1. Changes in TBG concentration should be taken into consideration when interpreting T 4 and T 3 values. 
Drugs such as estrogens and estrogen-containing oral contraceptives increase serum TBG concentrations. 
TBG concentrations may also be increased during pregnancy and in infectious hepatitis. Decreases in TBG 
concentrations are observed in nephrosis, acromegaly, and after androgen or corticosteroid therapy. Famiial 
hyper- or hypo-thyroxine-binding- globulinemias have been described. The incidence of TBG defiCiency is 
approximately 1 in 9000. Certain drugs such as salicylates in hiM the protein-binding of T , . In such cases. 
the unbound (free} hormone should be measured. Altematively, an indirect measure of free thyroxine, such 
as the FT4 1, may be used. 
2. Medicinal or dietary iodine interferes with in.m!llests of radioiodine uptake, producing low uptakes 
which may not indicate a true decrease in hormone synthesis. 
3. Persistent clinical and laboratory evidence of hypothyroidism despfte an adequate replacement dose 
suggests either poor patient compftance, impaired absorption, drug interactions, or decreased potency of the 
preparation due to improper storage. 
CIRiiiOIJeoesls, Mm.-Js, llllillll)lllrment ol flrtllily: 
Although animal studies to determine the mutagenic or carcinogeniC potential of thyroid hormones have not 
been performed, synthetic T4 is identical to that produced by the human thyroid gland. A reported associa-
tion between prolonged thyroid hormone therapy and breast cancer has not been confirmed and patients 
receiving Synthroid for established indications should not discontinue therapy. 
Prquecy: 
Studies in pregnant women have not shown that Synthroid increases the risk of fetal abnormaities ~ administered 
during pregnancy. H Synthroid is used during pregnancy, the possibility of fetal harm appears remote. Because 
studies cannot rule out the possibility ol harm, Synthroid should be used during pregnancy only ~ cJearJy needed. 
Thyroid hormones cross the placental barrier to some extent T 4 levels in the cord blood of athyroid fetuses 
have been shown to be about one-third of maternal levels. Nevertheless. maternal-fetal transfer ol T 4 may 
not prevent in...Jilml hypothyroidism. 
Hypothyroidism during pregnancy is associated with a higher rate of complications, including spontaneous 
abortion and preeclampsia. and has been reported to have an adverse effect on fetal and childhood development. 
On the basis of current knowledge, Synthroid should therefore not be discontinued during pregnancy, and 
hypothyroidism diagnosed during pregnancy should be treated. Studies have shown that during pregnancy T 4 
coucentratious may decrease and lSH coocentratioos may increase to values outside normal ranges. 
Postpartum values are sinD to preconception values. 8evalions in lSH may occur as early as 4 weells gestation. 
Pregnant women who are maintained on Synthroid should have their TSH measured periodically. An 
elevated TSH should be corrected by an increase in Synthroid dose. After pregnancy, the dose can be 
decreased to the optimal preconception dose. 
Norslng-rs: 
Minimal amounts of thyroid hormones are excreted in human mi It Thyroid hormones are not associated 
with serious advl!rse reactions and do not have known tumorigenic potential. While caution should be exer-
cised when Synthroid is administered to a nursing woman. adequate replacement doses of Jevothyroxine 
sodium are generally needed to maintain normal lactation. 
PHillric Use: 
Conoen~l hypothyrpidism: Rapid restoration of normal serum T 4 concentrations ;s essential to prevent dele-
tenous neonatal thyroid hormone deficiency effects on inteligence, 0\lml growth, and development Treatment 
should be initiated immediately upon diagnosis and geoeraly mairtained for life. The ther3peutic goal is to 
maintain serum total T 4 or FT 4 in the upper half of the normal ranoe and serum TSH in the normal ranoe. All initial starting dose of 10 to t5 mcoJkglday (ages ~3 months) will generally increase serum T4 
coocentrations to the upper half of the normal ranoe in less than 3 weeks. Clinical assessment ol growth, 
developmenL and thyroid status should be monnored frequently. In most cases, the Synthroid dose per 
body weight wiN decrease as the patient grows through infancy and childhood (see DOSAGE AltO 
ADMINISTRATION, Ptollllric D_,e, Tablo1 ). Prolonged use of large doses in infants may be associated 
with temperament problems. which appear to be transient. 
Thyroid function tests (serum total T4 or FT4, and TSH) should be monitored dosely and used to determine 
the adequacy of Synthroid therapy. Serum T 4 normalizalion is usualy lolowed by a rapid declile in TSH. 
Nevertheless. TSH normalizalion may lag behind T normalization by 2 to 3 months or klnger. The relative serum 
TSH elevation is more mar1<ed in the eartt ~ but can persist to some degree throughout life. In rare 
patients TSH remains relatively elevated despite clirical euthyroidism and age-specific normal total T 4 or FT 4 
IM!s. Increasing the Synthroid dosage to suppress TSH into the normal ranoe may produce overtreatmeot. with 
an elevated serum T 4 and clinical features of hyperthyroidism including: irritability. increased appetite with 
diantlea. and sleeplessness. Another risk of prolonged overtreatmeot in infants is premature cranial synostosis. 
Hypothyroidism permanence may be assessed wllen transient hypothyroidism is suspected. Levolhyroxine 
therapy may be interrupted for 30 days after three years of age and serum T 4 and TSH measured. Low T 4 and 
elevated TSH confirms permanent hypothyroidism; therapy should be re- instituted. n T 4 and TSH remain in 
the normal ranoe. a presumptive diagnosis of transient hypothyroidism can be made. In this instance, 
continued clinical monnoring and periodic thyroid fln:lion test reevaluation may be warranted. 
Acou red hyogt!Mojdjsm: The initial Synthroid dose varies with age and body weighL and should be 
adjusted to maintain serum total T4 or free T4 1evels in the upper half of the normal ranoe. In general, unless 
there are overriding cinical coocerns. children should be started on a tun replacement dose. Children with 
underlying heart disease should be started at lower dosages. with careful upward titration. Children with 
severe, longstanding hypothyroidism may also be started on a lower initial dose 1- by an upward 
titration, attempting to avoid premature epiphyseal closure. The recommended dose per body weight 
decreases with age (see DOSAGE AIID ADMINISTRATION, Pediatric Dosage, Table 1). 
Treated children may resume growth at a greater than normal rat! (period of transient catch-up growth). 
In some cases the catch-up may be adequate to normalize growth. However, severe and prolonged hypo-
thyroidism may reduce adutt height. Excessive thyroxine replacement may initiate accelerated bone 
maturalion, producing disproportionate skeletal age advancement and shortened adutt stature. 
Hypothyroidism permanence may assessed when transient hypothyroidism is suspected. Levothyroxine 
therapy may be interrupted for 30 days and serum T 4 and TSH measured. Low T 4 and elevated TSH 
confirms permanent hypothyroidism; therapy should be re-instituted. n T 4 and TSH remain in the normal 
ranoe. a presumptive diagnosis of transient hypothyroidism can be made. In this instance, continued 
clinical monnoring and periodic thyroid function test reevaluation may be warranted. 
ADVERSE REACTIONS 
Adverse reactJons other than those indicative of thyrotoXICOSIS as a resutt of therapeutic overdosage, enher 
innially or during the maintenance periods. are rare (see SYMPTOMS AltO TREATMENT OF OVERDOSAGE). 
Craniosynostosis has been associated with iatrogenic hyperthyroidism in infants receiYing thyroid hormone 
replacement therapy. Inadequate doses of Synthroid (levothyroxine sodium) may produce or fa~ to resoiYe 
symptoms of hypothyroidism. Hypersensitivity reactions to the product excipients, such as rash and 
urticaria. may occur. Partial hair loss may occur dumg the initial months of therapy, but is generally transient. 
The incidence of continued hair loss is unknown. Pseudotumour cerebri has been reported in pediatric 
patients receiving thyroid hormone replacement therapy. 
DOSAGE AltO ADMINISTRATION 
The dosage and rate of administration of Synthroid (Levothyroxine sodium) is determined by the indication. 
and must in Mry case be individualized according to patient response and laboratory findings. 
M1K Dosage: 
Hmqtltmjdjsm: 
The goal of therapy for primary hypothyroidism is to achieve and maintain a cinical and biochemical euthyroid 
state with consequent resolution of hypothyroid signs and symptoms. The starting dose of Synthroid, the 
frequency of dose tHration, and the optimal full replacement dose must be individualized for every patient 
and wit be influenced by such factors as age, weighL cardiovascular status. presence of other inness, and 
the severity and duration of hypothyroid symptoms. 
The usual tuM replacement dose of Synthroid for younoer. healthy adutts is approximately 1.6 mco/kg/day 
administered once daiy. In the elder1y, the lui replacement dose may be altered by decreases in T 4 metabolism 
and levothyroxine sodium absorption. Older patients may require less than 1 mco/kg/day. Children generany 
require higher doses (see PHillric Dosall)- Women wllo are maintained on Synthroid dumg pregnancy 
may require increased doses (see PRECAUTIONS- Pregnancy). 
Therapy is usually inniated in younger, healthy adults at the anticipated full replacement dose. Clinical and 
laboratory evaluations should be performed at 6 to 8 week intervals (2 to 3 weeks in severely hypothyroid 
patients). and the dosage adjusted by 12.5 to 25 meg increments until the serum TSH concentration is 
normaized and signs and symptoms resolve. In older patients or in younger patients with a tistory of 
cardiovascular disease. the starting dose should be 12.5 to 50 meg once daily with adjustments of 12.5 to 
25 meg every 3 to 6 -'<5 until TSH is normalized. n cardiac symptoms develop or worsen. the cardiac 
disease should be evaluated and the dose of Synthroid reduced. Rarely, worsening angina or other signs of 
cardiac ischemia may prevent achieving a TSH in the normal ranoe. 
Treatment of subclinical hypothyroidism may require lower than usual replacement doses, e.g. 1.0 
mco/kglday. Patients for whom treatment is not initiated should be monHored Yeartt for changes in clinical 
status. TSH. and thyroid antibodies. 
In patients with hypothyroidism resuling from pijuitary or ~ disease, the possililily of secondary 
adrenal insuffiCiency should be considered, and n present. treated with glucocorticoids prior to intiation of 
Synthroid. The adequacy of Synthroid therapy should be assessed in these patients by measuring FT 41, 
which should be maintained in the upper half of the normal ranoe. in addnion to clinical assessment. 
Measurement of TSH is not a reliable indicator of response to therapy for this condnion. 
F1!W patients require doses greater than 200 meg/day. M inadequate response to daily doses of 300 to 400 
meg/day is rare. and may suooest malabsorption, poor patient compliance. and/or drug interactions. 
o- Ofllirul ,.placomont is lcfliond, cllolcal anti lalloratory onllllli- sllotold bl C8lldoocttd at 
Joost 1110111ty Of wtleftnlr wanranlld lly a clllllll in pllloot slltn. Lnatllyrutloo sotllom prodocts 
from dille,.nl manlflcll,.rs sllooll~ not bl -d inltfdla ... ably onloss relntint ol tbl patient anti 
relltllllon of tbl ~-·· n nociSSiry, accompanies tho protloct nritdl . 
Syntkoid Injection by the intravenous or intramuscular route can be substituted lor the oral dosage form 
when rapid repletion is required or oral administration is precludied. The initial parenteral dosage should be 
approxrnately one-half the previously established oral dosage of Synthroid Tablets. Close observation of the 
patient is recommended, with adjustment of the dosage as needied. Administration of Synthroid Injection by 
the subcutaneous route is not recommended as studies have shown that the influx of T 4 from the subcutaneous 
sne is very slow, and depends on many factors such as volume of injection, the anatomic sne of injection, 
ambient temperature. and presence of venospasm. 
Myr,IPI CD"": 
Myxedema coma represents the extreme expression of severe hypothyroidism and is considered a medical 
emergency. tt is characterized by hypothermia, hypotension. hypoventilation, hyponatremia, and bradycardia 
In addnion to restoration of normal thyroid hormone levels, therapy should be directed at the correction of 
electrolyte disturbances and possille inleclion. Because the mortality rate of patients with untreated myxedema 
coma is high, treatmelt must be started immediately, and should include appropriate supportive therapy and 
corticosteroids to prevent adrenal insufficiency. Possible precipitating factors should also be identified and 
treated. Synthroid may be given via nasogastric tube, but the preferred route of administration is intravenous. 
A bolus dose of Synthroid is given immediately to replete the peripheral pool of T 4, usually 300 to 500 meg. 
Although such a dose is usuany well-tolerated even in the elderly, the rapid intravenous administration of large 
doses of Synthroid to patients with cardiovascular disease is clearly not without risks. Under such circum-
stances. intravenous therapy should not be undertal<en without weighing the atternat! risks of myxedema 
coma and the cardiovascular disease. Clinical judgement in this situation may dictate smaller intravenous 
doses of Syntllroid. The initial dose is 1-by daiy intravenous doses of 75 to 100 meg unti the patient 
IS stable and oral administration is feasible. Normal T 4 levels are usuany achieved in 24 hours. followed by 
progressive increases in T 3. Improvement in cardiac output, blood pressure, temperature, and mental status 
generally occur within 24 hours. with improvement in many mannestations of hypothyroidism in 4 to 7 days. 
TSH SgPcrpfol! In Umpld Clncrt 11M Urrrplt /fodrlrs: 
The rationale for TSH suppression therapy is that a reduction in TSH secretion may decrease the growth and 
function of abnormal thyroid tissue. Exogenous thyroid hormone may inhibit recurrence of tumour growth 
and may produce regression of metastases from weiHiifferentiated (lolticular and papillary) carcinoma of 
the thyroid. tt is used as ancillary therapy of these condijions following surgery or radioactive iodine therapy. 
Medullary and anaplastic carcinoma of the thyroid is unresponsive to TSH suppression therapy. TSH 
suppression is also used in treating nontoxic solitary nodules and multinodular goijers. 
No controlled studies have compared the various degrees of TSH suppression in the treatment of either 
benign or malignant thyroid nodular disease. Further. the effectiveness of TSH suppression for benign nodular 
disease is controversial. The dose of Synthroid used for TSH suppression should therefore be individualized 
by the nature ol the disease, the patient being treated, and the desired dinical response, weigMlg the potential 
benefrts of therapy against the risks of iatrogenic thyrotoxicosis. In general, Synthroid should be given in 
the smallest dose that will achieve the desired dinical response. 
For well-differentiated thyroid cancer, TSH is generally suppressed to less than 0.1 mUlL Doses of 
Synthroid grea er than 2 mcoJkg/day are usuany required. The ellicacy of TSH suppression in reducing the 
size of benign thyroid nodules and in preventing nodule regrowth alter surgery is controversial. 
Nevertheless, when treatment with Synthroid is warranted, TSH is generally suppressed to a higher target 
range (e.g .. 0.1 to 0.3 mUll) than that employed for the treatment of thyroid cancer. Synthroid therapy may 
also be considered for patients with nontoxic multinodular goijer who have a TSH in the normal range, to 
moderately suppress TSH (e.g., 0.1 to 0.3 mUll). 
Synthroid should be administ!red with caution to patients in wllom there is a suspicion of thyroid gland 
autonomy, in view of the fact that the effects of exogenous hormone administration wil be additive to 
endogenous thyroid hormone production. 
Pediatric D ..... : 
Cooqenjtal or acgujred hypothyrojdjsm: The Synthroid pediatric dosage varies with age and body weight. 
Synthroid should be given at a dose that maintains T 4 or free T 4 in the upper haH of the normal ranoe and 
serum TSH in the normal ranoe (See PRECAUTIONS, PHinic Use.) Normalization of TSH may lag signifi-
cantly behind T4 in some infants. In general. despije the smaller body size of children, the dosage (on a 
weight basis) required to sustain fuH deYelopment and general thriving is higher than in adutts. See Table 1. 
Therapy is usually initiated at the lui replacement dose (see Table 1 ). Infants and neonates with very low 
(< 5 mcg/dL) or undetectable serum T~ IMis should be started at higher end of the dosage ranoe (e.g.50 meg 
daiy). A lower dose (e.g .. 25 meg daiy) should be considered for neonates at risk ol cardiac failure, increasing 
every few days until a lull maintenance dose is reached. In children with severe. longstanding hypo-
thyroidism, Synlhroid should be initiated gradually, with an initial 25 meg dose for two weeks. then increasing 
by 25 meg tNery 2 to 4 weeks until the desired dose, based on serum T 4 and TSH levels, is achieved. 
Table 1: Dosa11 Goldolinos for Pedlllrtc ~olllyroldlsm 
Age Daily dose (meg) per kg 
of body weight • 
0-3 months 10-15 
3-6 months 8 - 10 
6-12 months 6 - 8 
1 - 5 years 5 - 6 
6 - 12 years 4-5 
> 12 years 2 - 3 
Growth and puberty complete 1.6 
'To be ldjusted oolhe bosis oldinicol rosponse and labof1lo<y tests (see PRECAIITlOIIS, PMIIdric - ). 
Serum T 4 and TSH measurements should be evaluated at the following intervals, with subsequent dosage 
adjustments to normalize serum total T 4 or FT 4 and TSH: 
2 and 4 weeks alter therapy Miation, 
every 1 to 2 months during the first year of Ide, 
every 2 to 3 months between 1 and 3 years of age, 
every 3 to 12 months thereafter until growth is completed 
Evaluation at more frequent intervals is indicated when cornpliance is questioned or abnormal laboratory values 
are olltained. Patient evaluation is also advisable approximat!ly 6 to 8 -'<5 alter any change in Synthroid dose. 
Synthroid Tablets may be given to infants and children wllo cannot swallow infact tablets by crushing the 
tablet and suspending the freshly crushed tablet in a sman amount of water (5 to 10 ml), breast milk or 
non-soybean based formula. The suspension can be given by spoon or dropper. DO NOT STORE THE 
SUSPENSION FOR AN'f PERIOO OF TIME. The crushed tablet may also be spmlded over a smal amount ol 
food, such as apple sauce. foods or formula containing large amounts of soybean, fibre, or iron should not 
be used for administ!ring Synthroid. 
AVAILABILITY 
Synthroid4t (Lnolllyroxino SOtliom) Ta"ots: round, colour coded, scored tablet debossed with "FLINr and 
potency. Synthroid Tablets contain the following inactive ingredients: acacia, confectioners sugar, lactose. 
magnesium stearate, povidone and talc. The strengths available and the colour additives by tablet strength 
are as follows: 
Strength (meg) Tablet Colour Colour Additive(s) 
25 orange FD&C Yellow No. 6 
50 whHe none 
75 violet FD&C Red No. 40 
FO&C Blue No. 2 
88 olive FO&C Blue No. 1 
FO&CY.-No. s 
D&C Yellow No. 10 
tOO yellow D&C Yellow No. 10 
FO&C Yellow No. 6 
112 rose D&C Red No. 27 & 30 
125 brown FO&cY.-No. s 
FO&C Red No. 40 
FO&C Blue No. 1 
150 blue FD&C Blue No. 2 
175 lilac FO&C Blue No. 1 
D&C Red. No. 27 & 30 
200 pink FO&C Red No. 40 
300 green D&C Yellow No. 10 
FO&cY.-No. 6 
FD&C Blue No. 1 
All strengths are available in bottles of 100 tablets each; 50. 75, 100. 125. 150. 200 and 300 meg strengths 
are also available in bottles of 1000 tablets each. 
Store at controlled room temperature 15'- 30'C (59" -86t). Synthroid Tablets should be protected from 
light and moisture. 
SynthroioJ4t (Lnatllyruxine SOtliom) lnjoctiOII is a lyophilized powder. Inactive ingredients indude: 10 mg 
Mannnot, USP, sodium hydroxide, 1.75 mg tribasic sodium phosphat!, anhydrous. Levothyroxine sodium 
powder for reconstitution for injection is a sterile preparation. n is supplied in a 10 mL single dose colour-
coded (yellow) vial containing 500 meg levothyroxine sodium, USP. Store at controOed room temperature 
15'- :we (59"- 86t). 
Diroctl0111 for Roc~i .. : Reconstitute the lyophilized ievothyroxine sodium by aseptically adding 
5 mL of 0.9% Sodium Chloride Injection, USP only. DO NOT USE BACTERIOSTATIC SODIUM CHLORIDE 
INJECTION, USP, AS THE BACTERIOSTATIC AGENT MAY INTERFERE WITH COMPLETE RECONSTITUTION. 
Shal<e vial to ensure complete mixing. Lise jmmediiLJely alter reconstitution. Do not add to other inlr.M!nous 
ftuids. Discard any unused portion. 
IIASF Phorma 
Knoll Pllarmi Inc., 100 - Part!woy, Slill600, llat1cham, Ontario l3R 6H3 
Feature Articles 
RECOGNITION AND MANAGEMENT 
WOMAN IN THE 
DEPARTMENT 
OF THE ABUSED 
EMERGENCY 
Treating victims of domestic violence has always been part of emergency room work. Major emergency departments offer 24-hour access and relative 
anonymity for victims of domestic violence. Emergency 
room staff occupy a unique position in the health care 
system and are strategically positioned to effectively 
intervene in the abuse of a woman by her par tner. 
Although the ER is often a woman's first opportunity for 
disclosure of abuse, a literature review revealed criticism 
of current management of battered women. 
This article will review current knowledge on 
domestic violence, effective screening processes, useful 
assessment techniques, the development of a safety plan 
and available support services in the community. 
EPIDEMIOLOGY OF DOMESTIC ABUSE 
In 1993, Statistics Canada estimated that 25% of 
Canadian women who have been married or lived 
common-law have been assaulted by their partner.1 It is 
difficult to obtain accurate data on this crime because of 
significant underreporting and the exclusion of couples 
who do not meet the legal definition of marriage/ 
common-law.2 The problem is likely much more serious.u 
In Ontario, 87% of those charged with domestic violence 
are men.3 The author acknowledges that men too can be 
victims of domestic abuse but this article will only discuss 
female victims. 
Socio-economic status, ethnicity, sexual orientation 
and pregnancy offer no exemption from experiences of 
abuse to women.3 It has been reported that for 40% of 
abused women the abuse begins during pregnancy and 
39% of women report that their children witness the 
violence.1 It is known that children who grow up where 
there is spousal abuse are more likely to be in violent 
relationships when they are adults and the risk of being an 
abuser is three times hiqher for men who witnessed 
violence by their fathers . It should be clear then that 
domestic violence is not an individual problem but 
instead a societal issue that affects us all. 
Over 20% of women who use the emergency room are 
battered women and almost half of the injuries sustained 
by women who present to the ER are the result of 
domestic violence. ·4 The abuse is not an isolated incident 
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in 2/3 of the cases.1 Forty percent of abused women seek 
medical attention on at least five different occasions .2 
There clearly exists an excellent opportunity by 
emergency room physicians and staff for intervention in 
domestic abuse. 
ABUSE 
Woman abuse is defined as the intentional and 
systematic use of tactics to establish and maintain power 
and control over the thoughts, beliefs and conduct of a 
woman.3 Abuse can be physical, sexual, psychological/ 
emotional and financial in nature. 3 It can involve 
intimidation, isolation, and threats, using the children and 
using social status.3 The Power and Control Wheel in 
Figure 1, adapted by the London Battered Women's 
Advocacy Centre, London, Ontario, from the Domestic 
Abuse Intervention Project, Duluth, MN, is a useful tool 
for understanding the various forms of abuse. The 
intentional nature of the abuse is confirmed by the shifting 
of abuse tactics according to what abusers believe will 
work in a given situation, the mood they are in and the 
response they are looking for from their partner.3 The 
tactics may appear to be random and inexplicable, but 
become fully explainable in the context of the abuser 
attempting to establish power in a relationship. 
Emotional and psychological consequences of abuse 
have been identified by abused women as being far more 
damaging then the physical assault itself.S Emotional 
abuse kills the spirit, and prevents the woman from 
succeeding later in life, to feel deeply and to make 
emotional contact with others.6 In fact, battering accounts 
for 1 in every 4 suicide attempts by women.2 All forms of 
abuse result in the loss of dignity, control and safety, and 
the feeling of powerlessness and entrapment.3 
Tactics of control can begin very slowly as coercive 
tactics that may not be criminal in nature.3 This makes it 
far more difficult for the women, as well as friends, family, 
or professionals to recognize it as abuse.3 Physicians 
should keep in mind that abusers often can present 
themselves as charming. This could influence a 
physician' s assessment.7 Abuse typically escalates in 
frequency and severity and once abusers use physical 
violence, they are likely to intensify the abuse.3 
INTERDISCIPLINARY HEALTH CARE TEAM 
Coordination among health care professionals is 
paramount to developing a consistent and 
interdisciplinary health care team. A study by Shields et a/. 
showed that when physicians, nurses, and social workers 
collaborated, the outcome appeared to be more 
comprehensive, and the emotional symptoms of the 
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abu ed woman were more likely to be discussed.8 It has 
also been found that an interdisciplinary team approach 
heightens the professional expertise of each member.8 
The emergency room nurse is the abused woman's 
first contact with the health care system. In many cases, it 
is a nurse who brings suspected cases of domestic abuse to 
the attention of the physician.8 When a patient indicates 
she is being abused, referral to a social worker for further 
a essment is extremely important. Other health care 
providers can assist the team by maintaining a non-
judgmental attitude.8 
DOMESTIC VIOLENCE SCREENING 
A study in 1987 suggested that the detection of 
domestic violence in the emergency department resulted 
in only one abused woman in twenty-five diagnosed .2 
More recently, routine screening has been shown to be 
effec tive in identifyin g abused women. 9 It has been 
suggested that physicians routinely ask all patients about 
the possibility of domestic violence. 3 
However, a survey in 1994 suggests this is 
not occurring; only 13% of 198 Canadian 
hospitals surveyed said universal 
creening was part of the ER protocol. 10 
A physician should always ask about 
the possibility of abuse in cases when a 
woman's physical injuries are not 
consistent with her explanation for them; if 
there is unexpec ted or unexplainable 
stress, anxiety, depression, or substance 
abuse; or if there are chronic unexplained 
symptoms? Table 1 is a summary of cues 
which may lead to an increa ed level of 
suspicion for domestic abuse. 
Figure 1 
Feature At i cles 
Table 1-Raising the Level of Suspicion of Domestk Abuse 2. l. 7• 11 
These eves should alert a physician to the possibility of abuse and prompt the 
initiation of direct S!reening: 
1) Frequent use of emergency deportment (typically 5pm-4am; though some 
women may wait until the next day when their children are in school) 
2) Recurrent trauma history with injuries especial~ to the head, neck, torso, 
breasts, abdomen or genitals. 
3) Abrasions and contusions are more common~ seen in battered women. 
4) Physical injuries that are muhi-site and bilateral do not normally occur in 
accidents. 
5) Delay in seeking medical treatment. 
6) Signs of old untreated injuries. 
7) Behavioural cases such as depression, suicidal ideation, anxiety, sleep 
disorders, panic attacks, symptoms of post traumatic stress disorder, 
substance abuse problems, chronic headaches and chronic pain of no 
apparent etiology. 
8) A partner who seems over protective answers for the woman or will nat leave 
her side. 
Women confid e m os t ly in friends, 
neighbours and family (44%) about being 
abused; only 25% of abused women tell a 
doctor. 1 A study by Hayden eta!. showed 
that 89% of abu ed women surveyed 
would feel comfor table in disclosing the 
abuse to health care professionals if 
asked. 12 Placing posters about domestic 
violence in the waiting room, washrooms, 
and examination rooms is recommended 
in emergency departments and indicates 
an openness to the discussion of abuse.7 
Screening should be done with the woman 
alone in a private area.3 Occasionally, her 
partner refuses to leave her side and this 
can present a problem for screening. The 
nursing staff should be informed of the 
suspicion of abuse and the attempt that is 
being made to separate the patient from 
the partner. One technique successfu lly 
u ed in the emergency room is to tell the 
patient and her partner that x-rays will be 
needed (radiographs are not actually done 
unless necessary).13 The physician can then 
meet the patient la ter in the x-ray 
department and screening can be done 
without the intimidating pre ence of her 
Power and Control Wheel used by London Battered Women's Advocacy Centre, 
London, Ontario. 
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Feature Aticles 
Table 2-Saeening 2. 3, 13, 14 
1) Screen alone in a safe environment. 
2) Use a non-threatening, nan-judgmental apprOCKh. 
3) Build trust and rapport by making goad eye £ontact with the patient. 
4) Use questions that are dired and easy to understand. 
5) If the woman does not speak English, do not use family members or a person 
known to her; use a professional fluent in her longuage. 
6) Use a leading statement su£h as: •aetause violen£e is so £ommon in so many 
women's lives, I've begun to ask about it routinely. • Or "We have seen many 
women with similar £omplaints and injuries presenting to the emergency 
department, and some are victims of violen£e at home.* 
7) Follow up with more spedfi£ questions: "I am £omerned that your injuries 
have £ome from someone hurting you, is this what happened to you?•, 
•Have you ever been hurt or hit by someone dose to you?•, •1 notite you 
have some bruising or your breasts and abdomen. Can you tell me what 
happened? Did somebody hit you?• 
8) Use the word "partner* if the abuser's gender is unknown. 
9) Resped that she may refuse to give information or reteive help. 
1 0) Regardless of out£ome, retard that abuse streening was done. 
Table 3-Signs of Physical Ab.se 01 Physkal Ex• 3• u 
1) Injuries (often multiple) found on head, fa£e, throat, £hest, breasts, bo£k, 
abdomen, genitals. 
2) The following types of injuries: abrasions, bruises, burns, dislo£ations, 
la£erations, bites, frattures (nose, jaw, davide, ribs, arms, fingers), 
strangulation. 
3) Eviden£e of old bruising and radiographi£ suggestion of past fractures. 
4) Soreness and general body pain from being hurled or shoved. 
5) Unusual affed or manner of £ommuni£ation - she says nothing, minimizes 
the injury, avoids eye £ontact, anxious about a minor injury. 
Table 4 - Creatilg a Safety Plan l. 4• ' 
A safety ~an should indude: 
1) Asking what she wonts to do, whether she mn stay with frientls/family or go 
to a shelter. 
2) A list of resour£es and brO£hures (wallet-sized) whi£h £ontain emergency 
phone number (pali£e, hospitals, shelters and help lines) and the IO£ation of 
nearby shelters. 
3) Information about edutational servites, legal and/or immigration assistaoce. 
4) Suggest she alert a supportive family member or friend of her situation. 
5) Prepare an estape pa£koge by having her gather the following items and 
keep them in an O((essible hidden plo£e or at a friend's home in £ose she has 
to leave in a hurry: important dO£uments, some money/bonk or £redit £artls, 
£lathing for herse~ and £hildren, plus the £hild's favourite toy. 
partner. Table 2 provides a summary of screening 
techniques and examples of ways to approach the 
question of abuse. 
The victim must first come to understand that what is 
happening constitutes abuse, then to see that it is 
unacceptable, and finally to confide in another person.3 
Screening should not be considered a failure if the woman 
does not wish to disclose.3 It is important to remain 
empathetic if this happens and inform the patient to 
return if they need someone to talk to or to contact a local 
woman's shelter. It should be made clear to the woman 
that all cases of abuse are unacceptable and that her health 
and safety are important . Most women are very 
vulnerable at the time of disdosure.3 They can be fearful, 
embarrassed, or in a state of emotional shock.3 At this 
time, many women will be overly compliant with the 
suggestions; it is not the physician's role to solve the 
problem for her but rather to support the woman in 
making decisions.3 Nevertheless, encourage her to contact 
the police. 13 Always document that domestic screening 
was done for reference in the future.3 It cannot be stressed 
enough that the physician's response to a disclosure of 
abuse sets the stage for both the current intervention, and 
for future interactions with health care providers.3 
EXAMINATION AND DOCUMENTATION 
Proper assessment should begin with taking a history 
of her presenting complaint and using the patient's own 
words to describe the injury I illness. She should be asked 
about other abuse, associated illness such as depression 
and self-medication / substance abuse. The physician 
should always ask about suicidal ideation? 
A thorough phys ical examination should be 
performed with the patient disrobed.3 The woman who 
appears to only have a broken arm might not mention the 
multiple bruises on her back or the bite mark on her 
shoulder.14 More importantly, an incomplete exam may 
miss areas of tenderness that may indicate internal injuries 
that are not detected on only a cursory exam. 3 A pelvic 
exam is necessary if sexual assault is suspected.15 Table 3 
provides a listing of signs often present on the physical 
exam of an abused women. Proper documentation is 
important. It not only serves as a legal medical document 
but also guides the user through the steps needed for 
effective intervention. Suspected domestic abuse should 
still be recorded in the patient's chart. 
A good medical record of domestic abuse would 
include: the presenting complaint or injuries (including 
dates, times, and locations of incidents), past injuries and 
frequency, body map documentation of injuries (type, 
location, size, color and age), and a description of other 
health problems that may be related to the abuse . 3 
Photographs of the patient's injuries should be arranged 
after obtaining written consent if possible. 2 Documentation 
of an assessment of her safety and the development of a 
safety plan is required once abuse has been diagnosed.3•15 
THE SAFETY PLAN 
A safety plan is composed of strategies which increase 
the woman's present safety and help her to be prepared in 
advance for the possibility of future v iolence.3 The 
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physician's role is to inform the patient of her options and 
respect the decisions that she makes which help her to 
take control of the situation.3 It is important to remember 
that safety intervention should reflect the reality that there 
are risks attached to every decision abused women make.3 
Finally, make it clear that although you support her 
decision to return, you do not expect the violence to end.3 
Assess the threat of violence for the women and her 
children. Immediate risk can be evaluated by inquiring 
about access to guns, past use or intimidation with 
weapons, recent escalation of violence, threats to kill, the 
presence of substance abuse, extreme jealousy, and 
whether there has been a separation (or threat of 
separation), job loss, a pregnancy, or a change in finances 
recently? The more of these questions that are confirmed, 
the more immediate risk to the woman. It is necessary to 
ask about suicidal ideation and whether the woman has 
considered a plan to kill the abuser.7 Any time violence 
has occurred or is strongly suspected, the team must 
assume that the woman is at risk and assist her in devising 
a safety plan. The prescription of tranquilizers and pain 
medication for management of real medical needs must be 
balanced against maintaining her ability to react to 
dangerous situations.3 Finally, never hesitate to arrange 
immediate admission or delay discharge if it is the only 
anctuary available to the victim.2 
SUPPORT SERVICES IN THE COMMUNITY 
It is a physician's duty to go beyond treating the 
physical injury . He or she must demonstrate greater 
commitment to aiding victims by knowledge of other 
professions who may offer psychosocial treatment and 
other services for the abused woman and other family 
members. In addition to specialized training in 
counseling, social workers link women to the resources 
they need. 
An updated list of community services in all practice 
areas will help provide continuity of care. Small 
pamphlets or wallet-sized cards that can be easily 
concealed are helpful.3 Resources should include: police, 
hospital services, crisis lines, counseling, shelters, legal 
and financial aid, immigration assistance, First Nations 
services, parental relief programs, Crown Attorney's office 
and family police consultants? 
CONCLUSION 
Abused women will likely come in contact with a 
health care professional for the first time in the emergency 
department. The treatment of a battered woman's medical 
and / or surgical problems without recognizing that she is 
being abused and without offering services is simply bad 
medical care. The more skilled physicians can become at 
recognizing the pattern of abuse in its early stages, the 
more opportunity there will be to prevent illness, 
pregnancy complications, permanently disabling injuries 
and even death. The utilization of an interdisciplinary 
team to treat victims of domestic violence increases the 
detection rate of abuse and significantly improves the care 
women receive in the emergency department. A busy 
emergency room physician who remains open, empathetic 
and has a genuine interest in the women's safety and 
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health will build trust and greatly enhance the possibility 
of disclosure of abuse. A thorough physical exam, proper 
documentation, the discussion of a safety plan and referral 
to community services is the standard of care for abused 
women. It is the author's belief that maintenance of a high 
level of suspicion in the emergency room and continued 
discussion of this once taboo topic will be the key to 
making a significant difference in these women's lives. 
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FEMALE CIRCUMCISION OR 
GENITAL MUTILATION: 
A Rational Approach? 
Note: Certain aspects of the descriptions of the following 
procedures are directly from informal interviews with several 
female members of the local Muslim community of Lo_ndon, 
Ontario (Considering the personal nature of the zssue, 
anonymity was maintained) 
INTRODUCTION 
Sexuality remains an obscure area, mined with cultural taboos and loaded with anxiety and fear . Thus it is not surprising the subject of genital mutilation 
provokes emotional reactions both from advocates of it as 
a justified cultural practice and from the Western world 
that wants to see the practice outlawed. Female Genital 
Mutilation is a general term used to describe any sort of 
physical manipulation performed by a person ( wRether it 
be a physician or a midwife) on the genitals of a female. 
There are four types of manipulations ( ritual, "Sunna", 
clitoridectomy and infibulation ) but often female 
circumcision is used as a collective descriptive term for all 
four types.4 The issue of female circumcision is complex 
and has led to a debate between cultural determinism and 
health. It is an almost universal belief that changes are 
needed in the conditions and practice of female 
circumcision but the extent of these changes is still not 
determined. 
DESCRIYTION AND TYPES OF CIRCUMCISION 
Female Circumcision or Female Genital Mutilation can 
be divided into four basic types, each varying in its degree 
of genital manipulation.2'4 The least severe type is called 
ritualistic circumcision, where the clitoris is merely nicked. 
This causes bleeding , but little mutilation or long term 
damage. The second form is simply called circumcision, or 
"Sunna" by the Muslims. This involves the removal of the 
clitoral prepuce-the outer layer of skin over the clitoris, 
sometimes called the "hood"; the glans and body of the 
clitoris remain intact. Occasionally, the tip of the clitoris 
itself is removed. Sunna has been equated with male 
circumcision, because the clitoris itself is generally not 
damaged. Thus, it is the only type of mutilation which can 
correctly be called circumcision. 
A third, more harsh form of the practice, is called 
excision or clitoridectomy. This is the most common form 
and involves the removal of the glans of the clitoris-
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usually the enti re clitoris-and often parts of the labia 
minora as well. 
Finally, the most severe form of the practice is 
infibulation, or "Pharaonic" circumcision, where virtually 
all of the external female genitalia are removed. With this 
type of circumcision, a dramatic excision is performed-
removing the entire clitoris and labia minora-and in 
addition, much or most of the labia majora are then sewn 
together with acacia tree thorns, and held in place with 
catgut or sewing thread.4 The entire area is closed up _by 
this process leaving only a tiny opening, roughly the SlZe 
of a match stick to allow for the passing of urine and 
menstrual fluid . The girl's legs then are tied together-
ankles, knees, and thighs- and she is immobilized for an 
extended period, varying from fifteen to forty days, while 
the wound heals and scar tissue forms.8 
EPIDEMIO LO GY 
CIRCUMCISION 
AND CO NDITIO NS O F 
The World Health Organization (WHO) estimates that 
85 to 114 million women across the world have been 
circumcised and 80 000 procedures are said to be 
performed in Somalia alone. ' The countries concerned 
number more than twenty in Africa, from the Atlantic to 
the Red Sea, the Indian Ocean and the Eastern 
Mediterranean.' An area of particular interest to 
international health officials has been the spread of 
traditional circumcision practices to Europe, Australia, 
United States and Canada by emigrants. The Centers for 
Disease Control and Prevention estimated that in 1996 
more than 150 000 women and ~Is in the United States 
were at risk of genital mutilation. 
In most parts of the world, the procedure is performed 
almost entirely by women; generally local midwives or the 
elderly in the villages or towns. The age at which girls are 
circumcised varies both geographically and ethnically. It 
varies from a few days old (for example, the Jewish 
Falashas in Ethiopia, the nomads of the Sudan, and some 
parts of Nigeria), to about seven years old (as in Egypt and 
many countries of central Africa), to adolescence (among 
the lbo of Nigeria). 4 It seems the specific beliefs and 
practices may vary from country to country. Although ~ot 
common, the surgery is sometimes performed by medical 
personnel in health clinics or hospitals. Usually only the 
affluent members of society can afford having the 
procedure in such health care facilities. 
The instruments used for circumcision range from 
kitchen knives, old razor blades, broken glass, and sharp 
stones used in villages, to scalpels used in local health 
clinics.4.8 These instruments are rarely sterilized before the 
operation, and, except in certain urban areas, anaesthesia 
is almost never used in the process. The incisions are 
usually made while the girl, often held down by several 
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women is lying down on a mat or is in a sitting position. 
The wounds are frequently treated with herb mixtures, 
ashes, animal dung or mud to stop the bleeding.4 
ORIGINS OF THE PRACTICE 
Although documentation is difficult to find, it is 
believed that female circumcision has been practiced for 
nearly 2500 years- prior to the birth of either Islam or 
Christianity. The cultural and geographical origins of the 
practice are unknown. The incidence is, however, so 
geographically dispersed and occurs among such a variety 
of cultures that it is reasonable to assume that the practice 
arose independently among different groups of people.4 It 
is interesting that circumcision is commonly assumed to 
be a part of Islamic beliefs when in fact it existed before 
the religion of Islam. Islam believes in the circumcision of 
males as being "Sunna" (blessed) but there is no mention 
of the circumcision of females in the Qur'an.7 It seems 
plausible that Islamic doctrine was interpreted through 
cultural traditions thus extending the practice of 
circumcision to women. 7 In the tribal societies female 
circumcision, as with male circumcision, was initially part 
of the traditional puberty rites, in which young women 
and men were introduced into the adult world-a "rite of 
passage".2 
Infibulation, the most extreme form of female 
circumcision, has been traced by some anthropologists 
and historians to ancient Egypt, hence, the name 
Pharaonic circumcision.4 Analysis of Egyptian mummies 
has shown that women were infibulated during this time, 
some believe that the practice may have originated there. 
Others believe that the practice may have existed long 
before- among herders as protection against rape for 
young girls who took animals out to pasture, or as a 
custom among the stone-age people within Equatorial 
Africa . It may have also been an outgrowth of human 
sacrificial practices, or the result of early attempts at 
population control.4 
JUSTIFICATIONS FOR THE PRACTICE 
The reasons and justifications for female circumcision 
are numerous and complex. As with most traditional 
practices, the ideological basis lies in the society's cultural, 
traditional, historical, political, economic and religious 
background . The commonly given reasons for the 
persistence of the practice include: sexual control over 
females, religious requirements, mythical beliefs, and the 
need to maintain a tradition that has been with these 
cultures for thousands of years.4.s 
In contrast to the reasons for male circumcision, one of 
the most frequently given reasons for female circumcision 
is the control of the sexuality of females.8 This is the case 
especially in areas where the practice is carried out on 
infants and very young girls, clearly not old enough to be 
initiated into the adult world . In these cultures, 
circumcision serves primarily to discourage promiscuity 
by reducing a woman's sensitivity and desire for sexual 
intercourse.8 The primary function of infibulation is to 
guarantee a bride's virginity. The preservation of virginity 
is essential for determining a woman's social position in 
these societies. For a young girl it is a practical choice not 
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to resist being circumcised because she is made to believe 
that her only role in life is to be a wife and a mother. If she 
does not find a husband, she may never be able to survive 
economically or otherwise. Thus if a girl does not undergo 
circumcision she may believe that her future will be 
tainted. In the interest of social position, family honor, and 
economics within some cultures, it is believed that the 
sexuality of women must be controlled.8 
The view that circumcision is a valid means of 
controlling the sexuality of women has been recently 
questioned. It is suggested that female infibulation is no 
guarantee of a woman's virginity at the time of marriage: 
an unmarried woman can have sexual intercourse and 
then be re-infibulated (also called the "Aladal operation") 
prior to marriage to disguise the fact from her husband.5 
A second reason often given as justification for female 
circumcision has been religion. 4 This response was 
especially common for males interviewed. The religion 
that seems to have incorporated the practice most heavily 
into its culture is Islam.8 In Africa, the operation is 
performed by Christians (Catholics, Protestants, and 
Copts), Muslims, Jews, Animists, and atheists, although 
the practice does not exist in the teachings of any formal 
religion.4 
A third justification is based on the following folk 
myths: the clitoris represents the male sex organ and if not 
cut will grow to be the size of the penis; females are sterile 
until they have been excised, and the operation will 
actually increase fertility, as well as the number of live 
births; the operation is a biologically cleansing process 
that improves the hygienic and / or aesthetic condition of 
female genitalia. In Sudan, it is believed that a woman is 
naturally "polluted" and can only be cleansed, and suited 
for marriage and childbirth, by being excised.4 
One of the myths helping to perpetuate the practice 
stems from the "Pharaonic belief in the bisexuality of the 
Gods". All males and females have both masculine and 
feminine souls that are represented in their sexual 
characteristics. The prepuce, or foreskin, of the penis, it is 
believed, represents the feminine soul in the male, while 
the clitoris represents the masculine soul in the female. 
According to the myth, adolescents cannot be admitted 
into the adult world until they have been rid of the 
physical characteristics of the opposite sex-hence the 
justification for both male and female circumcision.4 
The most widely held justification for the continued 
practice of female circumcision is the importance of 
tradition .8 In a questionnaire given to five rural 
communities in Nigeria, 280 men and women were asked 
about their experiences with the practice. In addition, their 
thoughts as to why the practice continues to exist was 
queried. The dominant reason given by both men and 
women was the need to maintain tradition. 4 In some 
cultures female circumcision can also be accompanied by 
elaborate ceremonies and joyous celebrations. There may 
be days of preparation, including cleansing, praying, 
consuming special food and drink, and performing rituals, 
such as dancing and singing. The girls are frequently 
given gifts and are showered with praise and words of 
support for being brave and becoming women.8 Although 
maintaining tradition is often used as justification for the 
physical manipulation of a young girl's genitals, this point 
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of view has drawn much opposition from the 
international community. 
MEDICAL COMPLICATIONS 
Immediate complications from the female circumcisal 
procedures can be many and varied. Haemorrhage may 
occur internally from the pudental and dorsal arteries of 
the clitoris. There may also be risk of post-operative hock. 
The resistance of the child may cause cuts in other organs: 
the urethra, the bladder, the anal sphincter, vaginal walls 
or Bartholin glands. Also since the instruments used have 
rarely been sterilized, tetanus (frequently fatal ), and 
septicaemia often result. It is also important to note that 
the procedures are done without anaesthetics thus are 
extremely painful for the female involved. The severe pain 
may cause psychological distress and trauma for 
especially young girls.2 
The long-term complications range from infections to 
maternal mortality. Chronic infections of the vagina and 
uterus are frequent because the vagina (in the case of 
infibulation) virtually becomes a semi-sealed organ of the 
body. A Keloid or dermoid cyst may form on or around 
the vulva . Other grave complications include 
dysmenorrhoea, since the menstrual flow cannot e cape 
freely through the minuscule opening. In some cases the 
menstrual flow mal be fully blocked and would require 
surgical correction. 
The most severe result of excision is the development 
of a neuroma of the dorsal nerve of the clitoris. ulval 
abscesses can also develop. Mutilated women can b come 
sterile due to infections which ascend into the 
reproductive organs. 
Further complications during childbirth are 
unavoidable for infibulated women. Splitting of the car is 
always needed to let the baby out. A long labour may 
result possibly leading to intrauterine foetal death, or birth 
trauma.' 
Anonymous reports from local physicians of Muslim 
origin, emphasize the growing interest in the relationship 
between the practices of female circumcision and the 
spread of AIDS. They state that Infibulation has probably 
become an extra risk factor in the spread of the HIV -virus 
by predisposition to formation of small mucosal tears 
during intercourse caused by the abnormal vulval 
anatomy and through a higher incidence of anal exual 
intercourse. It is clear that more data needs to be collected 
on the role these traditional practice might play in the 
transmission of the HIV -infection. 
FUTURE 1M PLICA TIONS 
An ultimate end to Female Genital Mutilation may not 
be in the near future but practical steps can be taken to 
change the current conditions. Basic health education for 
women and health personnel of the countries where FGM 
is practiced should be a primary concern for the entire 
world. If women are aware of increased health risks for 
themselves and their daughters they may reconsider 
circumcision. There also needs to be education regarding 
the risks of the unsanitary operating conditions. At least if 
the conditions are improved there may be a decrease in 
some medical complications such as infections. There is 
concern that banning of female circumcision at the 
government level will ca use an increase in unsafe 
underground circumcision practices. Hopefully with more 
information and education, decisions affecting the lives of 
women will be made by women, and not by cultural 
beliefs. 
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HORMONE REPLACEMENT THERAPY 
OF 
DISEASE 
IN THE PREVENTION 
CARDIOVASCULAR 
By Daniel G. Hackam BSc and J. David Spence BA, MBA, MD, FRCPC, FACP 
INTRODUCTION 
A s recently as 15 years ago, cardiovascular disease was considered a much more important cause of morbidity and mortality in men than in women. 
Few of the early longitudinal studies on the epidemiology 
of atherosclerosis even included women; hence for many 
years, heart disease and stroke was often regarded a 
di ease of middle-aged and elderly men. Today we know 
that cardiovascular disease is the o. 1 cause of death in 
women, 1 outranking cancer by a factor of 2 to 1; women 
also have a worse prognosis than men after myocardial 
infarction,2 and following surgery for coronary heart 
disease (CHD).3 
Although cardiovascular disease is the leading cause 
of death in both sexes, women tend to develop the clinical 
manifestations of atherosclerosis about 10 years later than 
men. 4 Among younger women, the risk of heart disease is 
one in nine, and by age 65, the risk climbs to one in three. 
It has long been thought that this difference in the rate of 
progression of atherosclerosis between women and men is 
due to estrogen, an advantage that obviously declines with 
the onset of menopause. This review focuses on the 
biological and clinical evidence regarding the role of 
hormone replacement therapy (HRT) in the prevention of 
va cular disease, and addresses concerns about the 
po sible effects of estrogen on the risk of breast cancer. 
BIOLOGICAL EVIDENCE 
The experimental evidence for estrogen's effectiveness 
as a cardioprotective agent is extensive. The best 
documented effect is estrogen's action on blood 
lipoproteins. Estrogen acts in the liver to raise prod uction 
of HDL cholesterol and reduce circulating levels of LDL 
cholesterol. Hence less cholesterol is carried to the 
v ascular endothelium and more cholesterol can be 
transported away . Several authors, however, have 
calculated that estrogen's effect on blood lipids probably 
only accounts for 25-50% of its apparent 
cardioprotectiveness. 5.6 
In 1993, two papers in the Lancet focused on 
vasodilator effects of estrogen. Rosano et al showed that 
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estrogen acutely improved exercise-induced myocardial 
ischemia, implicating a vasodilator effect of estrogen. 7 In a 
sub equent Hypothesis, they suggested that estrogen acts 
a a calcium channel antagonist, and marshaled 
arguments that the effect is not mediated by nitric oxide 
( 0 ). 8 However, Williams et a! showed in surgically 
postmenopausal monkeys that both long-term estrogen 
administration9 and acute estrogen administra tion 
prevented paradoxical constriction to acetylcholine, 
suggesting that the protective effect of estrogen with 
respect to vasodilation may indeed be mediated by NO. 
They subsequently showed using N-methyl-L-arginine, 
that the effects of psychosocial stress on endothelium-
mediated vasodilation was mediated by N0.10 
itric oxide is released in areas of high shear, and is 
not only a vasodilator, but has antiplatelet and other 
effects which reduce proliferation in the intima .11 Its 
counterpart, endothelin, is a hormone released by the 
endothelium in conditions of low shear, which is not only 
a vasoconstrictor, but which interacts with other factors to 
enhance coagulation and vascular proliferation. 12 Spence 
has hypothesized that nitric oxide and endothelin may be 
important in remodelling of arteries to conform to flow 
patterns, with filling in of low shear regions, analogous to 
meanders in a river. 
Recently, Polderman et al reported that women have 
low endothelin levels, men have high endothelin levels, 
and that when they undergo sex change surgery and 
hormonal therapy, their endothelin levels cross over to 
levels characteristic of their new sex. Juxtaposition of the 
findings of Polderman et al with those of Rosano et al 
suggests the possibility that the vasodilator effects of 
estrogen may be related to antagonism to endothelin. 
If estrogen reduces and testosterone increases the pro-
atherosclerotic effects of endothelin, then it may be 
possible not only to confer protection from atherosclerosis 
on postmenopausal women by estrogen replacement, but 
also to protect men with androgen antagonists. The 
challenge, for men at least, will be to find a way of 
antagonizing testosterone without causing impotence and 
gynecomastia . It may not be so undesirable to reduce 
aggression and hostility, which along with atherosclerosis 
are undesirable accompaniments of masculinization. It i 
po sible that drugs such as finasteride or its analogues, 
which interfere with 5-alpha red uctase, might lead to 
solutions to this problem. 
CLINICAL EVIDENCE 
Many observational studies have found a lower risk of 
CHD in women taking post-menopausal estrogen 
compared to non-users. Three meta-analyses done early in 
this decade summarized these findings and reported a 35-
50% lower risk of CHD in estrogen users compared to 
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nonusers. 13-15 Sarrett-Connor and Grady published a more 
recent meta-analysis based on all studies published 
through mid-1997. 16 Their summary estimate of the 
relative risk for CHD among women who ever used 
estrogen compared to never users was 0.70 (CI, 0.65 to 
0.75). By far the predominant HRT regimen in these 25 
studies was unopposed equine estrogen. 
Does the addition of a progestin, taken to protect 
women with intact uteruses against endometrial cancer, 
attenuate the preventive effects of estrogen on 
cardiovascular mortality? A number of studies have 
reported the effect of treatment with estrogen plus a 
progestin, usually medroxyprogesterone acetate, on CHD 
risk. Using the same statistical methods as above, Sarrett-
Connor and Grady found a summary relative risk for 
CHD, based on these studies, of 0.66 (CI, 0.53 to 0.84), 
highly similar to the estimate for unopposed estrogen 
therapy. These results, in conjunction with favourable 
experimental data on the effects of estrogen-progestin 
treatment, suggest that cardiovascular protection can be 
maintained with combination therapy. 
WHAT ABOUT BREAST CANCER? 
The fear of breast cancer is a highly emotional issue, 
and may be largely responsible for the political stance that 
can be summarized as follows: "Doctors are medicalizing 
a normal part of aging and putting all kinds of women on 
hormones they don't need so that multinational drug 
companies will make all kinds of money". It is easy for 
physicians to fall into the trap of dismissing this fear as 
irrational innumeracy; such attitudes only exacerbate the 
problem of communication and adversely affect the 
perceptions of women who are faced with the decision 
whether to initiate HRT. 
It appears that there are three sources of 
misunderstanding that contribute to a very substantial 
under-utilization of HRT among women who stand to 
benefit greatly from it: 1) misperceptions about th.e age of 
onset of breast cancer in relation to HRT; 2) a significant 
overestimate of the incremental risk of breast cancer 
attributable to HRT; and 3) a significant underestimate of 
the benefit in proportion to the risk. 
Since progesterone replacement markedly reduces, 
and hysterectomy eliminates the risk of uterine cancer, for 
most women the main risk of taking HRT is breast cancer. 
For women age 50 to 70, the cumulative risk of breast 
cancer is about 4.5% without HRT. The incremental risk 
attributable to HRT is 0.2% after 5 years of treatment, .6% 
after 10 years, and 1.2% after 15 years. This means that if a 
woman starts on HRT at age 60, the risk of breast cancer 
attributable to HRT, extended out to age 75, would be 
about 1.5%. The belief that HRT will bring on breast 
cancer at a young age, similar to that of their young 
friends, and on which their fear is based, is unfounded. 
That risk must be compared with the benefit, for 
women with vascular disease. It is important therefore to 
understand how high the risk is, for women that have 
developed angina, myocardial infarction, or carotid 
stenosis. As shown above, patients with vascular disease 
have a very high risk. The benefits of HRT appear to be 
even greater than those of cholesterol-lowering agents: 
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Fig•re 1. Six-year risk for women age 50-70 with and without hormone 
replacement the;apy (HRTJ. The bars show the 6-yeor risk of breast ca11<er versus 
the risk of death, stroke or myocardial infarction in patients with various vascular 
conditions: coronary artery disease with asymptomoti< carotid stenosis (CAD/ACS) 
asymptomatic carotid stenosis alone (ACS)h. Coronary artery disease (CAD) an~ 
symptomatic carotid stenosis (TIA/CS), wit and without hormone replacement 
therapy. The tap end of the bars for cardiovascular risk is without HRT, the banorn 
end With H RT; for breast cancer the top of the bar represents risk with H RT, the 
ban om without H RT. As shown the incr8ased risk of breast ca11<er with H RT is very 
small compared with the r~uction of risk with HRT in patients with vascular 
disease. Reprinted with permission. 
HRT reduces vascular disease by approximately 44%, 
compared to a 40% reduction in coronary events, a 37% 
reduction in bypass surgery and a 30% reduction in 
mortalitl: with simvastatin in patients wit~ coronary 
disease. 1 •18 Thus the number needed to treat will be lower 
than for lipid lowering drugs, and the benefit greater, with 
HRT. Women with symptomatic carotid stenosis, or a 
combination of carotid stenosis and coronary disease, have 
such a high risk that not taking HRT is probably a grave 
error. 
Figure 1 shows the balance of risks and benefits for 
HRT in relation to various stages of severity of 
cardiovascular disease, and for breast cancer. The 6-year 
risk was calculated by extrapolating time in a linear 
fashion from the published risk of vascular disease as 
discussed above, and from the risk of breast cancer with 
and without HRT in the collaborative analysis referred to 
above. It was assumed that the benefit of HRT was 44%; 
this is likely a conservative estimate, as women with 
vascular disease stand to benefit more than the averaie of 
the group in which such benefits were observed. 17' 1 As 
shown, the potential benefit of HRT in patients with 
vascular disease far outweighs the risk. 
CONCLUSION 
A number of ongoing clinical trials will further clarify 
the efficacy of HRT in the prevention of cardiovascular 
disease, as well as shed more light on the risk of breast 
cancer in HRT users. In the meantime, it seems likely that 
most post-menopausal women can safely benefit from the 
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cardioprotective effects of an estrogen-progestin regimen, 
and those women with risk factors for cardiovascular 
d isease (eg, a strong family his tory, diabetes mellitus, 
hypertension, homocyst(e)inemia and so forth) should be 
strongly encouraged to do so. 
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HORMONE REPLACEMENT THERAPY: 
between 
Patients 
Issues 
Physic 
f or 
• 1 an s 
Discussion 
and their 
JP is a 55 year old woman who has jus t undergone 
menopause. She is generally healthy and presents to her 
fami ly physician today for a general physical exam and 
PAP test. Her physician suggests that JP consider hormone 
replacement therapy. JP is unsure. She states "I have no 
family history of heart problems so I'm not sure that I need 
hormone replacement therapy. Besides, I've heard that it 
increases your chances of breast cancer. Is there something 
else I could do instead?" 
The subject of hormone replacement therapy (HRT) is one of the great debates in medicine today. Who should get HRT? What should they get? When 
should they start? How long should it be continued? Some 
physicians think that all post-menopausal women who do 
not have any absolute contraindications should be given 
HRT. Is such a blanket statement appropriate? o two 
women are the same, physiologically or contextually. The 
pros and cons of HRT must be evaluated for each 
individual. Physicians must be knowledgeable about the 
risks and benefits of HRT in order to be able to assist their 
patient in making an informed personal decision. The 
purpose of this paper is to highlight some of the key issues 
that physicians should discuss with their patients who are 
considering HRT. 
THE PR O S AND C O NS O F H O RMONE 
REPLACEMENT THERAPY 
Cardiovascular 
The lesser incidence of cardiovascular disease (CVD) 
in pre-menopausal women in comparison to men of 
similar age, and the significant increase in CVD in post-
menopausal women suggests that estrogen may be 
cardioprotective. In fact, studies have shown up to a 50% 
decrease in the risk of cardiovascular mortality in women 
who take HRT.1.2.J.4.S Cardioprotection is potentially the 
most beneficial effect of HRT, as CVD is the leading killer 
of post-menopausal women.5 
It is the estrogen component of combined HRT which 
is cardioprotective. In fact, it has been suggested that 
progesterone may oppose the beneficial effects of 
estrogen. Consequently, in women without a uterus, 
unopposed estrogen is ideal. 1•3 Women with a uterus 
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require the addition of progesterone to prevent 
endometrial cancer. One study showed that a hormone 
regime involving micronized progesterone maintained 
more of the cardioprotective effects than did a regime 
involving medroxyprogesterone acetate.1 Although the 
cardioprotection may be slightly less than that provided 
by unopposed estrogen, studies continue to confirm that 
combined HRT provides significant cardioprotective 
benefits.1.J 
Despite the large number of studies which report 
cardio ascular benefits from HRT, some researchers 
dispute the beneficial effects of short term therapy .6 
Furthermore, there has been some concern that almost all 
the studies reported to date have been partially funded by 
drug companies? Finally, it seems that the cardiovascular 
benefits of HRT may not be as great for women who have 
no significant risk factors for cardiovascular disease (i.e. 
have never smoked cigarettes; do not have high 
cholesterol levels, high blood pressure, or diabetes; have 
no parental history of early myocardial infarction; and 
have a body-mass-index of less than 25). 4 In thi s 
population the relative risk of mortality is 0.89, in 
comparison to the relative risk of 0.51 in the group with at 
least one cardiovascular risk factor.4 However, it is likely 
that the majority of women have at least one of the above 
listed risk factors. It is important to remember that CVD is 
the number one killer of postmenopausal women, 
resulting in six times as many deaths as breast cancer; 
therefore any degree of cardioprotection is certainly 
beneficial.5 
Prevention of CVD is one of the primary benefits of 
HRT. Therefore HRT should be seriously considered in all 
women with cardiovascular risk factors. 
Bone Health 
It is generally accepted that post-menopausal women 
undergo a period of rapid, estrogen-dependent bone loss. 
Decreasing bone density predisposes women to 
osteoporosis and fractures . Osteoporotic fractures are a 
major cause of morbidity and mortality in Canada today. 
Studies have shown that HRT inhibits bone resorption and 
maintains bone density.2.s·9•10 This significantly reduces the 
risk of osteoporotic fractures (up to 50% reductions in 
fracture rates have been reported).2.s The favorable effect 
on bone health is an important benefit of HRT and should 
be considered in all women, especially those with risk 
factors for osteoporosis. 
Some individuals wonder if calcium supplementation 
and other conservative treatment strategies such as 
weight-bearing exercise and vitamin D supplementation 
are sufficient to prevent accelerated bone loss. It seems 
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that while calcium and vitamin D supplementation are 
beneficial compared to a placebo, they are not as effective 
as HRT in preventing accelerated bone loss .8•9•10 
Individuals who have decreased bone density or 
significant risk factors for osteoporosis require more than 
just exercise and vitamin and mineral supplementation to 
maintain their bone density. They should seriously 
consider HRT, or a second line treatment such as 
bisphosphonates.9 
Breast Cancer 
A major issue of debate has been whether or not HRT 
increases the risk of developing breast cancer. There have 
been a number of contradictory findings. The National 
Cancer Institute of the United States recently carried out a 
meta-analysis and determined that the use of HRT does 
increase a woman's risk of developing breast cancer after 
five years of use.11 A strong piece of evidence to this 
regard comes from the Nurses' Health Study,4•12 a study of 
121 700 registered nurses followed between 1976 and 1992. 
The results of this study find the multivariate adjusted 
relative risk of breast cancer in individuals taking estrogen 
supplementation (wi th or without progestin) to be 
between 1.28 and 1.41 depending on the hormone 
regimen. 12 Although this is a relatively small increase in 
ri k, it is significant as the baseline risk that a woman will 
develop breast cancer at some point in her lifetime is one 
in eight. 13 It is important to note that the risk of breast 
cancer seems to increase with duration of treatment. The 
urses' Health Study show that, for individuals 
currently using HRT, the relative risk of mortality from all 
cau es in comparison to people who had never used HRT 
is 0.63, but that it increases to 0.80 after 10 or more years of 
u e.4 They attribute this to an increase in deaths due to 
breast cancer. An increased ri k of developing breast 
cancer is the primary drawback of HRT and must be 
weighed against the cardiovascular, bone health, and 
other benefits. 
Colorectal Cancer Risk 
Studies have shown that the use of HRT significantly 
reduces the risk of colorectal cancers (relative risk 
reported are 0.54 and 0.71 for colon cancer, and 0.91 for 
rectal cancer). 14 Since colon cancer is the second most 
common cancer in women, and the third most common 
cause of cancer death in the population, 13 this is an 
importa nt consideration for those evaluating HRT, 
especially if they have a family history of colon cancer. 
Endometrial Cancer 
Combined estrogen and progesterone HRT does not 
increase the risk of developing endometrial cancer. 1.2·15 
Studies have shown that unopposed estrogen does 
increase the risk of endometrial hyperplasia and 
endometrial cancer in women with an intact uterus, so a 
combi ned estrogen plus proges terone approach is 
mandatory for these individuals who choose HRT.1•2•15 
Physicians should note that when a progesterone cream is 
used instead of oral/systemic progesterone, blood levels 
of progesterone may be insufficient to provide a protective 
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effect on the endometrium.16 These women may effectively 
be taking unopposed estrogen and must be followed 
accordingly. 
Vaginal Dryness and Urinary Incontinence 
Some post-menopausal women report vaginal dryness 
and urinary incontinence. Studies have shown that oral 
and / or topical estrogen therapy reduces vaginal dryness 
and can improve urinary continence.2.5·16 
Menopausal Symptoms 
It has been reported that HRT reduces menopausal 
symp toms such as hot flushes, insomnia, and night 
sweats.5•16 
Neurologic 
It has been suggested that estrogen may delay the 
onset of Alzheimer's disease and ma y "s low the 
progression or prevent the cognitive impairment and 
neuronal degeneration associated with senile dementia 
and Alzheimer's disease."14 Further research is necessary 
before definite conclusions can be drawn. 
Weight Gain 
Women have expressed concerns regarding weight 
gain as a possible side effect of HRT. The PEPI Trial 
demonstrated that women in all treatment groups 
(including the placebo group) gained weight, and that the 
only significant difference in a comparison of weight 
changes was that the women in the placebo group gained 
more than the women in the unopposed estrogen group 
(2.1 and 0.7 kg respectively, at 36 months) .1 The reality is 
that weight gain is a result of consuming more calories 
than one burns on a daily basis . Women who are 
concerned about weight gain should be educated about 
this relationship and counseled on strategies to prevent 
weight gain, such as regular exercise and a healthy diet. 
Bleeding 
Sometimes HRT results in bleeding. This is more 
likely to be a problem if HRT is initiated before the 
woman s tops menstruating. The risk of breakthrough 
bleeding may be reduced if a withdrawal bleed is brought 
on by the administration of a progesterone challenge 
before beginning HRT.17 Breakthrough bleeding persisting 
for more than 6 months after the start of treatment or of 
new onset in someone taking HRT must be investigated 
by endometrial biopsy.17 If endometrial biopsy confirms 
no pathologic cause for the bleeding, the physician may 
consider changing the hormone regimen. One option is to 
use a cyclic regimen, whereby the bleeds should be 
regulated. Otherwise, it may just be a matter of time 
before the woman stops bleeding. 
Other Side Effects 
Some other side effects of HRT have been 
documented, including breast tenderness, headache, and 
depression. 17 Physicians may need to adjust hormone 
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doses, types of hormones (i.e. micronized progesterone 
instead of medroxyprogesterone acetate) , or even 
terminate treatment if a woman is experiencing adverse 
effects. Women who are considering HRT and are 
concerned about this issue should be reassured that the 
treatment regime can be adjusted or terminated if she 
experiences unacceptable side effects. 
In General 
The Nurses' Health Study determined that women 
who are taking HRT have a lower risk of death from all 
causes than do women who have never taken hormone 
supplementation (relative risk 0.63, increasing to 0.80 after 
10 or more years of use).4 
COMPLEMENTARY APPROACHES 
Women can reduce their risk of develo ping 
cardiovascular disease and osteoporosis by adopting a 
healthy lifestyle . This may be most beneficial when 
combined with HRT, but is perhaps even more important 
in women who are unwilling or unable to take HRT. Some 
elements of a heart and bone-healthy lifestyle are: 
• healthy diet (low fat, high fibre, well balanced with 
food containing sufficient vitamins and minerals)5•16 
• regular aerobic and weight-bearing exercise5•16 
• abstinence from smokinir·16 
• limiting caffeine and alcohol intake5 
• consider supplements: antioxidant vitamins C and E, 
calcium and vitamin D (beneficial for bone mineral 
density) s.7,16 
The consumption of foods high in phytoestrogens 
(natural estro~ens occurring in plants) may also be 
beneficial. 5•18•1 •20 The best known sources of 
phytoestrogens are soy products, although they are also 
found in legumes, wheat, berries, and seeds .5•18•19 
Phytoestrogens are considered to have a mild estrogenic 
effect, and consequently may reduce menopausal 
symptoms and be mildly bone and cardio-protectiveY ·19 
A study by Lovati et al. demonstrated that substituting 
soy protein for animal protein in otherwise identical low 
lipid diets (20% calories from protein, 26% calories from 
fat, and a total of 1400 - 2100 kcal daily) significantly 
reduced total and low density lipoprotein cholesterol in 
hypercholesterolemic women and men.20 The effects of 
phytoestrogens in the diet merit further investigation, but 
meanwhile, individuals may wish to consider the addition 
of soy products, or other foods high in phytoestrogens, to 
their diet. A healthy lifestyle including proper nutrition 
and exercise is the first step to a healthy body, and 
consequently physicians should discuss lifestyle issues 
with all of their patients. 
A Natural Approach 
Some women are uncomfortable with the idea of 
taking systemic HRT, and / or only willing to consume 
natural products. There are strategies for both of these 
patients. There are topical hormone preparations available 
for those unwilling to take oral medications, although they 
will likely not achieve the same systemic effect as oral 
medications.16 These women may also benefit from foods 
which are rich in phytoestrogens.5•18•19 For those who are 
looking for a natural approach, many of the available 
estrogens as well as micronized progesterone are all non-
synthetic options. 16 
Alternative Therapies 
In recent years society has increasingly turned 
towards the use of alternative therapies such as 
naturopathy and homeopathy. A number of alternative 
remedies have been proposed for the treatment of 
menopausal symptoms and the prevention of heart 
disease, osteoporosis, and cancer. There is little scientific 
evidence to support most of these therapies,16 and further 
discussion of these issues is beyond the scope of this 
paper. 
CONCLUSION 
HRT is a complex issue. The risks and benefits must 
be weighed and a decision must be made for each woman 
individually. A summary of ideas for patient counseling is 
included as Appendix 1. Currently there is a problem with 
non-compliance in women who have been prescribed 
HRT.16 It is important for women to be involved in the 
decision making process, to have their questions 
answered, and to be in agreement with the treatment 
decisions. An involved, informed patient is more likely to 
feel positive about and be compliant with HRT. Physicians 
should discuss HRT and lifestyle issues with all of their 
perimenopausal patients, helping those women to make 
educated personal decisions. 
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Appendix 1: COUNSELING THE PATIENT 
Facts to discuss with your patients: 
• HRT relieves many menopausal symptoms. 
• HRT is cardioprotective, especially for women who 
have any cardiovascular risk factors. Cardiovascular 
disease is the leading killer of postmenopausal 
women. 
• HRT helps maintain bone density, decreasing the risk 
of developing osteoporosis. 
• HRT decreases the risk of developing colorectal 
cancer. 
• HRT does not increase the risk of developing 
endometrial cancer. 
• HRT may cause an increase in the risk of developing 
breast cancer. 
• Some women experience mild side effects while on 
HRT; some of these may pass with time, but if not 
modification or termination of treatment is always an 
option. Consider a three month trial period. 
Questions for the woman to ask herself: 
• Do I have any cardiovascular risk factors? (smoking, 
high cholesterol levels, high blood pressure, diabetes, 
family history of heart disease before age 65, 
overweight) 
• Do I feel that I would benefit from cardiovascular 
protection provided by HRT? 
• Do I have risk factors for osteoporosis? (family 
history, low bone density, smoker, history of excessive 
alcohol intake, menopause before age 40, history of 
menstrual irregularity due to hormone deficiency, 
long-term use of glucocorticoids, high-dose thyroid 
replacement therapy, chemotherapy, heparin, primary 
hyperparathyroidism)5•17 
• Do I feel that I would benefit from bone density 
protection provided by HRT? 
• Do I have or am I willing to take on a heart and bone-
healthy lifestyle? (healthy diet; regular aerobic and 
weight-bearing exercise; abstinence from smoking; 
limiting caffeine and alcohol intake) 
• Am I experiencing menopausal symptoms? (hot 
flushes, urinary incontinence, etc.) 
• Do I have risk factors for breast cancer? (personal or 
family history of breast cancer; premalignant breast 
les ions; early menstruation ( <12); late 
menopause(>52); nulliparity; radiation treatment to 
the chest; family history of ovarian, uterine, or colon 
cancer; obesity}16 
• How concerned am I about the increase in the risk of 
breast cancer with HRT? 
• Do I have any other questions or concerns regarding 
HRT and its side effects which I would like to discuss 
with my physician? 
Ph ysicians: For recommendations regarding 
contraindications, baseline investigations, starting doses, 
surveillance and trouble-shooting, see "Recommendations 
for prescribing ovarian hormone therapy" CMAJ 1997; 
155(8)1130-1133. 
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AND OBSTETRIC FISTULA 
MATERNAL MORBIDITY IN 
DEVELOPING WORLD 
THE 
Obstetric fistula, the ve icovaginal fistula resulting from prolonged obstructed labour, is a condition rarely seen in the developed world today . In 
contrast, prior to the advent of surgical obstetrical care a 
hundred years ago, obstetric fistula was ery common in 
women throughout the world. Indeed, it is a condition 
known to have occurred historically, as demonstrated by 
the ancient Egyptian mummy of Queen Henhenit of the 
Xlth Dynasty (c. 2050 BC), who a~pears to have lived with 
a very large vesicovaginal fistula . 
Although obstetric fistula is virtually unheard of in 
most women in the western world today, for women in 
the developing world it is as if time has stood still. In 
Ethiopia alone a hospital has been built for the exclusive 
care of women with obstetrical fistulas, with 1000 new 
surgical repairs done each year. 2 The obstetrical fis tula 
rate for women in the deve loping world is largely 
unknown, but it is estimated to be high based on high 
reports of prolonged obstructed labour and maternal 
mortality. In Africa in particular, death in childbirth is 
common: the World Health Organization (W HO) 
estimates the maternal mortality rate in Africa to be at 
least 640 deaths per 100,000 live births (compared to 8 
maternal deaths per 100,000 live births in the USA).3 
Similarly, in Scandinavia, the lifetime risk of a woman 
dying in childbirth is 1 in 25,000, but in rural Africa the 
rate may be as high as 1 in 15.3 The extent of maternal 
morbidity in the developing world has been difficult to 
fully appreciate as much of it goes unreported. In general, 
overall maternal morbidity (including pregnancy-induced 
hypertension, ectopic pregnancy, postpartum infection, 
obstructed labour, uterine rupture, uterine prolap e and 
fistula) in developing countries has traditionally been 
estimated to be 16 episodes of illness for every maternal 
death.4 Given that approximately 500,000 women die 
every yea r from complications of pregnancy and 
childbirth, the extent of maternal morbidity is likely 
enormous (roughly 8 million women / year) . What is 
significant is that m uch of this is largely preventable. 
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The obstetrical fistula differs from the post-surgical 
vesicovaginal fistula (which results from focal trauma to 
healthy tissues) in that it is the result of extensive vascular 
injury and necrosis of pelvic tissues due to prolonged 
pressure from the fetal presenting part 2. Clearly, 
additional pathology can also occur during this process. In 
some parts of Africa, obstructed labour may last for over a 
week, leading to extensive tissue damage and numerous 
injuries to multiple organ systems.2 Thus, as Arrowsmith 
et al note, "caring for these patients requires much more 
than simply ' repairing' a vesicovaginal fistula". 2 
In addition to the vesicovaginal fistula, other 
documented injuries resulting from this "obstructed 
labour injury complex" include total urethral loss, stress 
incontinence, hydrouteronephrosis, renal failure, 
rectovaginal fistula, rectal atresia, anal sphincter 
incontinence, cervical destruction, amenorrhea, pelvic 
inflammatory disease, secondary infertility, vagi nal 
s tenosis, osteitis pubis, and foot drop .2 Because of the 
odor, possible childlessness and inability to carry out daily 
tasks, the social consequences of these injuries are often as 
severe: divorce, abandonment by family, worsening 
poverty, malnutrition, exclusion from religious activities 
and even suicide may ensue.z.s As Harrison observes, "an 
important feature of obstetric fistula is that it cannot be 
fully discussed without raising a wide range of social, 
economic and political issues".5 
Several environmental factors contributing to the 
development of obstetric fistula and other associated 
injuries have been postulated. Firstly, vesicovaginal fistula 
occur more frequently in young teenage women who 
marry and become pregnant at an early age.6 In these 
women, the pelvis is often not fully developed leading to 
cephalopelvic disproportion which results in obstructed 
labour, severe obstetric fistula, rectovaginal fistula and 
vaginal fibrosis . Poor nutritional states may worsen this 
phenomenon, as malnourished women are more likely to 
be of shorter stature and have smaller pelves.6 In one 
report from Nigeria, of 174 women with fistulas, 65% were 
acquired in the first pregnancy, none of the women had 
had any education (and only 15% of their husbands did), 
and over 90% married before menarche.7 Secondly, a lack 
of utilization of medical resources (i.e., labouring and 
delivering outside of a hospital setting) also plays a role.5 
Hospitals may be too far away or a woman may not have 
the resources available to access prenatal care or hospital 
care at the time of labour and delivery.5 Additionally, a 
woman in the developing world may only be able to seek 
medical care if her husband gives her permission to do o. 
If he is absent for some reason, she may be forced to 
labour and deliver at home, even if there is a hospital 
nearby.6 Thirdly, traditional practices may also play a role. 
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In parts of igeria, for example, the "gishiri" cut is often 
practiced in order to trea t obstructed labour, infertility, 
dysparunia, amenorrhea, goitre, backache or dysuria. This 
involves c u tting the anterior and occasionally the 
posterior aspect of the vagina with a razor blade, and can 
contribute to obstructed labour and the development of a 
fistula directly.2.s·6 Other traditional practices leading to 
fistula include the insertion of traditional medicines and 
caustic materials into the vagina to treat such things such 
a infertility and dyspar unia .6 Las tly, traditional beliefs 
that evil spirits or wrongdoing cause the manifestations of 
obstetric fistula impede understanding and knowledge of 
how to prevent this. 7 
Indeed, understanding and prevention are the keys. 
Obstetric fistula is more than just a complication of 
childbirth; in many women it is a chronic, social and 
physical death sentence that need not exist. If it can be 
virtually eliminated in the western world, the developing 
world should be no different. Perhaps most challenging of 
all is the need for a change in attitude towards women and 
their health care needs. It has been argued that traditional 
practices and customs such as early marria~e and the use 
of the "gishiri" cut should be eliminated. ·6 At the very 
leas t, women in the developing world need access to 
appropriate health care services including prenatal, 
intrapartum and postpartum care. Universal education 
about the use and availability of medical services cannot 
be overemphasized enough. Interdisciplinary cooperation 
between health care workers and specialists is needed in 
order that the numerous social and physical complications 
of obstructed labour are addressed. More information is 
needed on the exten t of maternal morbidity in the 
developing world. Maternal morbidity and mortality will 
not decline in the developing world until such action is 
taken, and until that time, women will continue to suffer 
needless! y. 
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-~-NORVASC (omlodipino bosytate) 
Tablets 2.5, 5 ond 10 mg 
Antihypertensivo-Antianginal Agent 
ACTlOII AND CI.JIIICAI. PKAIIIACOlOGY 
NORVASC (amlodipino bosytatol is a calcium ion influx inhibitor (calcium entry blocker or calcium ion antagonist). 
Amlodipine is a member of the dihydropyridine class of e~lcium antagonists. 
IIIIIICATICNIS AND CI.JIIICAI. USE 
~
NORVASC (amlodipine bosytate) is indicated in the trutment of mild-to-moderate ossantial hypertension. 
NORVASC should normally be used in those patients in whom traotment with diuretics or bote-blockers was found 
ineffective or hu been associated with unacceptable adverse effects. NORVASC can be tried as an initial agent tn 
those patients m whom the use of diuretics and/or beta-blockers is contraindicated or in petients with mad· cal 
conditions in which thesa drugs frequently cause serious adverse effects. Combination of NORVASC with a 
diuretic. a beta-blocking agent. or an angiotensin converting enzyme inhibitor has been found to be compatible and 
showed additive antihypertensive effect. 
CINMic - Allliu 
NORVASC is indicated for the management of ctvonic mble angina (effort-associeted angina) in patients who 
remaKt symptomatic despite adequate doses of beta-blockers and/or organic nitrates or who cannot tolerate those 
agents. ORVASC may be tried in combination with beu-blocbrs in chronic stable angina in patients with niJf'lMI 
ventricular function.. When such concomitant therapy is introduced. care must be taken to monitor blood pressure 
=~n:.snsion Cln occur from the combined effects of the drugs. 
NORVASC (amlodipine besytato) is contraindicated in patients with hyperunsitMty to tho drug or other 
:tz::.=ines and in patients with severe hypotension (less than 90 mmHg-systolic). 
--Alii-M4/w..,..._l_ Rarely, patients. particularly those with severe obstructive coronary artery disease, have developed documented 
increasad frequency, duration and/or severity of angina or acute myocardial infarction on sterting celcium channel 
blocker therapy or at the time of donga increase. The machtnism of this effect has not been elucidated. 
--(Aertic s.o-io) 
NORVASC shodd be used with caution in 1 presence of fixed left ventricular outflow obstruction 
taortic stenosis). 
u.. ill , _ willo .,........,. -
There art no adequate studies in patients with liver dysfunction and dosage recommendations have not bean 
em~~ed. In a _smaU number of patients with mild-to-moderate hepatic impairment given single dose of 5 mg, 
amlodopono hoH·Iife has boon prolonged. NORVASC should, therefore, be administered with caution in thosa 
~;.;:,.~ monitoring should be perlt>nnld. A lower starting dose may be required (stt DOSAGE AIIO 
--.. w--1 NORVASC gives no protection against tho dangers of abrupt beta-blocker withdrowaland such withdrawal should 
be done by tho gradual reduction of tho dose of beta-blocker. 
I'IIECAUTlOIIIS 
u.. ill l'oli-willo ~ -'* .... 
Although generally calcium chaMel blockers should only be used with caution in pttients with heart foilura, it has 
bttn obStMid that NORVASC had no overaU deleterious affect on survival and cardiovascular morbidity in both 
short-term and long-term clinical trials in these patients. While a significant proportion of tho patients in those 
studies had a history of ischamic hurt disease, angina or hypertension, the studios wort not designed to 
evaluate the treatment of angina or hypenension in patients with concomitant heart failure. 
H.,_;.. 
NORVASC (amlodipine bosytate) may occasionally procipiteto symptomatic hypotension. Careful monitoring of 
blood pressure is reconvnanded. especially in patients with a histofy of cerebrovascular insufficiency, and those 
til ·ng medications known to lower blood pressure. 
l'eri ...... IE-
MikHo-modtrate peripheral edema was the most common adverse event in the dinical trials tsae ADYEJISE 
I£ACT10NS). The incidence of peripheral edema was dose-dependent and ranged in frequency from 3.0 to 10.~ 
in 5 to 10 mg dose range. Care should be tlken to differentiate this peripheral edema from the effects of increasing 
taft ventricular dysfunction. 
U.. io "'-ocy 
Although amlodipine was not teratogenic in the rat and rabbit some dihydropyridine compounds have been found 
to be terotogtnic in animals. In rots, omlodipino has boon shown to prolong both the gtstation period and the 
duration of label. There is no clinical experience with NORVASC in pregnont women. NORVASC should be usad 
during pregnancy only~ the potentiol benefit outweighs tho potential risk to the mother and fews. 
lloni .. -. 
tt is not known whether amlodipine is excreted in human milk. Since amlodipine safety in newborns has not been 
established, NORVASC should not be given to nursing mothers. 
U.. io Cioi .... 
Tho use of NORVASC is not roconmondod in dildran 8nca sahlty and eflic:acy have not been --in that popu1non. 
u.. ill El4orly 
In tlderty patients ~ years) clearance of amlodipine is decreased with a resulting increase in AUC. In clinical 
trials the incidence of adverse reactions in elderly patients was approximately 6~ highar than that of younger 
poputabon (<65year3). Adverso reat110nS o>clude edema, muscle tromps ond diuintss. NORVASC should be used 
cautiously in elderly patients. Oosago adjustment is advisable (see DOSAGE AIIO -TIOIII). 
- - Gropolnoil Joice Pubishad data indicate thot through inhibition of the cytochrome P450 system, grapefruit juice can increase plasma 
levels and augment pharm~codynamic onocts of some dihydropyridine calcium chaMtl blocker>. Following orol 
odministration of 10 mg emlodipine to 20 male voluntttrs. pharmacokinetics of amlodipina were sim~ar when 
amlodipine was administered with and without grapefruit juice. 
""" -.ctiMs As with al drugs, care should be exorcisod when trilling pe1ionts wid> multiple medications. Dihydropyridine calcium 
channal blockers undergo biotransformation by the cytochrome P450 system. mainly via CYP 3M isoenzyme. 
Coadministration of amlodipine with other drugs which foQow tho some route of biotransformation may resuh in 
altered bioavdability of amlod'pino or these drugs. Dosages of sim~arly metabolized drugs. particularly those of 
~therapeutic ratio, and especially K1 patients with renal and/or hepatic impairment may require adjustment 
when starting or stopping concomitandy administered amlodipina to maintlin optimum thertpeutic blood levels. 
Drugs known to be inhibitors of the cytochrome P450 system include: azole antifungals, cimttidine, cyclosporine, 
erythromycin, quinidine, terfenadine. warfarin. 
Drugs known to be inducers of tho cytochrome P450 system include: phenoborbiteL phenytoin. rifampin. 
Drugs known to be biotransformod via P450 include: bonzodiazopinos. ftecainide. inipraminl, propofenone, ~­
Amlodopono has a low (rate of first-pass) hapabc cleoronct and consaquent high bioava~abiity, and thus. may be 
expected to have 1 kJw potenbal for clinicelty r-'evant effects associated with elevation of amlodipine plasma 
levels when used concomitantly with drugs that compete for or inhibit the cytochrome P450 system. 
~. w.rt.n.. Cyc.._._IJituioo: Pharmacokinttic interaction studies with amlodipino in healthy 
volunteers have indictted: 
• c-.. did not alter tho pharmacokinetics of amlodipino. 
• amtodipine did not change w.rt.n.·induced prothrombin response time. 
• amlodipine does not significantly alter the pharmacokinetics of cycleoperiL 
• amlodipine did not change serum tlitexill levels or lliflm. renal cleartnce. 
-· 
Concornitont administration of Mnlox" (magnesium hydroxide and oluminum hydroxide) had no affect on tho dis· 
position of a sing e 5 mg dose of amlodipine in 24 subjects. 
--=When beta-adrenergic receptor blocking drugs are administered concomitantly with NORVASC. 
patients should be carefuly monitored since blood pressure towering effect of beta~btockers may be augmented by 
omlodipina's reduction in peripharll vascular resistance. 
ADVDISE IIEACT10IIS 
NORVASC (amlodipine besytatt) hu bttn administered to 1,714 patients (805 hypertensive and 909 angina 
patients, in controlled clinical trials (vs: placebo alone and with active comparative agents). Most adverse 
reactions reported during therapy were of mild-to-moderato severity. 
~
In 1he 1ll5 hypertensive patients treated with NORVASC in controlod cinical trials. adverse effects -e reported in 
2!l.ft of paliera end required cisc<ninuotion of therapy due ID side effects in 1.9ll. of patieru. Tho most common 
adverse reactions in controlod r:inical trials_., edema (&.!lliL and hoadocho 18.3"~ Tho -.g advoru reoctions 
-• reported wid> an incidonc:o of~~ in tho contralod cinical trials progrom (r>.«J5J: 
~ lr: edema (8.9~). palpitetions (2-K), tachycardia (0.7~1. posturol dizziness (0.5"1- SUo_. 
pruritus(O.~).--tmusclecramps(0.5~). c..ol_........,.._ 
s.- haadacha 1~1. dizziness (3.'"'), paruthesio ID.5"1- -s.- flushing (3.1"1. 
increased swooting (0.~). dry mouth (0.~~ l'oydoillric: somnolence 11.4"1- ·· • + nausaa (2.4"1. 
;•I pein (1 . 1~1. dyspepsia (0.6"1. constipation (D.5~~- fotigue (4.1"1. pain (D.5~) . 
In tho controlod c~nical trials in 909 angina patients trutad with NORVASC, adverse enects were raportad in 
311.5~ of patients and required discontinuation of thtropy dut!D side offocts in~ of petiarn. The most convnon 
adverse reactions reported in controled clinical trials -a: edema 19.9"1 end haadacha (1.ft~ 
The 1-.g adverse ructions occurred at an incidence of~~ in the controlod clinical trials program (11=9~ 
Ca.-- tdama (9.~). palpitetions (2.'"'1. postural dizziness (0.6~). SUo IIIII Appotoolopo: rash 11 -'"'1. 
pruritus (OAI. Mooc oh ohlol+ muscle tromps 11.'"'~ c..olllllll.....,...-s,- haadacha 
(1A). dizziness 14.5"1. paresthesia (l.Dl'), hypoesthesio ID.9"~- ...._ s,-flushing (1.9ll.~ 
,..,._somnolence (1.2ll), insomnia ID.9"), nervousness (0.~).- • • ol: nausea (4.2~). 
abdominal pain 12.2"41. dyspepsia (1.4~). diarm11 (1.1"1. ftatulenca 11-'"'1. constipation (0.~1 . .....,._., 
s.- dyspnu (1 . 1~). s-iols-.: abnormal vision (1~). tinnitus (0.6~1. &o-at fatigue (4.K). 
pain (UJ~). asthenia (l.D'J(;). 
NORVASC has been evaluated for safaty in about 11.000 patients with hypertension and angina. 
The following events occurred in <1~ but>0.1" of patients in comparotive cfinical trials (double-blind 
comparative vs Pacebo or active agents; n = 2.615} or under conditions of open trials or marteting experience 
where a causal relationship is uncertain. 
__,arrhythmia (including ventricular tachycardia and atrial fibrilation), bradycardio, hypotension. 
poripharll ischemia, syncope_. tachycardio. posturol dizziness, postural hypotension. c..o1 111111 ........ I 
- s.- hypoesthoae, tremor, vertigo. - • f t onortxil, constipation, dysphagia, vomiting. 
gingival hyperplasia. s--ot asthenia', bock pain, hot flushes, malaisa, rigors, weight goin. -
s:,a..: arthralgia, arthrosis, myalgia. l'oydoillric: nxual dysfunction tmaJe' and female), insomnia, nervous· 
ness, depression, abnormal dreams, onxiety, depersonalization. .....,._., s.- epistaxis. Sltioo _. 
~ prOOtlls', rash erythematous, rosh maculopepular, arytherno multiforme. Spociol-c~s. 
diplopia, rtyt pain, tinnitus. Ur-.y 5r-micturition frequency, micturition disorder, nocturia. -
~5r- dry mouth, increased sweating. MoloMiic _.-thirst.~ purpura. 
Theae events occurred in less than I~ in placebo-controlled trials, but the incidence of these side effects was 
bo!ween 1 ~ and ~ in an multiple dose studies. 
The following events occurred in ;;0.1~ of patients: cardiac failure, skin discoloration. urticaria, skin dryness, 
Stevens-Johnson syndrome, alopecia, twitching. otexia, hypertonia, migroino, apathy, amnesia, gostrilis, 
pancreatitis, increas~d appetite. coughing. rhinitis. parosmia. taste perversion, and xerophthalmia. 
Isolated cases of angooedoma have boon reported. Angioedema may be accompanied by braathing difficulty. In 
postmarteting experience, jaundice end hepatic tnzyma tltvations (mostly consistent with cholestasis) in some 
cases severe enough to require hospitllization have bean reported in association with use of amkH:Iipine. 
SYIIPTOIIS AIIO TIIEATIIIEIIT OF OYBIIIOSAGE 
s,.,.... 
Ovtrdosago can causa excessive peripheral vasod~ation with marltod and probably prolonged hypotonsion and 
possibly a roftox tachycardia. In humons, oxperionct with owrdosago of NORVASC (amlodipine bosyltto) is limited. 
When amlodoprne was ongested at doses of 11J!i.250 mg some patients remained normotensive with or without 
gastric lavage while another patient experienced hypotension (9MO mmHg) which normalized folowing plasma 
expansion. A patient who took 10 mg of amlodipine with bonzodiuapino developed shock which was refractory 
to trutrnont and died. In a 19 month-old child who ingested 30 mg of amlodipino (about 2 rng/kg) there was no 
evidence of hypotension but tachycardia (110 bpm) was obstrvtd. lpecac was administered 3.5 hrs alter ingestion 
and on subsequent observation (overnight) no sequelae were noted. 
T-
Ciini~a~ sigrifica~t hypotensi~n due to overdosage requires active cardiovascular support including frequent 
monrtonng of cardiac and resporatory function, olovotion of extremities, and attention to circulating fluid volume 
and urine output. A vasoconstrictor (such as norepinephrine) may be helpful in restoring voscular tone and 
blood i><•ssuro, provided that there is no contraindication to its use. As NORVASC is highly protein bound. 
htmod1atysis ~ not likely to be of benefit. Intravenous calcium gluconata may be beneficial in reversing the 
effects ofcalcnrm channel blockade. Clearance of •mlodipino is prolonged in elderly patients and in patients =-= ~~= amlodoprne absorption IS slow, gastric lovage may be worthwhile in some casas. 
Dosage should be individuelized depending on patient's ~erance and responsiveness. For both hypertension 
ond angina. tho racornmended initial dosa of NORVASC (amlodipino bosytatol is 5 mg once daily. If necessary, 
dose can be increased after 1·2 weeks to 1 maximum dose of 10 mg once daily. 
U.. iotloe EWorlyorioo ,__ ......... _,--.. 
The recommended initial dose in patients over 65 years of age or patients with impaired renaJ function is 5 mg 
once daily. If required, increasing in tho dose should be dono gradually and with caution (stt i'IIECAIITlOIIII. 
u.. ioo ,_ -loopeitM llopolic-
Oosage requirements hoV1t not been osteblishad in patients with impaired hepatic function. When NORVASC is 
used in these patients, the dosage should be care and grodualy adjusted depending on patient's toltronce 
and response. A lower starting dose of 2.5 mg once daily should be considered (sao W~l. 
DOSAGE fOIIMS 
AniiMilily 
NORVA5C is ava~able as white octagonal tablets containing amlodipino bosytata equivalent to 2.5, 5 and 10 mg 
amlodopono per tablet The respective teblet strengths ora dobossad on one tablet face as "NRV 2.5", "NRV 5" 
end "NRV 10" with "Pfizer" on the opposite face. The 5 mg tablet is scored. Supplied in whitt plastic (high density 
= : n•) bottles of tOO tablets for 11th strangth Also tho 5 mg and 10 mg are supplied in bottles of 250 tablets. 
Store at t !>-JOI>C. Protect from ~ght. 
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MARVELON* 21 and MARYELON* 28 
(desogestrel and ethinyt estradiol tablets) 
Prescribing lnfonnatlon 
f'lla,.anllllcal Claulllcatlu: Synthetic steroidal combination oral 
contraceptive. 
IIMIIAiill: Conception Control. 
Cutraldlcat1111: 1. History of/or actual thrombophlebitis or 
thromboembolic disolders. 2. History of/or actual c:mbfovascu1ar lisolders. 
3. History of/or actual myocardial infan:lion or coronary arterial disuse. 
4. Active livtr disuse or history of/or actual benign or malignant livtr 
tumours. 5. Known or suspected carcinoma of the breast. 6. Known or 
suspected estrogen-depend neoplasia. 7. lMlcfoagnosed abnonnal vagilal 
bleeding. 8. AJry ocular lesion arisino from ophthalmic vascular disease, 
such as partial or complete loss of vision or defect in visual fields. 9. Wilen 
pregnancy is suspected Of diagnosed. 
Wlnrillp: 1. I'IHilplli .. Faclln fir c..-y Arflry llileal: Cigarette 
smcD1g increases the risli: of serious cardiovasaJiar side etfeds and mortaity. 
lli1l1 cmtrof pis imase !lis risli:, especialy wilh ilcreasi1g age. ConvilCi1g 
data are available to support an upper age limit of 35 years tor oral 
contracepliYe use in women who srnob. Other women who are iOOependently 
at high risk lor cardiovascular disease include those with diabetes, 
hypertension, abnormal li!lil prolie, or a lamiy lislory of these. Whether oral 
contraceplivts accentuate !his risli: is unclear. In low risk, non-smotino 
women ol any age, the benefits of oral contraceplivt use outwtigh the 
possible cardiovascular risks associated with low dose lormulations. 
Consequenlly, oral contraceptives may be presailed for these women up to 
the age of meriOjlaUse. 
Cigarette srnoldng incruses the risli: of seriotJs adverse effects on the 
heart and blood vessels. This risk increases with age and becomes 
significant in oral contraceplivt-users over 35 years of age. Women 
should be counselled not to smote. 
2. Oisalll- IIMicalill at 1111 urflnl -ilnDIIII Ill: 
A. nre•h1•~111c nf Carflnasular Dlnrhrs such as: 
Thrombophlebitis, pulmonary embolism, cerebrovascular disorders, 
myocardial Ischemia, mesenteric thrombosis, and retinal thrombosis. 
B. Cuflll111 lill i e~ '""l'tlt ta tlllll 111111 aaf t1 n1nlar 
........_ e.g. immobii22tion alt!r aa:idents or confinement to bed during 
tono-tenn ilness. Other non-hom1onal methods of contraceplion should be 
used regular aclivilies are resumed. For use of oral contraceptives .men 
surge~y is ~. see PRECAUTIOit$. c. Vilul Dlllcls, Partial " 
C.,lell. D. l'a!IIIIMitla, If o,IIIUI•Ic Yaalar llll-. E. Snen 
IIIHaclll of Ulbtn ElliiiiY If WII'HIIII of l'rHiistlll 11111'1111 
lluUctll. l'rlcalliHI: 1. l'llyslcal ED•Iutill llf ~lln·1': Before 
oral contraceptives are used, a thorough history and physical examination 
should be performed, includino a blood PBSSUre determilalion. Breasts, 
liver, extremities and pelvic organs should be examined. A Papanicolaou 
smear should be taken ~ the patient has been sexually active. The first 
foflow-up visit should be done three months after oral contraceptives are 
presaiJed. Therealler, examina!i1ns should be performed at least once a year 
or more lrequenlly ~ indicated. AI uch annual visit, examination should 
inc:b:le those proadures !hat were done at the initial visit as outlined above or 
per recommendations of the Canadian Task Force on the Periodic Heafth 
Examination. 2. Prq111cy: Oral contraceptives should not be taken by 
pregnant women. HowMr, I conception accidently 0CCU1S while 13ldng the 
pill, there is no conclusive evidence that the estrogen and progestin 
contained In the oral contraceptive will damage the developing child. 
3. ilnllllllfl11: In breastleeding women, the use of oral contraceptives 
results in the hormonal componenls being exa!led in breast mile and may 
reduce its quantity and quality. H the use of oral contraceptives is initiated 
alt!r the establishmenl of lactation, there does nof appear to be any effect on 
the quantity and quDty of the milk. There is no evidence !hat low dose oral 
contraceptives are harmful to the nursing inlant. 4. Hl,atlc Fuctl11: 
Patients who have had jaundice including a history of choleslalic jaundice 
during pregnancy should be givtn oral contracepliYes with great care and 
under dose observation. The devmpment of sever! generaired pruritus Of 
icterus requires that the medication be withdrawn until the problem is 
resoMd. H the jaundice should PltM to be choleslalic in type, the use of 
oral contraceptives should not be resumed. In patients taking oral 
contraceptives, changes in the composition of the bile may occur and an 
increased incidence of gallstones has been reported. Hepatic nodules 
(adenoma and local nodular hyperplasia) have been reported, particularly in 
tono-tenn users of oral contracepliYes. Afthough these lesions are extremely 
rare, they have caused lalil intra-abdominal hemorrllaoe and should be 
considered in women presenting with an abdominal mass, acute abdominal 
pain, or evidence of intra·abdominal bleeding. 5. ~: Patients with 
essential hypertension whose blood pressure is welk:onlrolled may be given 
oral contraceptives but only under close supervision. II a significant 
ele¥31ion of blood pressure in previously normotensive or hypertensive 
subjects occurs at any lime during the administration ol the drug, cessation 
ol medication is necessary. 6. 111raltt alf Hufac~t: The onset or 
exacerbation of ~ or the dMiopmenl of headache of a new pattern 
which is recurrent, persistent or severe, requires discontinuation of oral 
conlnleeptives and evaluation of the cause. 7. Oldoln: Current low dose 
oral contraceptives exert minimal · pact on glucose metabolism. Diabetic 
patients, or those with a lamily history of diabetes, should be observed 
closely to detect any worsening of carbohydrate metaboUsm. Patients 
predisposed to diabetes who can be kept under dose supervision may be 
givtn oral contracepliYes. Young diabetic patients whose disease is of recent 
origin, wekonlroled, and nof associated wilh hypertension Of olhef signs 
of vasadar disease such as oc:dar loodal changes, shWd be monitored more 
freQuently while using oral contraceplives. 8. Ocola llileal: Patients who 
aa pregnant or are 13ldng oral contraceptives, may experience oomeal edema 
!hat may cause visual dislw1lances and changes in tolerance to contact lenses. 
especially of the rigid type. Soft contact lenses usually do not cause 
disturtJanczs. H visual changes or alterations in tolerance to contact lenses 
occur, lernj)oraly or permanent cessation of- may be advised. 9 . ..._ 
Increasing age and a strong lanjy lislory are the most significant risli: faclors 
for the deYelopment of breast cancer. Other established risli: lactOfs inc:b:le 
obesity, nuliparity and late age at first ful.lerm pregnancy. The identified 
groups of women thai may be at imased risli: of deYeloping breast cancer 
beloo menopause are kJno-!enn users of oral conlraceplives (more than 8 
Y!OfS) and slart!rs a1 early age. In a lew women, the use of oral contracepliYes 
may ac:ce1erate the growth of an existing but undiagnosed breast cancer. Since 
any poferllial incrased risli: related to oral contraceptive use is smal, lhere is 
no reason to chanoe prescribing habits at present Women reaiving oral 
contracepliYes shWd be instructed in sell-examination of their breasls. Their 
physicians should be notified whenMr any masses are detected. A yearly 
clinical breast examination is also retofM1ended because, I a bRas! cancer 
should develop, estrogen·cocrtaining drugs may cause a rapid progression. 
10. Ya11111 llnfl11: Persistent irregular vaginal bleeding requires 
assessment to exClude under1yino pathology. 11. Flllrthls: Patients with 
libroids (leiomyomata) should be careluly observed. Sudden enlargement 
pain, or tenderness require discootinuation of the use of oral contraceptives. 
12. ~ DiiiNin: Patients with a history of ernoliol1al disturbu:es, 
especialy the depfessM! type, may be more prone to have a recurrtnee of 
depfession while 13ldng oral conlraceplives. In cases of a serious recurrence, a 
trial of an alternate method of contraception should be made which may help 
to ~ lite possible relationship. Women with premenstrual syndrome 
(PMS) may have a varied response to oral contraceptives, ranoing from 
symptomatic impnJYtment to worsening of the condition. 13. Lalllfatery 
Tills: Results of laboratory les1s should be interpreted in the light !hat the 
palienl is oo oral oontral:eplives The lolowing laboratory 1es1s are modified. 
A. l.lftr tuctltl Inti: Aspartate serum transaninase (ASD · variously 
reported elevations. Mah pl1osphatase and gamma gManWle transanWlase 
(GGD · sightly elevalld. B. Ca11a1at111 InS: M"ma elevation of test values 
reported I« such paramelefS as protlvornbin and Fadors VII, VIII, IX and X. C. 
n,nlll fllcllll InS: Prot!in bidng of thyroxine is incrased as iAdicated 
by increased total serum thyroxine concentrations and decreased T3 reskl 
uptal<e. D. ~ Smal changes of unproyen clinical significance may 
occur in 1ipopro1ei1 dlolesterollractions. E. G I I I 'J9llld: lH and FSH levels 
are suppressed by lite use of oral contraceptives. Wait two weeks after 
discontirlling the use of oral conlraceplives before measurements are made. 
14. n- s,a..: Pathologists shWd be advised of oral contracepliYe 
therapy when specinn obtained ITorn surgical procedures and Pap smears 
are subnilted I« examination. 15. 11111n II flrlllly: After discontinling oral 
contraceptive lhelllpy, the patient shoukl delay pregnai1Cf at least one 
normal spontaneous cycle has occurred in order to date the p<egnancy. An 
alternate contraceptive method should be used during this time. 
16. Mllllnllu: W n having a history of oligomenorrhea, secondary 
amenorrhea, or irregular cycles may remain anovulatory or become 
amenorrlleic following discontinuation ol ~ogestin combination 
therapy. Amenorrhea, especially ~ associated with breast secretion, that 
continues for six months or more after withdrawal, warrants a carelul 
assessment of hypothalamic-pituitary function . 17. nre.~ll•hllc 
C.,llalltls - 1'111--...y: There is an increased risli: of post-surge~y 
ltoOCiiboelilbolic ~ in oral contraceptive users, alt!r major surgely. 
If teasible, oral contraceptives should be discontinued and an alternalivt 
method substiluted alleast one moath prior to IWOR elective SliQSY. Oral 
contrac:epliYes should nof be resumed the first menstrual period after 
hospital discllarge lolowing SUrgefy. 18. Dnlllllrlclltll: The concurrent 
administration of oral conlraceplives wilh olhef drugs may !!SUI in an al!f1Jd 
response to either agent Reduced effectivtness of the oral contraceptive, 
shWd 1 occur, is more lbly wilh the low dose lorrrUations. n is ~to 
ascertain all drugs that a patient is taking, both prescription and non· 
~ before oral contraceptives are presailed. 
Birth control pills do not protect against sexualy transmitted disuses 
(STDs) including HIV/AIDS. For protection against STDs ft is advisable to 
use latex condoms in combilation wilh bi1h control pils. 
Drip Wlllcli lly lllcrNMIIII Elllcacy II Oral c.nc.,titn: 
...._._: Carbamazepile, ethosuximide, p/lenollarl)ita phenytoin, 
pRnidone. Induction of hepatic microsomal enzymes: Rapid metabolism of 
estrogen and increased binding of progestin and edlinyt estradiof to SHBG. 
Use higher dose OCs (50 meg elhinyt estradiol), another drug or another 
method. Aatl"1tlcs: Ampicinin, cotrimoxazote, penicinin. Enterohepalic 
circulation disturbance, · estinal hurry. For short course, use additional 
method or use another drug. For long course, use another method. 
Rifampicin. lncrused metabolism ol progestins. Suspected acceleration 
ol estrogen metabolism. Use another method. Chloramphenicol, 
metronidazole, neomycin, nitrolurantoin, suHonamides, tetracyclines. 
llldudion of hepatic microsomal enzymes. Also disturbance of enterohepatic 
cirtulation. For short course, use additional method or use another drug. For 
long course, use another method. Troleandomycin. May retard melabolism 
of DCs increasing risk ol cholestatic jaundice. For short course, use 
additional method or use another drug. For long course, use another 
method. Altlflllpl: Griseofulvin. Stimulation ol hepatic metabolism of 
contraceptive steroids may occur. Use another method. Stfatinl 11f 
""11tlcs: Benzodiazepines, barbiturates, chloralhydrate. glutethimide, 
meprobamate. Induction of hepatic microsomal enzymes. For short course, 
use additional method or another drug. For long cwse use another method 
or ligher dose OCs. Altlcia: Deaeased intestinal absorption of progeslins. 
Otlllr 011p: Phenylbutazone, antihistamines, analgesics, antimigraine 
preparations, V"ilanWI E. Reduced oc efficacy has been reported. Remains to 
be confirmed. 
llllllftatlol " llllllr Dill Acllll ~ Oral c.tract,tinl: 
Alcellll: Possible increased levels of ethanol or acelaldehyde. Use with 
caution. Al,~a- 11 AfllllriCI,tlf Altlb: Clonidine. Sedation effect 
increased. Use with caution. Alli-cN~~INb: All. DCs incruse clotting 
!actors, decrease efficacy. However DCs may potentiate action in some 
pa · nts. Use anollter method. Alti.._lsuts: AD. Auid retention may 
increase risk of seizures. Use another method. Alti-flHttic flip: Oral 
hypoglycemics and insulin. DCs may impair gklcose tolerance and increase 
blood glucose. Use low dose estrogen and progestin DC or another method. 
Monitor blood glucose. Alll-~y,.rttllln 1111t1: Guanethidine and 
methyldopa. Estrogen component cause sodium retention, progestin has no 
effect. Use low estrogen DC or use another method. Beta blockers. 
Increased drug effect (decreased metaboHsm). Adjust dose of drug ij 
necessary. Monitor cardiovascular status. Alltl.,mtcs: Atetaminophen. 
Increased renal clearance. Dose of drug may have to be increased . 
.wipyri!ine. Impaired metabolism. Decrease dose of drug. ASA. Etfecls of 
ASA may be decreased by the short term use of OCs. Patients on chronic 
ASA therapy may require an increase in ASA dosage. Ml_,.elc Aclll: 
Theoretically, a hypercoagulable state may occur because DCs augument 
clotting lactors. Avoid concomitant use . .._iMIIc All* Isoproterenol 
Estrogen causes decreased response to these drugs. ~ dose of drug as 
~- Discontinuing OCs can result in eii:eSSivt drug activity. Caflli11: 
The actions of caffeine may be enhanced as DCs may impair lite hepatic 
metabolism of caffeine. Use with caution. CHinllrol l-'11 111111: 
Clofibrate. DCs may increase the clearance of clofibrate leading to decreased 
IMI of clofibrale. Use wilh caution. Clrllcllllflla: Prednisone. lolaltedly 
increased serum levels. Possl>le need for decrease in dose. Cyclnjllri1ot: 
May lead to an increase in cydosporine levels and hepatotoxicity. Monitor 
hepatic function. The cydospoline dose may have to be decreased. fllic 
Aclll: OCs have been reported to inpair folate metabolism. ..,.,..111: 
Possible increased analgesia and CNS depression due to decreased 
metabolism of meperidine. Use combination with caution. f'll1loflllazill 
TIIINIIIIIztft: All phenothiazines, reserpine and similar drugs. Estrogen 
potentiates the hyperprolacline effect of these drugs. Use other drugs or 
lower dose DCs. If galactorrliea or hyperprotactinemia occurs use other 
method . Slfallnl 11f H"111ics: Chlordiazepoxide, lorazepam. 
Oxazepam, Diazepam. Increased effect (increased metabolism). Use with 
caution. n.,llrtllll: M. Deaeased oxidation, leading to possiJie mxicity. 
Use with caution. Monitor lheophytline levels. Tricyclic Altilll,.mlll: 
Ckrnipramine (possibly others). Increased side effects; i.e. depression. Use 
wilh caution. YlllMI 112: OCs have been reported to reduce serum levels of 
Vitamin BIZ. 
Mn111 Ructlta: An increased risk of lite following serious adverse 
reactions has been associated with the use of oral contraceptives: 
• Thrornbopl*liit • f'l*nonary ernboism • Mesenteric tllrcrnbosis • Netm-
ocular lesions, e.g, retinal thrombosis • Myocardial infarction • Cerebral 
tllrcrnbosis • Cer!bral hemorrflage • Hypertension • Beriign hepatic tumours 
• Galbladder disease • Congenital anomalies. The lollowing adverse reactions 
also have been reported in patients receiving oral contraceptives: Nausea and 
vomitilg, usually the most common adverse reaction, occurs in apj1IOXimately 
10% or less of patients during the first cycle. Other reactions, as a general 
rule, are seen less lrequently or only occasionaly, as lolows: • gastrolestinal 
symptoms (such as abdominal cramps and bloating) • brealdhrougli bleeding 
• spotting • change in menstrual flow • dysrnenorrtlea • amenorrllea during 
and after lrealmenl • lernj)oraly infertiity alt!r clisconlillance of treatment 
• edema • chloasma or melasma which may persist • breast changes: 
tenderness, enlargement, and secretion • change In weight (increase or 
decrease) • endocervical hyperplasias • possible diniootion in lactation when 
given irnrnediat!ly posl"jlartUm • ciQestalic jaundice • migraine • imase in 
size of uteme leiomyomata • rash (alelgic) • mental depression • reduced 
tolerance to carl>oliydrates • vaginal candiliasis • premenstruaHikt syndrome 
• · olerance to contact lenses • chanoe in comeal curvature (steepenino) 
• cataracts • optic neurtis • retinal tlvombosis • changes in ibldo • chorea 
• changes In appetite • cystitis·like syndrome • rhinitis • headache 
• nervousness • dizziness • hirsutism • loss ol scalp hair • erythema 
multiforme • erythema nodosum • hemonflagic eruption • vaginitis • porphyria 
• impaired renal function • Raynaud's phenomenon • auof ory disturbances 
• hemolytic uremic syndrome • pancreatitis. 
Trllllllllll C1Nr1111at1 If Al:dlllltll i1111t111: Serious I etfeds have nof 
been reported lolowing acute ingestion of large doses of oral contraceptives 
by youno children. Overdosage may cause liiusea, and withdrawal bleeding 
may occur in lernales. 
ilnlllllf Mlillllrltltl: • 21-Pill PACK: 21 active pis (wilh hormones) 
takerl daly I« three wee1<s. and then tab no pills I« one week. • 2&-Pill 
PACK: 21 active pills (with hormones) takerl daly I« three weeks, and then 
SI!Yell "reminder' pis (no hormones) l3bn daly for one week. 
Anlla~lllty 11 011111 ~-: MARVELON. 21 : Each sachet contains a 
blister dispenser with 21 round white tablets. Each tablet for oral 
administration con1ains 0.15 mg desogestrel and 0.03 mg etflinyl estradiol 
MARVELON .2B: Each sachet contains a bfister dispenser with 21 round 
while tablets and 7 round green tablets. Each white tablet lor oral 
administration con1ains 0.15 mg desogestrel and 0.03 mg ell*lyl estradiol 
Each gl!ell tablet!« oral administration contains inert ingredients. Marvelon 
is a Schedule F drug. 
S!Millty llf Sflrlll "-IIIIIUtilll: Stoo beiWten 1~J00c. 
Producl monograph Mlable on request 
~: 
1. Marvelon Product Monog raph. 2. Rabe T. et al. The effects of 
monop/Jisic illd l!iphasic ofif contraceptives on ovarian function iJJd 
endometril f thickness. The European Journal of Contraception and 
Reproductive Health Care. 2 (1997) :5-51. 3. IMS Heafth. 
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Long-acting BP control for mild-to-
moderate hypertensives 
• effective! control BP at target le el for a full 
24 hours and be ond'2 ' 
• intrinsical! long half-life maintain pia ma le els 
to reduce BP up to 24 hour after a mi eel dose~ •• 
• significant! greater BP reduction during the 
critical morning hour than nifedipine XL;§ 
• more effecti e than felodipine at the ame 
dose6 -
• 
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Kirkland, Quebec •TM Pfizer Products Inc. 
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E R E T 0 D A y . H E 
Impressive tolerability after 4 years 
• compared with antihypertensi es from four 
different cia ses, more orva c* patients 
remained on therap after 4 ears30 
• onl 3% withdrawal rate among 12,831 
patients in 16 clinical tudies9 
" orvasc" should always be prescribed as once-<laily therapy. 
Both treatments reduced daytime, nighttime and 24-hour mean 
an-bulatory blood pressures. orvasc" 5-1 0 mg o.d. ~ nifedipine 
XL 30-60 mg o.d. - 12 week open-aossover in 40 patients, critical 
morning hoUrs = (0500 to 11 00), (p<0.02). 
l'.orvasc" 5-10 mg o.d (n= 103) ~ felodipine ER 5-10 mg o.d. 
'n= 103 after 8 weeks (p=0.036) 82% of 'orvasc" patients reached 
t11get DBP of S90 nvnHg '~ 69% for felodipine. 
; orvasc- In= 114 1, 83'- Oi orvasc- patien remained on therapy 
after 48 monchs. 
orvasc" IS indicated in the treatmen1 of mild-to-modera e essential 
hypertensM:Jn \\--hen diuretics or beta-blod:ers are unsuitable. The most 
convnon acM!rse reactions include edema (8.9%) and headache 18.3%).' 
Consult ~escribir:'& information for important safety information 
and drug mteracbons. 
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